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This thesis focuses on the development of new methodologies for asymmetric 
synthesis. Here, we will investigate two independent methodologies:  
i) biocatalysed synthesis of N-heterocyclic systems and 
ii) enantioselective C-C bond formation with organometallic reagents. 
The first chapter of the thesis summarises the state of the art in the synthesis of N-
heterocyclic systems from chiral amines. The background on asymmetric synthesis of 
amines via classical and biocatalytic methodologies, is also described here. 
 
The second chapter of the thesis discusses our optimisation results on the 
biocatalysed transaminase triggered intramolecular aza-Michael reaction (IMAMR) 
of a keto-cyclohexanone substrate in the presence of different organocatalysts, with 
the aim to improve the diastereomeric ratio and the overall efficiency of the 
synthesis of histrionicotoxin (HTX) derivatives. We found that the use of (S)-diphenyl 
prolinol improved the diastereoselectivity of the spontaneous IMAMR, providing the 
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corresponding spirocyclic HTX derivative with a modest 3:2 d.r. (versus the 1:1 d.r. 
obtained in the absence of organocatalyst). The biocatalysed IMAMR of various alkyl 
substituted keto-cyclohexanones in the presence of (S)-diphenylprolinol as 
organocatalysts was also attempted.  
 
The third chapter of this thesis investigates the expansion of biocatalysed IMAMR to 
the vinylogous aza-Michael reaction. The attempted biocatalysed transamination 
reaction of two different ketodienones substrates resulted in complete 
decomposition under the reaction conditions. However, the biocatalysed triggered 
vinylogous aza-Michael reaction of two different ketodieno esters proved successful, 
providing the corresponding 2,6-disubstituted piperidine and 2,5-disubstituted 
pyrrolidine as a mixture of inseparable diastereoisomers, respectively. 
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Subsequent epimerisation and isomerisation of the double bond, provided the cis-
2,6-disubstituted piperidine, bearing a conjugated ester as the only diastereomer. 
However, in the case of the 2,5-disubstituted pyrrolidine, the tandem epimerisation-
isomerisation proved unsuccessful. The hydrogenation of the double bond in the 
lateral ester chain, allowed for the synthesis of ethyl 4-((2S,6S)-6-methylpiperidin-2-
yl)butanoate and provided a mixture of the cis- and trans- 5-methylpyrrolidin-2-yl 
butanoates.  Subsequent cyclisation to the corresponding quinolizinone and 
indolizidine was attempted. In this chapter, we also describe the first attempts in the 
use of thioesters and nitriles as Michael acceptors for biocatalysed IMAMR. 
 
The fourth chapter of this thesis focuses on the catalytic enantioselective addition of 
organozirconium reagents to aliphatic aldehydes using versatile Ar-BINMOLs as 
ligands. The optimal catalytic procedure for the addition of 1-hexene to 
cyclohexanecarboxaldehyde using (Ra,S)-Ph-BINMOL in the presence of Ti(OiPr)4  and 
ZnBr2 was found and the scope of the reaction was expanded to a variety of aliphatic 
aldehydes and functionalised nucleophiles. The reaction proceeds under mild 
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conditions and provides moderate yields and excellent enantioselectivities, making 
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The alkaloid family is one of the most diverse group of compounds found in natural 
products, containing over 12,000 different types.1 They often encompass nitrogen 
containing (hetero)cyclic systems and are secondary metabolites. Alkaloids have had 
a significant influence throughout organic and medicinal chemistry since they 
possess a wide range of pharmacological activities, including antimalarial (e.g. 
quinine)2, antiasthma (e.g. ephedrine)3, anticancer (e.g. homoharringtonine),4 
vasodilatory (e.g. vincamine)5, analgesic (e.g. morphine)6 and antibacterial (e.g. 
chelerythrine)7 properties (Figure 1). As a result, it would be extremely beneficial to 
society, to attain accessible synthetic methods in the laboratory towards these 
naturally occurring alkaloid products. 
Alkaloids often contain an aliphatic amine moiety and in most instances, the lone pair 
on the nitrogen enhances the solubility of the molecule, whilst the substituents 
increase the lipophilicity, a necessary feature to cross the blood-brain barrier.8, 9 
Amines are also really important binding groups during drug-target interactions; a 
plethora of aliphatic amines are widely occurring functionalities in molecules of 
diverse bioactivity, and their introduction is a highly important area of synthetic 
research.10 
 





Figure 1: Structure of alkaloids with pharmacological activities. 
  
Chiral amines are ideal precursors for these chiral N-heterocyclic systems. 
Cycloaddition, cyclisation or multicomponent condensation reactions of chiral 
amines are the most frequent methods used to construct N-heterocycles.11 The aza-
Diels Alder reaction,12 reductive amination13 and the intramolecular aza-versions of 
Michael (which will be reviewed later in section 1.4),14 Morita-Baylis-Hillman,15 
Henry16 and Mannich reactions13 have been successfully employed in the synthesis 
of chiral N-heterocycles. 
As the principal precursors of chiral N-heterocyclic systems, the synthesis of chiral 
amines has received much attention.17 The most common methods include: 
nucleophilic addition to imines,18 N-acetylenamide and imine reduction,19 reductive 
amination,19 nitrogen C-H insertion,20, 21 allylic amination,22 synthesis of 
propargylamines,23 olefin hydroamination,24, 25 organocatalytic26 and enzymatic27 
methodologies and catalytic hydroaminoalkylation.28  
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In the next sections, we will briefly discuss the main methods to prepare chiral 
amines from prochiral carbonyl compounds through two methodologies: asymmetric 
reductive amination and biocatalysis. 
1.2 Asymmetric synthesis of amines via reductive amination – Classical methods. 
 
The asymmetric reductive amination (ARA) of carbonyl groups is a popular and 
versatile method for producing chiral amine functionality. The reaction exploits an 
imine formed in-situ from a carbonyl compound and an amine, which is then 
enantioselectively reduced to the desired chiral amine using a chemoselective 
catalyst.29  
The first to report the enantioselective reductive amination was Blaser et al. during 
the synthesis of (S)-metolachlor, utilising an iridium catalyst in the presence of the 
chiral diphosphine ferrocene ligand L1 (Scheme 1) in 1999.30 The reaction proceeds 
with 78% ee in the presence of 0.0001 mol% of catalyst.  
 
Scheme 1: Synthesis of (S)-metolachlor.  
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Another example of iridium-catalysed ARA was reported by Zhang and co-workers, 
who developed a one-pot ARA using of the (S,S)-f-binaphane (L2) as the ligand for 
the hydrogenation of imines formed in situ from aryl ketones (Scheme 2).31 Ti(OiPr)4 
and I2 are used as additives, to accelerate the ARA by binding the Ir-f-Binaphane 
catalytic system. The reactions proceed with up to 96% ee. 
 
Scheme 2: Ir-Catalysed hydrogenation of imines from aryl ketones by Zhang and co-
workers. 
 
Moving on from iridium catalysis, Börner and co-workers reported the use of Rh(I) 
catalysts for the ARA of α-keto acids.32 Using L3 as ligand, (R)-benzylphenylalanine is 
obtained in 59% yield and 38% ee (Scheme 3, Route 1). Later, an extensive screening 
of 96 phosphorus based ligands33 revealed that diphenylphosphino ligand Deguphos 
(L4) is a more effective catalyst and is able to produce chiral amino acids with good 
yield and up to 98% ee (Scheme 3, Route 2).  




Scheme 3: Rh-Catalysed ARA by Börner et al. 
 
Merck34 and Takasago,35, 36 separately, reported the ARA of unprotected enamino 
esters and amides catalysed by Rh and Josiphos-type L5 and L6 and BINAP (L7) 
complexes, resulting in β-amino acid derivatives with high yields and 
enantioselectivities (Scheme 4a). This work inspired Bunlaksununusorn and co-
workers to develop a one pot synthesis for chiral β–amino esters using Ru-L8 catalyst 
(Scheme 4b).37 With the use of ammonium acetate as the nitrogen donor and 2,2,2,-
trifluroethanol (TFE) as a solvent, the desired amino esters are obtained in high yield 
and enantioselectivity.  




Scheme 4: a: ARA of unprotected enamino esters and amides catalysed by Rh-
Josiphos-type and Ru-BINAP complexes. b: Bunlaksununsorn's Ru catalysed ARA 
synthesis of β-amino esters. 
 
Merck later reported an ARA methodology for the synthesis of the anti-diabetic 
sitagliptin using the chiral Ru-L9 catalyst and ammonium salicylate (Scheme 5).38 The 
reaction provides the desired product with 91% yield and >99% ee. The ammonium 
salicylate not only pushes the equilibrium towards the desired product, but also 
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prevents the formation of the dimer by-product 19 (or breaks the dimer), resulting 
in the desired product.  
 
 
Scheme 5: Merck's synthesis of Sitagliptin via Ru-Catalysed ARA.  
 
Rubio-Pérez reported in 2009 a one-pot ARA using a palladium chiral catalysts for the 
construction of chiral amines from various carbonyl compounds (Scheme 6).39 The 
Pd-catalyst L10 is successful with aliphatic ketones substrates, providing moderate 
yields and high enantioselectivities up to 99%. Unfortunately, for aromatic ketones, 
the palladium species fails to provide enantioselectivities higher than 43%. These 
results are somewhat surprising in contrast to previous ARA reports.40-42  
 





Scheme 6: ARA using Pd-catalysts for the construction of chiral amines from various 
carbonyl compounds 
 
So far, this chapter has focused on the use of metal catalysis for asymmetric reductive 
amination (ARA), however, organocatalysts are also excellent catalysts for the 
synthesis of chiral amines. Organocatalysts are powerful synthetic tools, easy to 
handle, with lower toxicity and suitable for one-pot processes. Largely, 
organocatalysts contain C, H, N, O and S atoms, and often provide good 
enantioselectivities and yields.43, 44 The first organocatalytic ARA, reported by 
MacMillan et al. in 2005, describes the use of chiral hydrogen-bonding catalyst L11 
and Hantzsch esters for the enantioselective synthesis of primary amines from 
carbonyl compounds (Scheme 7).41 The in situ formed imine is activated by the 
catalyst by either protonation by the acid or through hydrogen bonding from the OH 
group. The activation of the Hantzsch ester occurs via hydrogen bonding with the 
P=O group of the phosphoric acid and the NH unit on the molecule itself. Both List45 
and Xiao46 later broadened the scope of this reaction to a metal Brønsted equivalent 
with the use of L12 and L13 (Scheme 7). Antilla et al.47 expanded the battery of 
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ligands by reporting the direct ARA of α-imino esters catalysed by chiral phosphoric 
acid L14.   
 
Scheme 7: MacMillan's method for the organocatalytic ARA of ketones and other 
catalysts used to broaden the scope of the reaction.  
Bengalia et al. screened various chiral Lewis bases as catalysts for the reduction of 
imines using tricholorosilane as reducing agent (Scheme 8a).48 The reaction affords 
high yields and high enantioselectivities with L15 as ligand for a variety of substrates. 
It is worth noting that the process is applied to produce a key intermediate in the 
  CHAPTER 1 
31 
 
synthesis of (S)-metachlor in 53% yield and 72% ee, very similar to the commercial 
procedure by Blaser et al.30 Jones and co-workers have reported the imidazole-based 
organocatalysed ARA of ketones, using L16 as catalyst (Scheme 8b).49 This microwave 
assisted method proceeds with good enantioselectivity, but moderate/low yields due 
to slow formation of the imine intermediate. However, the reaction has been 
successfully applied to the synthesis of the drug calciminetric (+)-NPS-R-568 with 67% 
yield and 89% ee.   
 
Scheme 8: Organocatalysed ARA with trichlorosilanes. a: Benaglia and co-workers 
methodology. b: Jones et al. methodology. 




1.3 Asymmetric synthesis of amines via ω-transamination – 
Biocatalysis 
 
Recently, the use of biocatalysis to install chiral amine functionality has been 
developed.50 Compared to chemo-catalytic reactions, enzymatic syntheses are a 
much greener alternative to classical synthesis, as they allow milder conditions, are 
not usually air- or water-sensitive and usually proceed at ambient temperature and 
neutral pH. In addition, they avoid the need for highly flammable metal-organic or 
heavy metal compounds, reducing metal contamination, while providing excellent 
stereoselectivity in a single step.51, 52 Lipase, transaminase (TA), imine reductase 
(IRED), amine dehydrogenase (AmDHs) and amine oxidase (AO) - primarily 
monoamine oxidase (MAO) - are the enzymes which are used in the enantioselective 
construction of chiral amines.27 This chapter will focus on reviewing the use of TAs 
enzymes for the synthesis of chiral amines.  
 
TA enzymes, in particular ω-TA, allow for the synthesis of optically pure chiral amines 
from prochiral ketones and aldehydes via a reversible reaction with an amino donor 
in the presence of a cofactor; pyridoxal-5’-phosphate (PLP).53 By contrast, -TA can 
only synthesise amino acids, as they require the presence of a carboxylic acid.53 The 
ω-TA catalysed reaction can produce chiral amines from prochiral ketones via either 
a kinetic resolution (Scheme 9a) or an asymmetric synthesis, (Scheme 9b). The 
American biopharmaceutical company Celgene was the first to report this pioneering 
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work in 1990 in an industrial setting with the use of (R)- and (S)- selective ω-TAs for 




Scheme 9: Production of chiral amine via transaminase enzymes. 
 
The majority of the early research was focused towards ω-TA assisted kinetic 
resolution, although its use is limited as the maximum theoretical yield is 50%.52 The 
ω-TA asymmetric catalysis somewhat fell behind due to ketones having low reactivity 
as amine acceptors and unfavourable reaction equilibria. The use of ω-TA for 
asymmetric synthesis was first explored by Shin and Co-workers in 1999.55 This 
approach is much more beneficial for the pharmaceutical industry as it is a more 
economical and efficient route.56  
TA enzymes are PLP-dependent enzymes. PLP is a vitamin B6 derivative and during 
the catalytic cycle it is covalently bonded to the active site of the enzyme.57 The TA 
reaction consists of a two-step reaction (Scheme 10). First, an oxidative deamination 
of an amine donor occurs; the amine donor donates the amine group to the enzyme-
PLP, which produces the pyridoxamine-5’-phosphate (PMP) form of the enzyme and 
the corresponding ketone. The second step consists of a reductive amination of the 
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amine acceptor. Here, the amine group of the PMP-enzyme is transferred to the 
amine acceptor and PLP is regenerated.  
 





Scheme 10: General reaction mechanism of PLP with amines and carbonyls within a 
ω-TA active site. 
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A limitation of the biocatalysed-TA reaction for the synthesis of chiral amines is that 
it is often difficult to obtain good yields due to the reversible character of the 
reaction. The low reactivity of ketones as amine acceptors, makes the 
thermodynamic equilibrium often unfavourable since the products are frequently 
less energetically stable than the substrate.58 Several approaches, such as the use of 
‘smart donors’59-61 or enzymatic cascades,62-64 enable a shift in the equilibrium of the 
reaction. One of the more popular methods to shift the equilibrium, in a large-scale 
reactions, is the use of an excess of the amine donor and the removal of the carbonyl 
co-product.63, 65, 66 In many industrial processes, isopropylamine (IPA) is the preferred 
amine donor as it is achiral, cheap and produces acetone as a by-product, which can 
be easily removed via in-situ evaporation, thus pushing the equilibrium towards the 




Scheme 11: Large Scale TA using IPA and the removal of acetone co-product. 
 
Arguably, one of the most successful examples of the use of ω-TAs in industry is the 
synthesis of the antidiabetic drug sitagliptin (18). In silico design and directed 
evolution allowed for the production of the (R)-selective ω-TA enzyme ATA-117, 
capable of accepting the bulky substituted dicarbonyl derivative prositagliptin (17, 
Scheme 12).67 This pioneering discovery highlights the potential of biocatalysis on an 
industrial scale and it is a great example of how beneficial protein engineering is. 
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Successful results were achieved by redesigning the binding pocket site on the (R)-
selective ATA-117 enzyme. The final variant consisted of 27 mutagenesis after 11 
rounds of enzyme evolution.67 There are many examples of how protein engineering 
can be employed for the creation of enzymes which can be used in industrial 




Scheme 12: Synthesis of sitagliptin via chemocatalytic and biocatalytic methods. 




1.4 Synthesis of N-heterocyclic systems from chiral 
amines 
1.4.1. Intramolecular Aza-Michael Reaction (IMAMR) 
The intramolecular aza-Michael reaction (IMAMR) is a powerful tool for the 
production of nitrogen heterocycles  which are abundant throughout biologically 
active substances – from amines.69, 70 The IMAMR consists of a conjugate addition 
process using nitrogen-centered nucleophiles and enables the construction of 
nitrogen heterocycles in a single step (Scheme 13).69 One or more stereogenic 
centres are produced during the conjugate addition process, making an asymmetric 




Scheme 13: General IMAMR. 
One of the first examples of an IMAMR was reported by Harris and co-workers in 
1980 for the synthesis of imidazolidinones 37 (Scheme 14).71 Simple deprotection of 
35 using HCl, gives intermediate 36, which spontaneously cyclises to provide the 
desired product 37 in 75-98% yield.  





Scheme 14: One of the first reported examples of IMAMR by Harris in 1980. 
 
An example of a non-enantioselective (but stereoselective) IMAMR was reported by 
Stockman et al.; a double tandem IMAMR for the direct production of quinolizidine 




Scheme 15: Stereoselective IMAMR for the synthesis of (± )-Hippodamine reported 
by Stockman et al.  
 
N-Sulfinyl amines have also been employed by Fustero and del Pozo for the synthesis 
of the alkaloid ()-pelletierine (47) and ()-pinidinol (51, Scheme 16).73 The Michael 
acceptor is synthesised via a cross-metathesis (CM) of the chiral N-sulfinyl amines 44 
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and 48 with methyl vinyl ketone. Subsequent deprotonation of intermediates 45 or 
49, using catalytic amounts of potassium tert-butoxide at 40 C allows the 
cyclisation by IMAMR, which proceeds in high yield and diastereoselectivity. The 
addition of hydrochloric acid in dioxane allows the removal of the chiral N-sulfinyl 
group and affords ()-pelletierine and ()-pinidinol in very good yields and excellent 
enantioselectivities (Scheme 16).  
 
 
Scheme 16: IMAMR for the synthesis of ()-pelletierine and ()-pinidinol.  
 
The synthesis of the natural products pictamine and clavepictines A and B utilising a 
diastereoselective IMAMR was achieved by Ma and co-workers in 2006 (Scheme 
17).74 Consequent to the removal of the Boc protecting group, a spontaneous aza-
  CHAPTER 1 
41 
 
Michael reaction occurs on the α,β-unsaturated sulfone 53 providing the 
quinolizidine 54 with high diastereoselectivity. The single isomer 54 is obtained due 
to steric repulsive interaction from the siloxy group and the sulfone functionality.  
  
Scheme 17: Diastereoselective IMAMR synthesis of picatine. 
 
 
Later, Fustero reported the total synthesis of hippodamine utilising a double-IMAMR 
approach and using chiral N-sulfinyl amines as both the nitrogen source and chiral 
auxiliary.75 The use of a bulky tert-butyl moiety allows the first IMAMR to provide cis-
57 and trans-58 in a 3:1 ratio; the selectivity is most likely due to a rigid transition 
state. The tert-butyl sulfinyl group can be removed via HCl in dioxane and then upon 
basification, the second IMAMR takes place and produces the trans isomer 59 in 85% 
yield with >99 ee (Scheme 18). 






Scheme 18: Double tandem IMAMR for the synthesis of quinolizidine reported by 
Fustero et al.  
 
Organocatalysed aza-Michael reactions have increased in popularity for the 
asymmetric synthesis of N-containing heterocycles and have become the third pillar 
of asymmetric catalysis alongside metals and biocatalysis.76 
The first examples of organocatalytic IMAMR were simultaneously discovered by 
Fustero77 and Fan.78 Fustero reported the synthesis of three piperidine alkaloids [(+)-
sedamine (64), (+)-allosedamine (65) and (+)-coniine (68)] by an asymmetric 
organocatalysed IMAMR (Scheme 19). The use of Jørgensen catalyst (L17, 20 mol%) 
and Cinchona‐based primary‐tertiary diamine (L18, 20 mol%) allows the 
enantioselective IMAMR on carbamates 62 and 66, bearing a remote ,-
unsaturated aldehyde, which provides the desired piperidines 63 and 67 in high yield 
and enantioselectivities.77 The organocatalytic conjugate addition of nitrogen 
nucleophiles to ,-unsaturated carbonyl compounds involves the activation of the 
substrate by the catalyst through the corresponding iminium ion, which facilitates 
  CHAPTER 1 
43 
 
the intramolecular addition of the nucleophile to the -carbon atom. Scheme 20 
demonstrates how the nitrogen nucleophile attacks the less sterically hindered 
iminium transition state of the organocatalysts, which produces the enantioselective 
IMAMR product.  
 
 
Scheme 19: Synthesis of (+)-sedamine, (+)-allosedamine and (+)-coniine via 
organocatalytic IMAMR. 
 





Scheme 20: Mechanism of the conjugate addition of nitrogen nucleophiles to α,β-
unsaturated carbonyl compounds using organocatalyst L18. 
 
Hong et al. have reported the synthesis of 2,6-disubstitued piperidines 70 and 72 via 
IMAMR using the Jørgensen's pyrrolidine organocatalyst L19 on the chiral amine 69 
(Scheme 21).79 The use of (R)- or (S)-L19 allows the construction of both cis-70 and 
trans-72 piperidines with high yields of 97% and 78% and moderate stereoselectivity 
of >20:1 and 10:1, respectively. Both (+)-myrtine (71) and (−)-epimyrtine (73) were 
achieved after 4 steps. 
 






Scheme 21: Synthesis of (+)-myrtine and ()-epimyrtine by Hong and co-workers. 
 
Unlike aldehydes, less reactive ketones or more sterically hindered substrates 
require primary amines rather than secondary amines as organocatalysts. The 
formation of the corresponding iminium ion – the active reactive intermediate – is 
more favoured when the organocatalysts is a primary amine.80 
The asymmetric syntheses of piperidines via IMAMR of α,β-unsaturated carbamates 
reported separately by Sánchez77 and Fan81 are examples of IMAMR using a primary 
amine organocatalysts and ketones as substrates (Scheme 22). The formation of the 
corresponding iminium ion between catalyst L20 and the enone 74 promotes the 
intramolecular nucleophilic addition to the β-carbon. Under acidic conditions, the 
quinuclidine group of the catalyst L20 is protonated; this allows for the more 
favourable Re face attack during the transition state via hydrogen bonding with the 
carbamate oxygen atom. 






Scheme 22: Asymmetric synthesis of 2-substituted keto piperidines via an amine-
catalysed IMAMR by Fan and co-workers.    
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1.4.2 Biocatalysed transamination reactions for the synthesis of alkaloids 
More than 15% of known natural products are alkaloids.82 The use of biocatalysis for 
the construction of these molecules offers attractive ‘greener’ alternative to classical 
chemical syntheses.83-85 The first to report the use of TAs for the synthesis of alkaloids 
were Turner and co-workers in 2010.86 In their work, ω-TAs are used in part of a 
cascade system, in which keto-ester 78 undergoes transamination using ATA-
113/117 (commercially available enzymes developed by Codexis) and the product 
spontaneously lactamises to produce chiral piperidine 82 in excellent ee (Scheme 
23a). The spontaneous lactamisation reaction drives the equilibrium towards the 
product, which is obtained in 90% yield. The reaction can be performed on a 50 g/L 
scale, illustrating the use of the methodology on an industrial scale.     
Kroutil et al. used a dynamic kinetic resolution (DKR) strategy with ω-TAs (ATA-117) 
to synthesise 3-4-aryl-GABA derivatives, which are known to play an important role 
in the nervous system.87 This is one of the first DKR performed involving an enzymatic 
enantioselective amination reaction catalysed by ω-TAs. The strategy is based on the 
deracemisation of 4-oxo-3-phenylbutyric acid ethyl esters 83 catalysed by a -
transaminase. The enzyme preferentially selects the one of the enantiomers which 
spontaneously cyclises into the lactam precursor of GABA (Scheme 23b). The optical 
purity of the obtained lactam 88 results exclusively from the stereo-recognition of 
the -transaminases for the stereogenic centre in α-position of the aldehyde 83 and 
not from kinetic effects due to depletion of the preferred substrate enantiomer. A 
co-enzyme lactase dehydrogenase (LDH) removes the side product pyruvate by using 
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NADH to convert the product to lactate resulting in shifting the equilibrium towards 
the desired product. 
 
 
Scheme 23: Transamination/cyclisation systems for the synthesis of chiral amines. 
 
Lavandera and Gotor reported the synthesis of chiral lactams from γ- and δ-keto 
esters using both commercially available and ‘in house’ -transaminases-induced 
cascades (Scheme 24).88 The TA-triggered reductive amination followed by a 
spontaneous cyclisation proceeded under mild conditions and afforded the chiral 6-
substituted piperidin-2-ones and 5-substituted pyrrolidin-2-ones (92) in excellent ee 
and predominantly good yields (94-99% and 66-90% respectively). Lower 
  CHAPTER 1 
49 
 
concentrations of the substrates, as well as a careful choice of temperature were 
required in order to achieve the best conversion to the desired products.  
 
 
Scheme 24: Transamination of γ- and δ-keto esters for the synthesis of chiral 
lactams by Lavandera and Gotor. 
 
The enantiopure alkaloid 1-benzyl-2,3-dimethyl-1,2,3,4-tetrahydrosioquinoline (98) 
has been synthesised by Kroutil’s methodology using a chemoenzymatic sequence 
(Scheme 25).89 The enzymatic reaction of 93 using A. terreus ω-TA, which was 
adapted from Aspergillus terreus90 successfully produces the corresponding 1,3-
disubstituted tetrahydroisquiniline 94 with high yield of enantioselectivity. 
Subsequent methylation and amide formation provides 96. Bischler-Napieralski 
cyclisation ring closure using palladium on charcoal succeeded by Pd-catalysed 
hydrogenation afforded the desired product 98 with an excellent 30% overall yield. 
 






Scheme 25: Synthesis of 1-benzyl-2,3,4-dimethyl-1,2,3,4-tetrahydroisquinolines.  
a Reaction conditions: AlaDH (12 U), FDH (11 U), NAD+ (1 mM), ammonium formate 
(150 mM). 
 
Kroutil et al. described the synthesis of 2,6-disubstituted piperidines 101, a common 
motif in many alkaloids, by the transamination of the least hindered ketone in 1,5-
diketones 99, followed by a spontaneous cyclisation by condensation, that provides 
the enantiopure chiral imine 100 in good yields and enantioselectivities (Scheme 26, 
Step 1).91 Soon-after, the same group expanded this monoamination followed by 
subsequent hydrogenation with palladium on carbon (Scheme 26, Step 2), which 
affords the alkaloid isosolenopsin (101, R= n-C9H19).92 The reaction proceeds with 
good regio- and stereoselectivity and the desired product is achieved over 2 steps in 
64-65% yield and >99 ee (Scheme 26),92 using DMF to pre-dissolve the substrate in 
order to achieve full conversion.   
 





Scheme 26: Synthesis of 2,6-disubstituted piperidines via monoamination of 
diketones. 
 
Other examples using enzymatic approaches for the synthesis of 2,5-disubsubstited 
pyrrolidines, include cascade reactions using TAs and monoamine oxidases,93 imine 
reductases94 and reductive aminases (Scheme 27).94, 95 All of this work highlights the 
ability of the enzymatic cascades to provide good regio- and stereoselectivity in the 
synthesis of heterocyclic systems.  




Scheme 27: TA biocatalytic cascades for the synthesis of 2,5-disubsubstited 
pyrrolidines. 
 
Kroutil and co-workers have also reported the monoamination of triketones for the 
construction of the pyrrolizidine alkaloid xenovenine (Scheme 28);96 a great example 
of how ω-TA’s can be used for the synthesis of more complex, bicyclic molecules in a 
regio- and enantioselective manner. The bioamination (using either (R)- or (S)-ω-TA) 
of triketone substrate 108 is selective towards the less bulky methyl ketone and 
affords the enantiopure cyclic imine 109 in >99% conversion and ee. Two subsequent 
steps (a reduction and spontaneous condensation, followed by a second reduction) 
affords the target xenovenine 110 and 111 in 48% and 30% yield, respectively.  
 





Scheme 28: Monoamination of triketones for the construction of the natural 
xenovenine. 
Until recently, there were no examples of biocatalysis used in conjunction with a 
IMAMR to produce chiral heterocyclic systems. Our group, however successfully 
reported the TA-triggered IMAMR of several ketoenone substrates 112, allowing the 
synthesis of 2,6-disubstituted piperidines 115 in a simple manner (Scheme 29).70 The 
spontaneous IMAMR drives the reaction equilibrium towards the formation of the 
desired piperidines as a mixture of cis- and trans -isomers, making unnecessary use 
of an excess of amine donor (iPrNH2). Subsequent epimerisation via a retro-aza-
Michael reaction occurs upon standing in MeOH, affording the desired cis-products 
115 in >99% de. This pioneering work allows for disconnections which are not 
possible from using conventional chemical synthesis or catalysis. Additionally, it 
provides greener reaction conditions with excellent conversion and isolated yield.70  
 





Scheme 29: Biocatalysed synthesis of 2,6-disubstituted piperidines from ketoenones. 
 
This work was recently expanded to construct β-enaminones 117 from prochiral 
ketoynones 116 (Scheme 30a).97 The reaction proceeds with good yields and 
excellent enantioselectivities (83-99%) for a variety of substrates, showing the 
potential of the methodology. A one-pot tandem IMAMR/ condensation cascade, to 
synthesise more complex, bicyclic systems 119, has also been reported (Scheme 
30b).  
 





Scheme 30: Synthesis of β-enaminones via transamination of ketoynones. 
 












2. Transamination of keto-cyclohexenone compounds for the 














Several natural alkaloids, such as histrionicotoxins (HTXs) and pinnaic acid (Figure 2), 
contain very interesting spirocyclic scaffolds. In particular, HTX has shown to have 
potent biological activity and blocks neuromuscular transmission. It is extracted from 
the skin of poison arrow frogs, Dendrobates histrionicus, which are native to the 
tropical Amazon rain forest, and was first isolated by Daly, Witkop and co-workers in 
1971.98, 99 However, extraction from the original source is not feasible, as it is 
expensive and complicated due to the protection of the Dendrobatid source as an 
endangered species. Therefore, accessible synthetic routes for the stereoselective 




Figure 2: Structure of alkaloids -trans-Histrionicotoxin and Pinnaic acid.
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2.2 Aims and Objectives 
 
This chapter aims to explore the construction of increasingly complex chiral N-
heterocycles via our recently developed TA-triggered intramolecular aza-Michael 
protocol.70 The use of organocatalysis in a synergistic manner with the biocatalysed 
reaction will also be explored.  
In particular, we intend to apply our TA-triggered IMAMR methodology for the 
synthesis of spirocyclic systems 120 (i.e. HTX derivatives, Scheme 31). Preliminary 
investigations by Ryan et al. have demonstrated that the Michael addition reactions 
onto -substituted and/or ,-disubstituted enones (e.g. 121 (n= 1, R = H, Me) are 
hampered by their lower reactivity.44 We believe that activation of these substrates 
via an iminium ion formation will render the -carbons more electrophilic for 
nucleophilic attack than their carbonyl precursors, facilitating the conjugate addition 
processes. If the formed iminium ion bears a chiral environment, we predict that a 
stereoselective nucleophilic addition might be possible.  
Thus, this project will firstly investigate the use of organocatalysts to improve the 
diastereomeric ratio and the overall efficiency of the synthesis of HTX derivatives 120 
(Scheme 31). A screening of different organocatalysts, such as proline, diarylprolinol 
ethers, peptides, MacMillan’s chiral imidazolidinones and cinchonine derived 
organocatalysts will be carried out, in the hope that they are compatible with the 
reaction conditions of the bioenzymatic reaction. 






Scheme 31: Retrosynthetic analysis of the core structure of HTX. 
  CHAPTER 2 
60  
 
2.3 Results and Discussion 
2.3.1. Synthesis of keto-cyclohexenone substrates 126a-e. 
Following known procedures proposed by Suemune et al.100, the synthesis of 126a 
was performed via a two-step process (Scheme 32). The addition of the Grignard 
reagent 123 onto the commercially available 3-ethoxy-2-cyclohexanone (122) in 
diethyl ether formed the desired compound 124 in 69% yield. The second step of the 
synthetic route consisted of a Wacker oxidation of alkene 124. Although Suemune100 
described the use of 0.5 eq. of PdCl2 and 4 eq. CuCl in 76% yield, our research group 
previously discovered that the use of 0.1 eq. of PdCl2 and 2 eq. CuCl afforded the 




Scheme 32: Synthetic route to desired ketocyclohexanones 126a-d. 
 
 
The substituted cyclohexanones 125c-e were achieved by means of a Baylis-Hillman 
reaction on 124, using the corresponding bromoalkane with potassium tert-butoxide 
in Et2O at room temperature (Scheme 32). The use of bromoethane, 1-
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bromopropane and 1-bromobutane as the corresponding bromoalkanes provided 
125c-e in moderate to low yields of 35%, 38% and 27% respectively. The Wacker 
oxidation of substrates 125c-e provided the subsequent substituted 
ketocyclohexenones 126c-e in a good yields of 78, 83 and 71% respectively.  
The synthesis of the -methyl substituted keto-enone 126b was achieved according 
to the synthetic route depicted in Scheme 33. The initial attempt to synthesise 
intermediate 128 from commercially available 2-methyl-cyclohexan-1,3-dione (127), 
in the presence of glacial acetic acid only provided a moderate yield of 43% (Scheme 
33, Route 1). Fortunately, the reaction of 127 with p-toluenesulfonic acid hydrate in 
ethanol, under reflux, with continual removal of the ethanol/toluene/water 
azeotrope by a Dean-Stark trap, yielded the desired 128 with an improved yield of 
90% (Scheme 33, Route 2). Next, the reaction of 138 with 4-pentenylmagnesium 
bromide (123) provided adduct 125b in 60% yield after column chromatography. 
Subsequent Wacker oxidations of 125b provided the target methyl-substituted keto-




Scheme 33: Synthesis of 2-methyl-3-(4-oxopentyl)cyclohex-2-en-1-one (126b). 





2.3.2. Biocatalysed synthesis of spirocycles 129a-e in the presence of 
different organocatalysts. 
Our group had previously investigated the transamination of the ketocyclohexanone 
substrate 126a (Scheme 34) utilising commercially available ω-TA biocatalyst ATA-
256 from the protein engineering company Codexis.44 Ryan et al. reported that the 
use of 2 eq. of IPA as amine donor, at 50 C afforded, after three days, the target 
spirocyclic system 129a in full conversion as a 1:1 mixture of inseparable 
diastereomers (d.r., determined by GC-MS) in an overall isolated yield of 84%.44 Ryan 
also attempted, without any success, the epimerisation of the diastereomeric 




Scheme 34: Transamination of 126a for the synthesis of 129a via the methodology 
of Ryan et al.44 
 
Due to the relevance of generating greener and more efficient reactions, we decided 
to explore the use of organocatalysts in a synergistic manner with the biocatalysed 
transformation, in the hope that it would improve the d.r. and the yield of the 
reaction. Our investigations started by following the same procedure as Ryan et al. 
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with the addition of stoichiometric amounts of the organocatalyst (S)-proline (L21). 
Under these conditions (ATA-256, DMSO 10% [v/v], HEPES (100 mM, pH 7.5), PLP (20 
mM), at 50 °C), the reaction provided a conversion of 78% (determined by GC-MS by 
integrating both starting material and product peaks) of 129a with a d.r. of 1:1 (Table 
1, entry 3) after 48 h. Although the conversion in the presence of L21 was lower than 
without it, we decided to lower the temperature of the reaction to check if L21 could 
provide an increase in stereocontrol. Limited by the temperatures at which the 
enzymes can be employed, we attempted the reaction at 30 C. As expected, at 30 
C, the reaction in the absence of organocatalyst provided lower conversion than at 
50 C (compare entries 1 and 5), and the addition of L21 at this temperature, did not 
have any effect in either conversion or diastereoselectivity of the reaction (compare 
entries 5 and 7).  
Next, we increased the amount of DMSO to 20% [v/v] (the maximum amount of 
DMSO allowed by the enzyme) in the hope that a higher content of organic solvent 
would improve the efficiency of the organocatalysts L21. The reaction at 30 C 
without the organocatalyst provided a lower conversion when increasing the solvent 
to 20% (81 vs 69%, entries 5 and 9) and the addition of L21 under these conditions 
decreased the conversion even further to 41% (85 vs 41%, entries 7 and 10). In all 
cases, the d.r. remained unchanged at 1:1. The use of MeOH as co-solvent was also 
investigated (10% [v/v]) at 30 C, but the conversion of the reactions without and 
with the organocatalyst provided lower conversions than DMSO ( 37 and 12%, entries 
11 and 12).  
 












C) L* Conv (%)
b
 











1.  256 (S) DMSO 
(10) 
50 - n.d >99 
(84)c 
1:1 
2.  ‐ DMSO 
(10) 
50 - 0 0 ‐ 
3.  256 (S) DMSO 
(10) 
50 L21 38 78 1:1 
4.  ‐ DMSO 
(10) 
50 L21 0 0 ‐ 
5.  256 (S) DMSO 
(10) 
30 ‐ 22 81 1:1 
6.  ‐ DMSO 
(10) 
30 ‐ 0 0 ‐ 
7.  256 (S) DMSO 
(10) 
30 L21 38 85 1:1 
8.  ‐ DMSO 
(10) 
30 L21 0 0 ‐ 
9.  256 (S) DMSO 
(20) 
30 ‐ 59 69 1:1 
10.  256 (S) DMSO 
(20) 
30 L21 30 41 1:1 
a  Reaction conditions: ω-TA (5 mg/ mL), 126a (50 mM), iPrNH2 (2 eq), HEPES buffer (100 
mM, pH 7.5), PLP (20 mM), 180 rpm, 48 h. 
b 
Determined by GC-MS. 
c Carried out by Dr James Ryan at Manchester Metropolitan. University during his PhD 
(Ref44). Isolated yield after column chromatography in brackets.  
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C) L* Conv (%)
b
 











11.  256 (S) MeOH 
(10) 
30 ‐ 16 37 1:1 
12.  256 (S) MeOH 
(10) 
30 L21 10 12 1:1 
13.  ‐ MeOH 
(10) 
30 L21 0 0 ‐ 




‐ 5 20 1:1 




L21 3 21 1:1 




L21 0 0 ‐ 
17.  256 (S) DMSO 
(10) 
30 L21e 0 0 ‐ 
18.  025 (R) DMSO 
(10) 
30 ‐ 27 35 1:1 
19.  025 (R) DMSO 
(10) 
30 L21 67 74 1:1 
a Reaction conditions: ω-TA (5 mg/ mL), 126a (50 mM), iPrNH2 (2 eq), HEPES buffer (100 
mM, pH 7.5), PLP (20 mM), 180 rpm, 48 h. 
b 
Determined by GC-MS. 
d Temperature was set to 25 °C for 24 h and then raised to 28 °C for another 24 h. 
e Reaction was carried out without IPA.  
 
We also explored lowering the temperature even further (using DMSO as co-solvent), 
in order to slow down the aza-Michael reaction and improve the d.r. of the reaction. 
Thus, the reaction with ATA-256 at 25 oC for 24 h, followed by 24 h at 28 C, resulted 
in a dramatic decrease of conversion (20 and 21%, entries 14 and 15) and no 
  CHAPTER 2 
66 
 
improvement in the d.r in the presence of L21 (entry 15) after 48 h. To ensure that 
L21 was not acting as the amine donor, we attempted a control reaction in the 
absence of IPA (Table 1, entry 17). As expected, there was no conversion to the 
desired product 129a and only starting material could be detected by GC-MS, 
confirming that the organocatalyst was not acting as an amine donor for the enzyme.   
Finally, we substituted the (S)–selective ATA-256 for the (R)–selective ATA-025 in the 
reaction with (S)–proline (L21), to investigate the match/mismatch effect between 
the newly formed amine bearing stereocenter and the organocatalyst. The ATA-025 
biocatalysed reaction at 30 C, in the absence of L21, provided 35% conversion (entry 
18). We were pleased to observe an increased 74% conversion (entry 19) when the 
same reaction was carried out in the presence of L21; although the d.r. remained at 
1:1, there is a clear indication that the proline L21 is accelerating the IMAMR.  
It is important to mention that all the control experiments, without any enzyme were 
performed for all solvents and at all temperatures, and, as expected, no conversion 
and only starting material was observed (entries 2, 4, 6, 8, 13 and 16, determined by 
GC-MS). 
Working under the reaction conditions for entry 7, Table 1 (ATA-256, 10% DMSO 
[v/v], 30 oC) we screened different organocatalysts, L22-30 (Figure 3). We began the 
screening of organocatalysts with the proline derivatives L22 and L23. Proline 
derivatives are popular and diverse organocatalysts; first shown to be highly effective 
for asymmetric intermolecular aldol reactions,101 they have since expanded its 
applicability in the synthesis of heterocycles,102 in particular via asymmetric Michael 
additions.103 Proline derivatives are a non-toxic, stable and soluble in water,104 
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making them an ideal starting point for our investigation. The other organocatalysts 
which were used during the investigation were chosen as they were ready available 
within the lab and have been previously used for organocatalytic IMAMR.69 
The use of L22 and L23 as organocatalysts did not improve conversion or d.r. 
(compare Table 3 entries 1 and 2 with Table 1, entry 3). However, as the reaction was 
only performed with 10% DMSO [v/v], not all of the organocatalyst was fully 
dissolved, preventing perhaps the organocatalysts from working to their full 
potential. Therefore, we decided to increase the amount of solvent used to 20% 
DMSO [v/v] and for the first time we obtained, using L22, an improvement in the d.r. 
to 3:2 with similar conversion (85%, entry 4) than the reaction without organocatalyst 
(81%, entry 1). When the reaction was carried out with L23, 74% conversion and 3:2 
d.r. was obtained (Table 3, entry 5). We then tested a variety of other organocatalysts 
none of which improved either the conversion or the d.r. (Table 3, entries 5-16). 
Finally, we used L30 within the reaction which provided an improved yield of 89% 
after 48 h but the d.r. obtained was 1:1 (Table 3, entry 17). It is also worth noting, 
that all the control reactions that consisted of only the organocatalyst, without any 
enzyme, failed to form the desired 129a.  
With L22, using 20% DMSO [v/v], as the most effective organocatalysts, we 
investigated once again the mismatch effect using the (R) selective ATA-025 (Table 3, 
entry 20). Unfortunately, the conversion of the reaction decreased to 64% and the 
d.r. reverted back to 1:1. We also attempted the reaction with a lower loading of 
organocatalyst (50 mol%, Table 3, entry 21). Although the d.r. of the reaction 
remained at 3:2, the conversion decreased to 69% after 48 h.  





Figure 3: Structures of organocatalysts used for the transamination of 126a. 
  





























1.  256 (S) DMSO (10) 30 - 22 81 1:1 
2.  256 (S) DMSO (10) 30 L22 68 76 1:1 
3.  256 (S) DMSO (10) 30 L23 36 64 1:1 
4.  256 (S) DMSO (20) 30 L22 74 85 3:2 
5.  256 (S) DMSO (20) 30 L23 33 74 3:2 
6.  256 (S) DMSO (20) 30 L24 35 54 1:1 
7.  - DMSO (20) 30 L24 0 0 - 
8.  256 (S) DMSO (20) 30 L25 60 82 1:1 
9.  - DMSO (20) 30 L25 0 0 - 
10.  256 (S) DMSO (20) 30 L26 14 29 1:1 
11.  ‐ DMSO (20) 30 L26 0 0 ‐ 
12.  256 (S) DMSO (20) 30 L27 18 32 1:1 
13.  ‐ DMSO (20) 30 L27 0 0 ‐ 
14.  256 (S) DMSO (20) 30 L28 7 20 3:2 
15.  ‐ DMSO (2 0) 30 L28 0 0 ‐ 
16.  256 (S) DMSO (20) 30 L29 45 67 1:1 
17.  ‐ DMSO (20) 30 L29 0 0 ‐ 
18.  256 (S) DMSO (20) 30 L30 87 89 1:1 
19.  ‐ DMSO (20) 30 L30 0 0 ‐ 
20.  025 (R) DMSO (20) 30 L22 24 64 1:1 
21.  256 (S) DMSO 
(20) 
30 L22c 55 69 3:2 
a Reaction conditions: ω-TA (5 mg/ mL), 126a (50 mM), iPrNH2 (2 eq), HEPES buffer (100 
mM, pH 7.5), PLP (20 mM), 180 rpm, 48 h. 
b 
Determined by GC-MS. 
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As organocatalyst L22 is not water-soluble and requires 20% DMSO [v/v] for the 
reaction to succeed, we decided to explore the compatibility of a range of other 
organic solvents with our enzyme (Table 4). We began with acetonitrile (10% [v/v]), 
and although the d.r. remained at 3:2, the conversion substantially decreased to 25% 
(Table 4, entry 1). THF (10% [v/v]), also showed no improvement in d.r., remaining at 
3:2 ratio and dramatically decreased the conversion to 3% after 48 h. When 
isopropanol (10% [v/v]) was used as a co-solvent, L22 could not be dissolved and, as 
a result, the d.r. of 129a reverted back to 1:1 but with an improved conversion of 
91% was achieved. It is also worth noting that no transamination occurred in any of 
the control reactions (Table 4, entries 2, 4 and 6). 

















1.  256 (S) Acetonitrile 
(10) 
L22 9 25 3:2 
2.  ‐ Acetonitrile 
(10) 
L22 0 0 - 
3.  256 (S) THF (10) L22 1 3 3:2 
4.  ‐ THF (10)  0 0 - 
5.  256 (S) Isopropanol 
(10) 
L22 86 91 1:1 
6.  ‐ Isopropanol 
(10) 
L22 0 0 ‐ 
a Reaction conditions: ATA-256 (5 mg/ mL), 126a (50 mM), iPrNH2 (2 eq), HEPES buffer 
(100 mM, pH 7.5), PLP (20 mM), 180 rpm, 48 h. 
b Determined by GC-MS. 
c Organocatalyst did not dissolve in the reaction media.  




With L22 as our optimal organocatalyst, we then assessed the amounts and different 
types of amine donors (Figure 4). The ‘smart’ amine donor A2 and the more sterically 
demanding methylbenzylamine (MBA, A4), have shown to be extremely effective in 
previous work with -TA enzymes.105  
Increasing the amount of isopropylamine (IPA, A1) to 4 eq. in the presence L22 
showed no improvement in either the conversion or the stereoselectivity of the 
reaction (Table 5, entries 1 and 2). When A2 (2 eq.) was employed as amine donor, 
unfortunately, the conversion of the reaction could not be determined as the product 
could not be extracted from the aqueous layer as a result of the amine donor 
polymerising (Table 5, entries 3 and 4).59 We then used 1.1 and 3.3 eq. of A3, neither 
of which provided any conversion to the desired 129a (Table 5, entries 5-8). This 
could be due to a mismatch effect between the amine donor and the enzyme. For 
this reason, we tried 2 eq. of A4 as amine donor, and, to our surprise, we obtained 
100% conversion after 48 h (Table 5, entries 9 and 10) but a 1:1 d.r. when the 
organocatalyst L22 (entry 11) was used. Revisiting the mismatch effect, we tested 
ATA 025 with A4 using organocatalyst L22 (Table 5, entry 11). This unfortunately, 




Figure 4: Structures of different amine donors used for the synthesis of 129a. 
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L* A (eq.) Conv (%)b 










1.  256 (S) L22 A1 (4) 75 78 3:2 
2.  256 (S) - A1 (4) 19 67 1:1 
3.  256 (S) L22 A2 (2) n.d.c n.d.c ‐ 
4.  256 (S) - A2 (2) n.d.c n.d.c ‐ 
5.  256 (S) L22 A3 (1.1) 0 0 - 
6.  256 (S) - A3 (1.1) 0 0 - 
7.  256 (S) L22 A3 (3) 0 0 - 
8.  256 (S) - A3 (3) 0 0 - 
9.  256 (S) L22 A4 (2) 94 100 1:1 
10.  256 (S) - A4 (2) 98 100 1:1 
11.  025 (R) L22  A4 (2) 0 3 1:1 
a Reaction conditions: ATA-256 (5 mg/ mL), 126a (50 mM), iPrNH2 (2 eq), HEPES 
buffer (100 mM, pH 7.5), PLP (20 mM), 180 rpm, 48 h. 
b Determined by GC-MS. 
c Unable to extract product after amine donor polymerisation 
 
Next, we explored the biocatalysed transamination reaction of the α,β-disubstituted 
keto-cyclohexenones 126b-126e in the presence of L22 as organocatalyst (Table 6). 
Preliminary results undertaken by Ryan et al. established that the transamination of 
α,β-disubstituted keto-cyclohexanones (using 2 eq. of IPA as amine donor, at 50 C) 
provided, after three days, lower conversions as the alkyl chain length in the α 
position increases.106  
Under the optimised conditions for the synthesis of 129a (ATA-256, IPA (2 eq.), L22 
(1.2 eq.) DMSO (20% [v/v]), Table 3, entry 7), unfortunately, the n-ethyl, isopropyl 
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and tert-butyl substituted substrates 126c-e provided no conversion to the desired 
129c-e after 48 h. For the transamination of 126b in the presence of the 
organocatalyst L22, only traces of the corresponding cyclised product 129b were 
observed via GC-MS (3% conversion) after 48 h. The lack of conversion for substrates 
126b-e is most likely due to tetrasubstituted enones being less reactive than 126a, 
as well as steric clash from the alkyl substituent with the organocatalyst, hindering 
the formation of the product. Based on Ryan’s previous results106 in the absence of 
organocatalysts, we cannot rule out that the transamination is not taking place 
because the alkyl chain in the substrate is too bulky for the pocket of the enzyme.  
  




Table 6: Transamination of α-alkyl substituted keto-cyclohexenones 126b-e in the 
presence of organocatalysts L22.a  
 









after 48 h 
1.  129b 
 
256 (S) 0 0 
2.  129b 
 
- 0 4 
3.  129c 
 
256 (S) 0 0 
4.  129c 
 
- 0 0 
5.  129d 
 
256 (S) 0 0 
6.  129d 
 
- 0 0 
7.  129e 
 
256 (S) 0 0 
8.  129e 
 
- 0 0 
a Reaction conditions: ATA-256 (5 mg/ mL), 126b-e (50 mM), iPrNH2 
(2 eq), L22 (1.2 eq.) HEPES buffer (100 mM, pH 7.5), PLP (20 mM), 
180 rpm, 48 h. 
b Determined by GC-MS. 
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2.4  Conclusion and future work 
In conclusion, we have successfully synthesised keto-cyclohexenone substrates 
126a-e in an efficient manner over 3 steps. The optimisation of the transamination 
triggered IMAMR of 126a using organocatalysis was studied. (S)-(−)-α,α-2-
pyrrolidinemethanol (L22) was found to be the most successful organocatalyst, 
alongside DMSO as a co-solvent (20% [v/v]) and IPA (2eq.) as the amine donor, 
affording 129a in a 3:2 d.r. and in good isolated yield 76%. However, transamination 
of α,β-disubstituted keto-cyclohexenones 126b-e was unsuccessful as a result of the 
substrates being less reactive than 126a and possible steric interactions between 
substituents on the substrate and the organocatalyst. We believe that future 
attempts of transamination of keto-cyclohexenone substrates using organocatalysts 
should include TAs enzymes that have genetically engineered to withstand organic 
solvent such as those reported by Kroutil et al.76    




2.5  Experimental  
General methods and considerations.  
TLC: All thin layer chromatography (TLC) was run on Sigma Aldrich silica gel 60 F254 
aluminium plates and visualised by UV light and by either staining solutions KMnO4 
or phosphomolybdic acid. 
FT-IR: Spectra were recorded on a Nicolet® 380 Fourier Transform Infrared 
Spectrometer. Only the most significant frequencies have been reported (in cm-1) for 
characterisation.  
Flash Chromatography: Purification was carried out by either column 
chromatography using Geduran® Silica gel 60 or by Biotage® IsoleraTM Systems. The 
eluents used are mentioned below.  
NMR: 1H-NMR, 13C-NMR, and 31P-NMR spectra were recorded on a JEOL® ECS-400 
NMR spectrometer (400, 100.6 and 162 MHz, respectively) using CDCl3 as solvent. 
The chemical shifts values are recorded in ppm with the residual CDCl3 referenced to 
7.26 and 77.00 for 1H NMR and 13C NMR respectively. Data is reported as follows: 
chemical shift, multiplicity (singlet = s, doublet= d, triplet= t, quartet= q, multiplet= 
m), coupling constants (J) in Hz and integration.  
GC-MS: Conversion and low resolution mass spectra were recorded on either Agilent 
6850 Series connected to an Agilent 5973 mass selective detector using a HP-5ms (30 
m x 0.25 mm x 0.25 μm) or on an Agilent Technologies® 7890B GC connected to an 
Agilent Technologies® 5977b MSD using a HP-5MS (30 m x 0.25 mm x 0.25 μm). 
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Helium was used as the carrier gas at 10 psi, and the samples were ionised by an 
electronic impact (EI) source at 70 ev.  
HPLC-DAD: Attempts to determine the enantioselectivity were carried out on an 
Agilent 1100 series HPLC equipped with a G1313B diode array detector and a G1311A 
Quat pump. Chiral columns used for analysis were Lux 5µ Cellulose-1 and Lux 5µ 
Amylose-2 (Phenomenex®, 250 mm x 4.6 mm). ATA-256 enzymes, respectively.  
HRMS: High resolution mass spectra were obtained on a 6540 LC-QToF spectrometer 
and the samples were ionised ESI techniques and introduced through a high pressure 
liquid chromatography (HPLC) model Agilent Technologies® 1260 Infinity Quaternary 
LC system. 
MW: Irradiated reactions were carried out on an Anton Paar® Monowave 300 
Microwave Synthesis Reactor, using 10 or 30 mL glass vials (sealed with a PTFE-
coated silicone septum and closed with a snap cap made of PEEK). 
Optical rotations: All optical rotation measurements were performed on Bellingham 
+ Stanley® ADP220 Polarimeter with a 0.5 cm cell (c given in g/100 mL) using DCM as 
a solvent.  
Materials: All commercially available reagents were purchased from Acros, Alfa 
Aesar, Manchester Organics, Fisher, Fluorochem and Sigma-Aldrich and were used 
without further purification unless stated otherwise. Anhydrous, THF, DCMS, Et2O 
and toluene were obtained from Pure SolvTM Solvent Purification Systems. All 
commercially available transaminase enzymes, ATA-256 and ATA-025, were 
purchased in the form of lyophilised cell extract from Codexis.  
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Glassware: All reactions which required inert conditions, the glassware was flame 
dried under vacuum and argon was used for the inert gas.  
General procedure for the synthesis of 3-(4-pentenyl)-2-cyclohexen-1-one and 2-
methyl-3-(pent-4-en-1-yl)cyclohex-2-en-1-one (124 and 125b):  
A solution of Grignard reagent 123, prepared from 5-bromo-1-pentene (1.3 eq, 3.08 
mL, 26 mmol) and magnesium turnings (1.2 eq, 564 mg, 24 mmol) in diethyl ether 
(25 mL), was added to the corresponding cyclohexenones 122 or 128 (1 eq, 20 mmol) 
in diethyl ether (20 mL) at room temperature for 30 min. After the addition, the 
reaction mixture was stirred at RT for 1 h and then quenched with sat. NH4Cl solution 
(50 mL). The aqueous mixture was extracted with EtOAc (3 × 20 mL) and the 
combined organic layers were washed with aqueous HCl (2M, 20 mL). The organic 
layer was then washed with brine (2 × 50 mL), dried over MgSO4 and concentrated 
under reduced pressure. The crude material was purified by flash silica gel 
chromatography (EtOAc / cyclohexane, 1:9). 
 
3-(4-pentenyl)-2-cyclohexen-1-one (124): Compound 124 
was synthesised using the general procedure for the 
synthesis of 124 and 125b from 3-ethoxy-2-cyclohexenone 
(122, 2.81 g, 20 mmol) to give the named compound as a yellow oil. Yield: 2.27 g, 
69%. RF: 0.20 (EtOAc / cyclohexane, 1:9). FTIR (neat) Vmax: 2931, 2867, 1666, 1624, 
1251, 1191, 910, 888 cm-1. 1H NMR (400 MHz, CDCl3) δ: 5.86 (s, 1H), 5.82 – 5.70 (m, 
1H), 5.05 – 4.90 (m, 2H), 2.34 (t, J = 6.6 Hz, 2H), 2.26 (t, J = 6.0 Hz, 2H), 2.23 – 2.15 
(m, 2H), 2.06 (q, J = 7.0 Hz, 2H), 2.01 – 1.92 (m, 2H), 1.64 – 1.53 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ: 200.2, 166.5, 138.0, 125.9, 115.4, 37.5, 33.3, 29.8, 26.1, 22.8. 
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HRMS (m/z): Calculated C11H17O [M+H]+: 165.1274, found: 165.1279. Data in 
accordance with literature.100  
2-methyl-3-(pent-4-en-1-yl)cyclohex-2-en-1-one (125b): 
Compound 125b was synthesised using the general 
procedure for the synthesis of 124 and 125b from 2-methyl-
3-ethoxy-2-cyclohexenone (128, 643 mg, 4.17 mmol) to give the named compound 
as a yellow oil. Yield: 446 mg, 60%. RF: 0.48 (EtOAc / cyclohexane, 3:7) FTIR (neat) 
Vmax: 2954, 1634, 1605, 1383, 1353, 1233, 1201, 1121, 1097, 1050, 934, 919 cm-1. 1H 
NMR (400 MHz, CDCl3) δ: 5.86 – 5.74 (m, 1H), 5.08 – 4.95 (m, 2H), 2.38 (t, J = 4 Hz, 
2H), 2.35 – 2.29 (m, 2H), 2.28 – 2.19 (m, 2H), 2.13 – 2.05 (m, 2H), 1.95 – 1.88 (m, 2H), 
1.76 (s, 3H), 1.59 – 1.49 (m, 2H). 13C NMR (101 MHz, CDCl3) δ: 199.8, 159.0, 138.1, 
131.1, 115.3, 37.9, 34.9, 33.9, 31.0, 26.8, 22.8, 10.8. HRMS (m/z): Calculated C12H19O 
[M+H]+: 179.1236, found: 179.1325. Data in accordance with literature.107  
General procedure for the alkylation of 3-(4-pentenyl)-2-cyclohexen-1-one (125c-
e):  
t-BuOK (1.5 eq, 1.44 g, 12.8 mmol) was added to 3-(4-pentenyl)-2-cyclohexen-1-one 
(124, 1 eq, 1.39 g, 8.4 mmol) in dry Et2O (34 mL) and the mixture was left to stir at RT 
for 15 min. The appropriate alkyl halide (1.2 eq, 10.2 mmol) was then added dropwise 
to the reaction and left to stir for 1 h at RT. The reaction mixture was quenched with 
sat. NH4Cl solution (50 mL) and the mixture was extracted with EtOAc (3 × 20 mL). 
The organic layer was then washed with brine (2 × 50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The crude material was purified by flash silica 
gel chromatography (EtOAc 1:9 cyclohexane) to provide 125c-e. 




Compound 125c was synthesised using the general procedure 
for the alkylation of 3-(4-pentenyl)-2-cyclohexen-1-one, using 
bromoethane (1.2 eq, 0.39 mL, 5.16 mmol) as the corresponding alkyl halide to give 
the named compound as a yellow oil. Yield: 287 mg, 35%. RF: 0.64 (EtOAc / 
cyclohexane, 3:7). FTIR (neat) Vmax: 2954, 2930, 2868, 1706, 1641, 1620, 1456, 1431, 
1363, 1350, 1188, 991, 909 cm-1. 1H NMR (400 MHz, CDCl3) δ: 5.87 – 5.74 (m, 1H), 
5.07 – 4.96 (m, 2H), 2.37 – 2.21 (m, 8H), 2.10 (q, J = 6.8 Hz, 2H), 1.95 – 1.85 (m, 2H), 
1.61 – 1.51 (m, 2H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 198.9, 158.4, 
137.9, 136.9, 115.1, 38.0, 34.2, 33.8, 30.5, 27.2, 22.5, 18.2, 14.1. Data in accordance 
with literature.106  
2-propyl-3-(4-pentenyl)-2-cyclohexen-1-one (125d): 
Compound 125d was synthesised using the general 
procedure for the alkylation of 3-(4-pentenyl)-2-cyclohexen-
1-one using 1-bromopropane (1.2 eq, 0.33 mL, 3.7 mmol) as the corresponding alkyl 
halide to give the named compound as a yellow oil. Yield: 239 mg, 38%. RF: 0.68 
(EtOAc / cyclohexane, 3:7). FTIR (neat) Vmax: 2956, 2929, 2868, 1704, 1662, 1641, 
1619, 1456, 1431, 1417, 1327, 1108, 991, 909 cm-1. 1H NMR (400 MHz, CDCl3) δ: 5.88 
– 5.73 (m, 1H), 5.09 – 4.96 (m, 2H), 2.37 (t, J = 4.0 Hz, 2H), 2.32 (t, J = 6.0 Hz, 2H), 2.28 
– 2.20 (m, 4H), 2.14 – 2.07 (m, 2H), 1.95 – 1.87 (m, 2H), 1.61 – 1.51 (m, 2H), 1.37 – 
1.26 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 199.5, 159.0, 138.2, 
135.8, 115.4, 38.3, 34.5, 34.0, 30.8, 27.4, 27.3, 23.1, 22.8, 14.5. HRMS (m/z): 
Calculated C14H23O [M+H]+: 207.1749, found: 207.1723. Data in accordance with 
literature.106  




Compound 125e was synthesised using the general procedure 
for the alkylation of 3-(4-pentenyl)-2-cyclohexen-1-one, using 
1-bromobutane (1.2 eq, 0.39 mL, 13.6 mmol) as the alkyl halide, to give the named 
compound as a yellow oil. Yield: 183 mg, 27%. RF: 0.7 (EtOAc / cyclohexane, 3:7). 
FTIR (neat) Vmax: 2953, 2929, 2861, 1705, 1662, 1620, 1456, 1431, 1530, 1326, 1187, 
1112, 991, 909 cm-1. 1H NMR (400 MHz, CDCl3) δ: δ 5.92 – 5.64 (m, 1H), 5.02 (m, 2H), 
2.37 –2.34 (m, 2H), 2.32 -2.29 (m, 2H), 2.26 – 2.22 (m, 2H), 2.13 – 2.08 (m, 2H), 1.94 
– 1.88 (m, 2H), 1.60 – 1.52 (m, 4H), 1.33-1.25 (m, 4H), 0.87 (t, J = 9.0 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ: 199.4, 158.7, 138.1, 135.9, 115.3, 38.2, 34.4, 33.9, 32.0, 30.7, 
27.3, 25.0, 23.1, 22.7, 14.1. HRMS (m/z): Calculated C15H25O [M+H]+: 221.1905, 
found: 221.1906. Data in accordance with literature.106  
 
General procedure for Wacker oxidation of intermediates 124 and 125b-e:  
To a solution of PdCl2 (10%, 50 mg, 0.60 mmol) and CuCl (2 eq, 12.0 mmol) in DMF 
(20 mL) and water (5 mL), that had been stirred under an O2 atmosphere for 1 h, a 
solution of 124 or 125c-e (1 eq, 6.00 mmol) in DMF (5 mL) was added drop wise and 
the reaction mixture was stirred at room temperature overnight. The reaction 
mixture was quenched with NH4Cl (20 mL) and ammonia hydroxide solution (1M, 10 
mL) and extracted with diethyl ether (3 x 40 mL). The combined organic extracts were 
then washed with brine (2 x 60 mL) and dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude material was purified by flash silica gel 
chromatography (EtOAc / cyclohexane 3:7) to provide compounds 126a-e. 
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3-(4-oxopentenyl)-2-cyclohexen-1-one (126a): Compound 
126a was synthesised from 124 (988 mg, 6.02 mmol) using 
the general procedure for Wacker oxidation of intermediates 
124 and 125b-e to give the named compound as a yellow oil. Yield: 1.03 g, 95%. RF: 
(EtOAc / cyclohexane, 1:1). FTIR (neat) Vmax: 2940, 2889, 1712, 1668, 1623, 1455, 
1428, 1348, 1252, 1181, 1159, 966, 887, 757, 499, 487 cm-1. 1H NMR (400 MHz, 
CDCl3) δ: 5.75 (s, 1H), 2.38 (t, J = 7.2 Hz, 2H), 2.25 (t, J = 8.0 Hz, 2H), 2.20 (t, J = 5.9 Hz, 
2H), 2.12 (t, J = 7.6 Hz, 2H), 2.04 (s, 3H), 1.93 – 1.84 (m, 2H), 1.74 – 1.62 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ: 208.1, 199.9, 165.6, 126.1, 42.7, 37.4, 37.3, 30.2, 29.6, 22.7, 
20.7. HRMS (m/z): Calculated C11H17O2 [M+H]+: 181.1223, found: 181.1223. Data in 
accordance with literature.100  
 
2-methyl-3-(4-oxopentenyl)-2-cyclohexen-1-one (126b): 
Compound 126b was synthesised from 125b (227 mg, 1.28 
mmol) using the general procedure for the general procedure 
for Wacker oxidation of intermediates 124 and 125b-e to give the named compound 
as a yellow oil. Yield: 198 mg, 80%. RF: (EtOAc / cyclohexane, 1:1). FTIR (neat) Vmax: 
2935, 2869, 1713, 1658, 1430, 1355, 1170, 1085.  1H NMR (400 MHz, CDCl3) δ: 2.46 
(t, J = 7.2 Hz, 2H), 2.37 (t, J = 8.0 Hz, 2H), 2.35 – 2.29 (m, 2H), 2.26 – 2.19 (m, 2H), 2.14 
(s, 3H), 1.96 – 1.86 (m, 2H), 1.77 – 1.67 (m with a s at 1.75, 5H). 13C NMR (101 MHz, 
CDCl3) δ: 208.2, 199.6, 158.1, 131.3, 43.0, 37.8, 34.5, 30.7, 30.1, 22.6, 21.3, 10.8. 
HRMS (m/z): Calculated C12H19O2 [M+H]+: 195.1385, found: 195.1371. . Data in 
accordance with literature.106  




Compound 126c was synthesised from 125c (240 mg, 1.25 
mmol) using the general procedure for the general procedure 
for Wacker oxidation of intermediates 124 and 125b-e to give the named compound 
as a yellow oil. Yield: 203 mg, 78%. RF: 0.57 (EtOAc 1:1 cyclohexane). FTIR (neat) 
Vmax: 2934, 2872, 1713, 1658, 1620, 1362, 1169, 1102 cm-1. 1H NMR (400 MHz, CDCl3) 
δ: 2.53 – 2.45 (m, 2H), 2.39 – 2.20 (m, 8H), 2.15 (s, 3H), 1.95 – 1.87 (m, 2H), 1.81 – 
1.69 (m, 2H), 0.97 – 0.88 (m, 3H). 13C NMR (101 MHz, CDCl3) δ: 208.3, 199.3, 157.6, 
138.0, 43.2, 38.2, 34.0, 30.5, 30.2, 22.7, 21.9, 18.5, 14.3. HRMS (m/z): Calculated 
C13H21O2 [M+H]+: 209.1536, found: 209.1534. Data in accordance with literature.106  
2-propyl-3-(4-oxopentenyl)-2-cyclohexen-1-one (126d): 
Compound 126d was synthesised from 125d (96 mg, 0.47 
mmol) using the general procedure for the general procedure 
for Wacker Oxidation of intermediates 124 and 125b-e to give the named compound 
as a yellow oil. Yield: 86 mg, 83%. RF: 0.35 (EtOAc / cyclohexane, 3:7). FTIR (neat) 
Vmax: 2957, 2932, 2870, 1714, 1659, 1456, 1430, 1365, 731 cm-1. 1H NMR (400 MHz, 
CDCl3) δ: 2.46 (t, J = 7.1 Hz, 2H), 2.39 – 2.26 (m, 4H), 2.26 – 2.17 (m, 4H), 2.13 (s, 3H), 
1.94 – 1.84 (m, 2H), 1.79 – 1.66 (m, 2H), 1.34 – 1.20 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz) δ: 208.2, 199.3, 158.0, 136.0, 43.2, 38.2, 34.1, 30.5, 30.1, 27.2, 
23.0, 22.6, 21.8, 14.4. HRMS (m/z): Calculated C14H23O2 [M+H]+: 223.1693, found: 
223.1699. Data in accordance with literature.106  




Compound 126e was synthesised from 125e (105 mg, 
0.48 mmol) using the general procedure for the general 
procedure for Wacker Oxidation of intermediates 124 and 125b-e to give the named 
compound as a yellow oil. Yield: 75 mg, 71%. RF: 0.38 (EtOAc / cyclohexane, 3:7). 
FTIR (neat) Vmax: 2954, 2931, 2870, 1714, 1659, 1620, 1456, 1430, 1364, 1170 cm-1. 
1H NMR (400 MHz, CDCl3) δ: 2.47 (t, J = 7.2 Hz, 2H), 2.38 – 2.28 (m, 4H), 2.26 – 2.19 
(m, 4H), 2.14 (s, 3H), 1.93 – 1.85 (m, 2H), 1.78 – 1.68 (m, 2H), 1.35 – 1.18 (m, 4H), 
0.87 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 208.2, 199.3, 157.7, 136.3, 43.2, 
38.2, 34.1, 32.1, 30.5, 30.2, 25.0, 23.1, 22.7, 21.8, 14.1. HRMS (m/z): Calculated 
C15H25O2 [M+H]+: 237.1849, found: 237.1844. Data in accordance with literature.106  
 
2-methyl-3-ethoxy-2-cyclohexenone (128): To a solution of 2-
methyl-1,3-cyclohexanedione (127, 2.60 g, 10.00 mmol) in 
toluene (20 mL) was added p-toluenesulfonic acid hydrate (49 mg, 
0.25 mmol) and ethanol (6 mL). The mixture was stirred under Dean Stark conditions 
with continuous removal of water formed. An extra portion (5-10 mL) of a mixture of 
ethanol/toluene (1:3) was added to the reaction mixture every hour. After 12 h, TLC 
analysis showed that the reaction was complete. The reaction was concentrated 
under reduced pressure and the residue was purified by flash chromatography 
(EtOAc / cyclohexane, 1:1), to give the named compound as a colourless oil. Yield: 
2.33 g, 73%. RF: 0.37 (EtOAc / cyclohexane 1:1). FTIR (neat) Vmax: 2955, 1634, 1605, 
1383, 1354, 1233, 1200, 1121, 1096 cm-1. 1H NMR (400 MHz, CDCl3) δ: 4.05 (q, J = 8.0 
Hz, 2H), 2.59 – 2.47 (m, 2H), 2.33 (t, J = 8.0 Hz, 2H), 2.03 – 1.90 (m, 2H), 1.69 (s, 3H), 
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1.34 (t, J = 7.0 Hz, 3H).13C NMR (101 MHz, CDCl3) δ: 199.1, 171.6, 115.2, 63.6, 36.4, 
25.5, 21.1, 15.5, 7.6. HRMS (m/z): Calculated C9H15O2 [M+H]+: 155.1072, found: 
155.1066. Data in accordance with literature.108  
General procedure A, for the transamination of ketoenones 126a-e in the presence 
of organocatalyst:  
Commercially available (S)-selective ATA-256 or (R)-selective ATA-025 (25 mg) was 
rehydrated in HEPES buffer (4.0 mL, 100 mM, pH 7.5) containing PLP (2.00 mM), 
isopropylamine (2 eq, 43 μL, 0.5 mmol) and the corresponding L21-30 organocatalyst 
(1.2 eq, 0.298 mmol). The pH of the mixture was adjusted to 7.5, using aq. HCl 
solution (1 M), and the total volume of the reaction was adjusted to 4.5 mL by 
addition of HEPES buffer. The ketoenone substrate 126a-e was added (50 mM, 0.5 
mL in DMSO) and the reaction mixture incubated at 30 oC, 180 rpm for 48-72 h. The 
reaction was monitored by GC-MS. After completion, the pH of the supernatant was 
adjusted to 12 using aq. NaOH solution (4 M) and the resulting mixture was extracted 
with EtOAc (3  10 mL). The combined organic extracts were washed with NaOH 
solution (1 M, 10 mL). The organic layer was then dried over Na2SO4 and 
concentrated under reduced pressure. The crude material was purified by flash 
chromatography. 
General procedure B, for the transamination of ketoenones 126a-e in the absence 
of organocatalysts: The general procedure A above was followed, omitting the 
addition of the organocatalyst. 
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General procedure C1, for the control experiments for the transamination of 
ketoenones 126a-e in the presence of organocatalysts: The general procedure A 
above was followed, omitting the addition of the enzyme. 
General procedure C2, for the control experiments for the transamination of 
ketoenones 126a-e in the absence of organocatalysts: The general procedure A 
above was followed, omitting the addition of both the enzyme and the 
organocatalyst. 
()-(2S)-2-methyl-1-azaspiro[5.5]undecan-8-one [()-129a)]: 
Compound 129a was synthesised from 126a (45 mg, 0.25 mmol) 
using general procedure A, with ATA-256 as the enzyme and L21 
as organocatalyst, to give the named compound as pale yellow oil. Unseparable 
mixture of diastereomers, d.r. 3:2 (determined GC-MS). Yield: 34 mg, 76% RF: 0.13 
(MeOH CH2Cl2, 1:1). [α]D23 = – 103.5 (c 0.85, CHCl3). 1H NMR: (400 MHz, CDCl3) δ: 
2.90 – 2.78 (m, 1H, diastereomer 1), 2.78 – 2.65 (m, 1H, diastereomer 2), 2.53 (br s, 
2H), 2.30 – 1.98 (m, 8H), 1.95 – 1.48 (m, 16H), 1.19 – 1.05 (m, 2H), 0.96 (d, J = 7.3 Hz, 
3H, diastereomer 1), 0.94 (d, J = 7.3 Hz, 3H, diastereomer 2), 0.91 – 0.78 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ: 211.1, 57.2, 56.9, 56.9, 48.4, 45.8, 45.6, 41.3, 41.1, 40.1, 
35.9, 35.4, 34.6, 34.5, 30.1, 23.2, 21.0, 20.8, 20.7, 20.2 HRMS (m/z): Calculated 
C11H20NO [M+H]+: 182.1525, found: 182.1538. Data in accordance with literature.106  
(+)-(2R)-2-methyl-1-azaspiro[5.5]undecan-8-one [(+)-
129a)]:Compound 129a was synthesised from 126a (45 mg, 0.25 
mmol) using general procedure A, using ATA-025 as enzyme and 
L21 as organocatalyst, to give the named compound as pale yellow oil. d.r. 1:1. 
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(determined GC-MS). Yield: 32 mg, 32% RF: 0.13 (MeOH 1:1 CH2Cl2). [α]D26 = + 23.3 
(c 1.2, CHCl3) Data in accordance with literature.106 











3. Tandem biocatalysed transamination- vinylogous aza-Michael 












The vinylogous Michael reaction is a 1,6-conjugate addition where the nucleophilic 
attack occurs at the δ position in the α,β,γ,δ-bisunsaturated system (Scheme 35).109 
Whilst asymmetric nucleophilic 1,2- and 1,4-additions have been extensively 
studied,110 research on the asymmetric 1,6-addition is somewhat limited, as the 
regio- and stereocontrolled addition is more challenging. This is a consequence of the 
lower reactivity of α,β,γ,δ-bisunsaturated system. The longer distance between the 
electron with drawing group (EWG) and the reactive site (δ position) results is less 
stereo- and regio- control.111 Regioselectivity issues also arise from competition with 
the other reactivity sites (the β-position and the carbon of the carbonyl), leading to 
a number of regioisomeric by-products (Scheme 35). In fact, Hayashi reported that 
for organocatalytic additions to α,β,γ,δ-bisunsaturated carbonyls, 1,2- and 1,4-
additions are actually favoured over the 1,6-addition.112 
 
 
Scheme 35: Vinylogous Michael reaction with 1,2- and 1,4-addition by-products.  
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Over the past decade, there has been an increase in research into the asymmetric 
vinylogous Michael reaction. However, most examples in this area use carbon and 
oxygen as nucleophiles, with very few examples of the use of nitrogen nucleophiles, 
and most of them of non-asymmetric.  
The first organocatalytic enantioselective 1,6-addition of β-ketoesters and glycine 
imine derivatives using carbon nucleophiles, was reported by Jørgensen (Scheme 
36).109 Under phase-transfer conditions, using the Cinchona derived catalyst L31, the 
1,6-addition reaction of the β-ketoesters 130 to the different ketones, esters and 
sulfones acceptors 131 proceeds with high yield and ee’s of 80-90%. The group also 
reported that treatment of 132 (EWG =CO2Et) with 1,8-diazabicyclo[5,4.0]undec-7-
ene (DBU) in THF promoted isomerisation of the double bond, resulting in a 
spontaneous IMAMR to afford 133 as a single isomer and no change in the 
enantioselectivity. The conjugate addition with benzophenone imine derivatives 134 
to the unsubstituted dienes 135 also affords the desired products 136 with high 
enantioselectivity and moderate-high yields using L32 (Scheme 36). 
 





Scheme 36: Organocatalytic 1,6-addition of β-ketoeters and benzophenone imines 
to unsubstituted dienes by Jørgensen. 
 
There are a number of asymmetric 1,6-additions reactions using carbon nucleophiles 
that have been reported, including the work of Jørgensen,113 Melchiorre,114 and 
Ye,115, 116 using a variety of substrates such as dienals and dienones. The use of 
oxygen nucleophiles in asymmetric 1,6-addition reactions has also been reported in 
the literature by Jørgensen,117 Enders118 and Hong.119 For example, Hong et al. 
reported a organocatalytic intramolecular oxa-1,6-addition of a 2,4-dienal as part of 
the total synthesis of (+)-dactylolide (Scheme 37). Melchiorre and co-workers have 
also reported the use of thiols as nucleophiles for the asymmetric 1,6-addition of 
alkyl thiols to cyclic dienones.120  





Scheme 37: Organocatalytic intramolecular oxa-1,6- addition of a 2,4-dienal 
reported by Hong et al. 
Nitrogen-centered nucleophiles have not been a popular choice for 1,6-addition 
reactions, with few examples known, even for non-asymmetric variants of the 
reaction. Blay et al. described an intermolecular enantioselective aza-1,6-addition 
using a bifunctional thiourea-Brønsted base L33 as catalyst for the synthesis of 
isoxazolin-5-ones 139 (Scheme 38).111 They were the first to report the use of 
isoxazolinones N-nucleophiles 138 for the addition to p-quinone methides 137. p-
Quinone methides have a cyclic bis-vinylogous framework, and the aromatisation in 
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the final product (139) facilitates the 1,6-addition. The desired product 139 is 
achieved with moderate to good yields and with high ee.  
 
Scheme 38: Organocatalytic enantioselective aza-1,6-addition of isoxazolin-5-ones 
138 to p-quinone methides 137 by Blay et al. 
 
There are very few examples intramolecular vinylogous aza-Michael reactions 
(IVAMR) in the literature. Silva and co-workers reported the use of a IVAMR in the 
synthesis of the chromenopyridodiazepinone polyheterocycle 147 (Scheme 39).121 
The one-pot reaction proceeds initially with a intramolecular aza-1,4-addition to 
provide intermediate 145, which undergoes an spontaneous aza-1,6-addition 
reaction to generate intermediate 146. A subsequent imine condensation generates 
the diazepines 147. The reaction, performed at room temperature in THF, provides 
the desired polyheterocyclic products 147 in moderate-good yields 52-73%.  






Scheme 39: Tandem reaction for the synthesis of chromenopyridodiazepinone 
polyheterocycles by Silva and co-workers. 





3.2 Aims and Objectives  
As discussed in section 1.1 of this thesis, alkaloids are vitally important molecules in 
medicinal chemistry and more efficient and stereoselective routes towards these 
diverse compounds is a constant need. In particular, a large number of these alkaloids 
contain a 2,6-disubstitued piperidine motif and have become a specific target as a 
result of their strong pharmacological properties (Figure 5).122   
 
 
Figure 5: Examples of alkaloids that contain a 2,6-disubstituted piperidine motif. 
 
Being aware of the potential of the biocatalytic IMAMR methodology that has been 
previously developed by our group,70 herein, we propose to expand our work to 
develop a biocatalysed intramolecular vinylogous aza-Michael reaction (IVAMR, 
Scheme 40). This reaction would be synthetically relevant since, as to the best of our 
knowledge, the enantioselective vinylogous aza-Michael reaction is not even known 
under classical conditions (metal catalysis or organocatalysis). Moreover, this 
strategy would provide access to piperidines/pyrrolidines with side chains that would 
be readily suitable for further functionalisation (e.g.hydrogenation and imine/lactam 
  CHAPTER 3 
96 
 
formation to provide bicyclic quinolizidines and indolizidines). Both these scaffolds 
are seen in a plethora of bioactive (often neuroactive) compounds.123-125 To achieve 
this, the aims of this chapter will be as follows: 
(i) synthesise keto-α,β,,δ-unsaturated substrates with a range of 
electron withdrawing functionalities.  
(ii) Transamination of the vinylogous precursors using ready available 
ω-TA enzymes with full characterisation. 
 
Scheme 40: Proposed intramolecular vinylogous aza-Michael reaction promoted by 
a biocatalysed transamination reaction 
  CHAPTER 3 
97  
 
3.3 Results and Discussion 
3.3.1 Synthesis of ketodienones 156a-b and ketodieno esters 162a-b. 
The synthesis of the desired substrates 156a-b to study the intramolecular vinylogous 
aza-Michael reaction (IVAMR) started with a Lemieux-Johnson oxidation of 1-methyl-
cyclopetene (151) using osmium tetroxide in catalytic amounts and N-
methylmorpholine N-oxide (NMO) as the re-oxidant. This reaction afforded the 
desired aldehyde 152 with a good yield of 79% with no purification needed (Scheme 
41, Route 1). However, with the desire to utilise a more sustainable oxidation, and 
avoid the expensive and toxic OsO4, we also performed the oxidative ring opening of 
151 using ozone. Thus, the ozonolysis reaction of 151, using the conditions reported 
by Lee and co-workers,126 provided 5-oxohexanal (152) in a moderate yield of 56% 
(Scheme 41, Route 2). Although the yield of the ozonolysis reaction was lower than 
that of the Lemieux-Johnson oxidation, the reaction is easier, cheaper, safer (if kept 
inside a fume cupboard) and can be readily scaled up, making it the preferred 
methodology for the synthesis of 152. Next, the Wittig olefination of 152 using ylid 
153 was explored. Under classical reflux conditions in dichloromethane, 154 was 
obtained in 28% isolated yield 48 h. However, we found that under microwave 
irradiation, the reaction proceeded at a higher rate, reaching completion after 4 h 
and providing 154 in 49% isolated yield.  




Scheme 41: STEP 1: Synthesis of 5-oxohexanal (152) via Lemieux-Johnson oxidation 
(route 1) and ozonolysis reaction (route 2). STEP 2: Synthesis of 154 via Wittig 
reaction under reflux (route 1) and MW irradiation (route 2). 
 
The synthesis of the methyl ketodienone 156a was then achieved by a second Wittig 
reaction on the intermediate 154, under microwave irradiation, using the ylide 155a. 
The isolated yield for 156a was low (28%), due to the complexity of the purification 
step (Table 7, entry 1). The enone 156a’ was identified as a side product (19%) in the 
microwave assisted reaction(Table 7, entry 1). We believe that 156a’ is formed via a 
retro-aldol reaction from 154. Separation of 156a and 156a’ by column 
chromatography proved challenging, as both compounds have very similar RF values. 
Fortunately, when the reaction was performed in a pressure tube, with 
dichloromethane at 90 °C (Table 7, entry 2), full conversion to the desired 156a was 
achieved after 48 h, and the formation of the retro aldol product 156a’ was not 
observed under these conditions (Table 7, entry 2).  
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Table 7 Synthesis of ketodienone substrates 156a and 156b.a,b  
 
Entry Product Method Conv. to desired 
product 156a-b 
(%)c 
Conv. to retro 
aldol product 




1 156a Microwavea 81 19 28 
2 156a Pressure 
tubeb 
>99e 0 37 
3 156b Microwavea 75 25 23 
4 156b Pressure 
tubeb 
>99e 0 40 
a Reaction conditions: 154 (0.2 mmol), 155a or 155b (0.4 mmol), DCM (1 mL), MW 120 °C, 4 h. 
b Reaction conditions: 154 (0.2 mmol), 155a or 155b (0.4 mmol), DCM (1 mL), pressure tube, 90 
°C, 48 h. 
c Determined by GC-MS. 
d Isolated yield after flash chromatography. 
e Determined by 1H NMR. 
 
The synthesis of the phenyl ketone 156b was also achieved using the same strategy, 
by Wittig reaction of 154 and ylide 155b. When the reaction was performed under 
microwave irradiation, both the desired product 156b and the side product 156b’ 
could be seen in the crude product in a ratio of 75:25, respectively (Table 7, entry 4). 
All the attempts to separate 156b and 156b’ by column chromatography were 
unsuccessful. After 3 chromatography columns and a crude yield of 23%, the product 
was still not pure. Conversely, when the Wittig reaction of 154 with the ylide 155b 
was performed in a pressure tube with DCM at 90 °C for 48 h, full conversion to the 
desired product 156b was obtained with a moderate yield of 40% (after purification 
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by column chromatography), without any formation of the undesired 156b’. In 
summary, the Wittig olefination by means of heating the reaction in a pressure tube 
was a much more effective methodology, as no retro-aldol side products 156a’-b’ 
were observed making purification much easier and thus providing a higher yield.   
As the Wittig olefination reactions of intermediate 154 proceeded with a somewhat 
low yield, we decided to explore an alternative synthetic route to our target 
substrates 156a-b, performing a Horner-Wadsworth-Emmons reaction (HWE) 
between the aldehyde 152 and the phosphonate 160 (Scheme in Table 8). The 
preparation of phosphonate 160 was achieved by means of an Arbuzov reaction with 
allyl bromide (157) and triethylphosphite at 140 °C, which provided the desired 
diethyl allylphosphonate (158) in 61% yield.127 A subsequent cross metathesis (CM) 
reaction with 159 using Grubbs 1st generation catalyst (L34) afforded 160 in a 
moderate yield of 68% (Scheme 42).  
Unfortunately, the HWE reaction of 160 and 152, using sodium hydride as the base 
for the deprotonation of the phosphonate proved unsuccessful (Table 8, entry 1) and 
only starting material was observed in the crude reaction mixture. We then tried 
lithium diispropylamide (LDA) as the base, which also did not provide the desired 
product, and only the starting materials 152 and 160 could be seen in the crude 1H 
NMR (Table 8, entry 2). We then attempted the deprotonation of 160 with nBuLi, 
using HMPA and HDMS as additives, neither of which was successful (Table 8, entries 
3 and 4). As a result of the unsuccessful HWE reaction, this synthetic route was not 
viable and we decided to pursue the original route using the original Wittig 
olefination (Scheme in Table 7) even despite the low yields.  





Scheme 42: Synthesis of phosphonate 160. 
 
Table 8: Study of HWE reaction as an alternative synthesis for ketodienone 156aa 
 
 






1 NaH (1) ‐ 0 0 
2 LDA (1) ‐ —40 0 
3 nBuLi (1) HMPA (1) —78 0 
4 nBuLi (1) HMDS (1) —78 0 
a Reaction conditions: (i) 160 (0.45 mmol), base (1 eq, 0.45 mmol), THF (5 mL), 0.5 h. 
(ii) 152 (0.45 mmol), THF (4 mL) 
b Determined by GC-MS 
 
 
Next, we applied a HWE reaction to synthesise the ketodieno esters 162a and 162b. 
Substrate 162a was prepared using a methodology reported by Hong and co-
workers126 via HWE reaction of 152 with commercially available phosphonate 161, 
using LDA in THF at – 40 °C for the deprotonation step. Gratifyingly, the reaction was 
successful affording 162a in 78% yield. The synthesis of substrate 162b was 
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performed by the oxidative cleavage of commercially available 5-hexen-2-one (163) 
to afford 4-oxopentanal (164) in good yield, followed by a HWE reaction using 




Scheme 43: Synthesis of ketodieno esters 162a-b. 
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3.3.2 Transamination of substrates 156a-b, and 162a-b.  
We began our investigation on the biocatalyst-promoted aza-1,6-addition reaction 
using commercially available ATA-256, with 2 equivalents of IPA as the amine donor 
and DMSO (10% [v/v]) as the organic solvent, as those were the optimal conditions 
found for the synthesis of 2,6-disubstituted piperidines from ketoenone substrate 
112 (Scheme 29).70 Firstly, we attempted the transamination of the methyl 
ketodienone substrate 156a at 30 °C in DMSO (10% [v/v], Table 9, entry 1). 
Unfortunately, we saw no conversion to the desired 165a. Instead, we observed 
decomposition of the starting material 156a, which could no longer be detected via 
GC-MS or in the crude 1H-NMR spectrum. The decomposition of 156a was also 
observed in the control experiment (in the absence of the enzyme) carried out under 
the same conditions (Table 9, entry 2). We believe that the decomposition could be 
taking place via retro-aldol reactions, although possible products of the retro-aldol 
reactions, such as the aldehyde 152, were not observed by GC-MS or by 1H-NMR 
analysis of the reaction crude. With the aim to increase the reaction rate of the TA 
step and thus avoid the decomposition of 156a, we increased the temperature of the 
ATA-256 biocatalysed reaction to 50 °C (Table 9, entry 3), but the outcome of the 
experiment did not change and decomposition of the starting material 156a still took 
place. Similarly, when MeOH (10% [v/v]) was used as a co-solvent instead of DMSO 
decomposition also occurred (Scheme 8, entry 5).  
Next, we attempted the reaction with the phenyl ketodienone substrate 156b in the 
hope that the substrate would be more stable with a bigger functional group and 
would not decompose. However, using ATA-256 and 2 eq of iPrNH2, with 10% [v/v] 
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DMSO, no transamination took place and again decomposition occurred at 30 and 50 
°C, and when MeOH (10% [v/v]) was used as a co-solvent in place of DMSO (Table 9, 
entries 7, 9 and 11). The control reactions (with no enzyme present) for the phenyl 
substrate 156b also yielded no conversion to the desired amine at either 30 or 50 °C, 
and, as expected, all also resulted in decomposition of the starting material (Table 9, 
entries 8, 10 and 12).  


















after 48 h 
1.  256 (S) 156a DMSO  30 0c 0c 
2.   156a DMSO  30 0c 0c 
3.  256 (S) 156a DMSO  50 0c 0c 
4.   156a DMSO  50 0c 0c 
5.  256 (S) 156a MeOH 30 0c 0c 
6.   156a MeOH 30 0c 0c 
7.  256 (S) 156b DMSO  30 0c 0c 
8.   156b DMSO  30 0c 0c 
9.  256 (S) 156b DMSO  50 0c 0c 
10.   156b DMSO  50 0c 0c 
11.  256 (S) 156b MeOH 30 0c 0c 
12.   156b MeOH 30 0c 0c 
a Reaction conditions: ω-TA ATA-256 (5 mg/ mL), 156a or 156b (50 mM), amine donor (2 eq), 
HEPES buffer (100 mM, pH 7.5), PLP (20 mM), Solvent (10% [v/v]), 180 rpm, 48 h. 
b
Determined by GC-MS. 
c Complete decomposition of the starting material 156 was observed. 
 
Following this, we began a small optimisation of the amine donor with the hope that 
it would drive the equilibrium towards the desired 165a-b at an increased reaction 
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rate preventing decomposition of 156a-b (Table 10). We began by increasing the 
amount of IPA (A1) to 4 eq. (instead of 2 eq.), unfortunately no conversion to either 
of the desired products 165a-b was observed (Table 10, entries 1 and 3). During the 
investigation for the transamination of keto-cyclohexenone substrates, discussed in 
section 2.3.2, we found that the use of MBA (A4) as an amine donor had a faster 
reaction rate than IPA (A1, Table 5, entry 10). However, when these conditions were 
applied to the biocatalysed transamination of substrates 156a-b, no conversion was 
observed to 165a-b and decomposition of the starting material took place. It is also 
worth noting that in all the control reactions, in the absence of enzyme, the 
decomposition of substrates 156a-b was also observed (Table 10, entries 2, 4, 6 and 
8).  
  










Conv to 165 
(%)
b  
after 24 h 




after 48 h 
1.  256 (S) 156a A1 (4) 0c 0c 
2.  ‐ 156a A1 (4) 0c 0c 
3.  256 (S) 156b A1 (4) 0c 0c 
4.  ‐ 156b A1 (4) 0c 0c 
5.  256 (S) 156a A4 (2) 0c 0c 
6.  ‐ 156a A4 (2) 0c 0c 
7.  256 (S) 156b A4 (2) 0c 0c 
8.  ‐ 156b A4 (2) 0c 0c 
a Reaction conditions: ATA-256 (5 mg/ mL), 156a or 156b (50 mM), amine donor (x eq), HEPES 
buffer (100 mM, pH 7.5), PLP (20 mM), DMSO (10% (v/v)), 180 rpm, 48 h. 
b
Determined by GC-MS. 
c Complete decomposition of the starting material was observed. 
 
 
As neither of the ketodienone substrates 156a-b yielded the desired products 165a-
b, we moved onto the transamination of the ketodieno ester substrate 162a. The 
transamination of 162a with ATA-256 at 30 °C provided 166a in 48% conversion 
(determined by GC-MS) after 48 h (Table 11, entry 1). The crude 1H-NMR spectrum 
revealed that the product was obtained as a mixture of isomers: cis-166a, trans-166a 
and cis-166a-I in a ratio of 1:0.3:0.1. At 38 °C, the reaction proceeded with 61% 
conversion after 48 h and only cis-166a was observed.(Table 11, entry 4). Increasing 
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the temperature to 50 °C, which is the maximum temperature the enzyme could 
withstand, the reaction proceeded with full conversion to the desired product 166a 
after 48 h (Table 11, entry 5) in a 3:2.5:1 (cis-166a, trans-166a and cis-166a-I) ). When 
EtOH was used as the co-solvent in the reaction (10% [v/v]), the conversion, at 50 oC, 
after 48 h dropped to 67% (Table 9, entry 7). All the control reactions in the absence 
of enzyme were performed, and no transamination reaction was observed in any 
case. (Table 11, entries 2, 4, 6 and 8). 
  






















1  256 (S) DMSO 30 40 1 : 0.3 : 0.1 
2  ‐ DMSO 30 ‐ ‐ 
3  256 (S) DMSO 37 61 1 : 0 : 0 
4  ‐ DMSO 37 ‐ ‐ 
5  256 (S) DMSO 50 >99 3 : 2.5 : 1  
6  ‐ DMSO 50 ‐ ‐ 
7  256 (S) EtOH 50 67  2 : 1.5 : 1  
8  ‐ EtOH 50 ‐ ‐ 
a Reaction conditions: ATA-256 (5 mg/ mL), 162a (50 mM), iPrNH2 (2 eq.), HEPES buffer 
(100 mM, pH 7.5), PLP (20 mM), solvent (10% [v/v]), 180 rpm, 48 h. 
bDetermined by GC-MS. 
cDetermined by 1H NMR on the reaction crude.
 
 
The standard work up after a biocatalysed transamination reaction usually consists 
of 3 steps: (1) adjusting the pH of the reaction to 12 using NaOH (5M); (2) carrying 
out an extraction using ethyl acetate (3 x EtOAc); and (3) washing the combined 
organic layers with 2 M NaOH (Figure 6, work-up 1 and experimental section for 
further details).70 Although the conversion of the reaction at 50 °C (Table 11, entry 
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5), determined by GC-MS and 1H-NMR, was <99%, the isolation of 166a was 
unsuccessful after a standard work-up (Figure 6, work-up 1).  
Therefore, we began optimisation of the work-up of the transamination reaction. 
Performing the first 2 steps of the standard work-up process and replacing the final 
step (washing the organic layer with 2 M NaOH) with passing the crude sample 
through a quick silica plug (using acetone as eluent), provided 23 mg of crude 
material (note that 52 mg of 166a corresponds to 100% theoretical yield), with a large 
amount of DMSO present, indicating 1% yield for 166a (determined by 1H NMR 
spectroscopy) (Figure 6, work-up 2). 
An alternative work-up for biocatalysed reactions, reported by Kroutil and co-
workers,128 involves preliminary removal of the enzyme via filtration using a HPLC 
filter. Our first attempt using this methodology consisted of filtration of the reaction 
mixture using a 0.2 μL HPLC filter, having previously adjusted the pH of the reaction 
mixture to 12 using 6 M NaOH. A subsequent extraction of the filtrate with EtOAc did 
not provide any crude product 166a (Figure 6, work-up 3).  





Increasing the rotational speed to 14,000 rpm (opposed to 6000 rpm) when 
extracting the supernatant, whilst using the traditional biocatalysis work-up showed 
a negligible improvement in yield (4%, determined by 1H NMR on the crude reaction) 
of the desired 166a (Figure 7, work-up 4). Passing the reaction solution through a 0.2 
μL HPLC filter, followed by extraction of the supernatant with EtOAc in a centrifuge 
apparatus at 14,000 rpm, without performing a basic wash, increased the yield to 6% 
(Figure 7, work-up 5). 
Basify til pH=12 with 6 M NaOH 
Centrifuge 6000 rpm 
Extract supernatant with 
EtOAc  
In centrifuge 6000 rpm 
Wash organic layer  
with 2 M NaOH 

















Centrifuge 6000 rpm 









with EtOAc in 




0.2 m Filtration  
Figure 6: Optimisation of work up for the transamination of 162a based on 
traditional biocatalysis work-ups. 




Figure 7: Optimisation of work up for the transamination of 162a using a centrifuge 
apparatus at 14,000 rpm.  
 
We believe that a likely cause for the low yields for the isolation of 166a are a result 
of our product being water-soluble. In an attempt to overcome this problem, we 
investigated basifying the reaction mixture using solid sodium bicarbonate instead of 
aqueous NaOH (2 M) (Figure 8). Work-up 6 (basify with solid NaCO3 till pH = 8, 
followed by extraction with EtOAc and two chromatography purification steps) 
showed an improved yield of 26% (determined by 1H NMR). Following a similar 
Centrifuge 14,000 rpm 
0.2 m Filtration of 
supernatant 
Extract supernatant with 








Extract supernatant with 
 EtOAc in centrifuge  
14,000 rpm 
Wash organic layer with 2M NaOH 
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approach, only basifying the reaction solution until the highest pH was reached (pH= 
8.6) and passing the reaction solution through a 0.2 μL HPLC filter slightly decreased 






Basify with solid NaHCO3  
until pH remained  
unchanged (pH=8.6) 
Extract supernatant with 
EtOAc in centrifuge 6000 rpm 
Dry with MgSO4 
evaporate solvent 
Column chromatography 







Extract supernatant with EtOAc 
In centrifuge 6000 rpm 





H‐NMR yield Work-up 6 
Work-up 7 
Centrifuge 6000 rpm 
Figure 8: Optimisation of work up for the transamination of 162a using solid  
NaHCO3 as a base.  
Basify till pH=8 with solid NaHCO3 
0.2 m Filtration 
of supernatant 
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Savile and co-workers reported that, for larger scale reactions, acidification to 
destroy the enzyme can be used prior to extraction.66 However, when we attempted 
this method, we were unable to retrieve any of the desired product, most likely due 
to the acid decomposing of 166a (Figure 9, work-up 8). We also explored the use of 
a MiVac vacuum concentrator to remove all the aqueous and organic solvent from 
the crude mixture (Figure 9, work-up 9), unfortunately this provided an insoluble 
pellet from which the product could not be extracted.  
 
Figure 9: Optimisation of work up for the transamination of 162a. Work-up 8: 
Acidification. Work-up 9: Removal of solvent using a MiVac vacuum concentrator.  
 
Acidify with 2M HCl 
Basify filtrate with 2M NaOH 






Extract supernatant with EtOAc 
In centrifuge 6000 rpm 
  
0.2 m Filtration 
Work-up 8 
Reaction aq. and org. 
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Strong cation exchange (SCX) chromatography columns are composed of resins, 
which have acidic functionalised groups, and are able to capture amines and other 
basic compounds in order to extract them from aqueous solutions.129, 130 The SCX-2 
isolute column consists of a propylsulfonic acid bonded functionalised silica. The 
columns are specially designed to trap amines, which can be easily liberated from the 
column using a methanolic ammonia solution.131 Passing the reaction mixture 
(previously filtered with a 0.2 m HPLC filter) through a SCX-2 isolute column, using 
EtOAc as eluent, followed by release of the amine with methanolic solution (see 
experimental section for further details), we were able to isolate 166a in 39% yield 
(Figure 10, work-up 10). Initial sonication of the reaction solution, in an attempt to 
destroy the enzyme as a preliminary step, followed by passing either the crude 
reaction through an HPLC filter and an isolute column (Figure 10, work-ups 11 and 
12) showed no improvement in the yield of 166a. 




Figure 10: Optimisation of work up for the transamination of 162a using sonication.  
 
In a last attempt, we performed the reaction with the ATA-256 enzyme absorbed 
onto a resin (ECR1030M), in the hope that the immobilised enzyme would simplify 
the work up. Unfortunately, transamination to the desired product 166a did not 
occur and only starting material 162a could be seen by both GC-MS and 1H NMR 
spectroscopy.  
To conclude, we chose to adopt Work-up 10 (Figure 10) as the optimal work-up 
methodology for the transamination of 162a, which provided the highest isolated 
yield (39%).  
 
































passed through  
silica plug 
(acetone eluent) 
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Since the crude yields of the reaction did not match the full conversion observed in 
the GC-MS, we investigated the stability of the starting material 162a under the 
reaction conditions. The control reaction (in the absence of enzyme) at 50 °C (iPrNH2 
(2 eq), HEPES buffer (100 mM, pH 7.5), PLP (20 mM), DMSO (10% [v/v]), 180 rpm, 48 
h) provided less than 1% recovery of the starting material, indicating that the starting 
material 162a is degrading. In an attempt to monitor the decomposition in real time 
three different internal standards; biphenyl (IS1), docosane (IS2) and acetophenone 
(IS2) were investigated in the control reactions (Scheme 44). These were chosen as 
they were readily available in the lab and appear in the GC-MS at a different retention 
time to our substrate 162a. Unfortunately, due to the low solubility of the internal 
standards in the reaction media, all attempts to monitor the decomposition of 162a 
by GC-MS analysis failed. 
  
Scheme 44: Investigations into the stability of 162a. 
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Next, we investigated the isomerisation of the isolated products 166a. The crude 
product of the IVAMR provided a mixture of the isomers cis-166a, trans-166a and cis-
166a-I in a 3:2.5:1 ratio, respectively (Table 11, entry 5). The epimerisation reaction 
in 2,6-disubstituted piperidines towards the most stable cis-isomer is a well known 
reaction.132-136 We believe that a tandem epimerisation of carbon 2 - via retro 
vinylogous aza-Michael reaction - followed by a subsequent olefin isomerisation 
could provide cis-166a-I as the only isomer in our reaction (Scheme 45). 
 
Scheme 45: Proposed mechanism of tandem epimerisation-isomerisation for the 
synthesis of cis-166a--I. 
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Stirring the isolated mixture of cis-166a, trans-166a and cis-166a-I (3:2.5:1) in EtOH 
at 60 °C for 24 h, unfortunately, did not induce any isomerisation to the desired 
product cis-166a-I (Table 12, entry 1). Increasing the temperature to 80 °C for 24 h 
increased the ratio 0.3:0:1 (cis-166a, trans-166a and cis-166a-I) but after 48 h no 
more isomerisation occurred (Table 12, entries 2 and 3). Stirring the mixture in 
ethanol at RT, in the presence of silica gel, only slightly promoted the isomerisation 
process (Table 12, entry 4), with the ratio of cis-166a, trans-166a and cis-166a-I to 
4.5: 0:1. Heating the mixture, with silica gel, to 60 °C increased the ratio of cis-166a, 
trans-166a and cis-166a-I to 3:0 :1. Whilst raising the temperature to 80 °C in a 
pressure tube combined with silica gel resulted in an improved ratio of 0.5:0:1 (cis-
166a, trans-166a and cis-166a-I,Table 12, entries 7 and 8).  
The isomerisation was also attempted at RT in the presence of solid NaOH but 
unfortunately, the sample decomposed under these conditions (Table 12, entry 8). A 
similar result was observed when the isomerisation was performed at RT, in the 
presence of neutral alumina (Table 12, entry 9). When the mixture was heated at 120 
°C for 8 h using MW, full conversion to the desired cis-166a-I was observed (Table 12, 
entry 10). Analysis of the 2D-NOESY spectrum (Figure 11), showed that there is 
coupling between HA and HB indicating that there is interaction across space and 
confirms that the cis-isomer cis-166a-I was formed during the 
epimerisation/isomerisation process. 





Table 12: Optimisation for the isomerisation of 166a.a 
Entry Additive  Temp (°C) Time (h) cis-166a : trans-166a : 
cis-166a-I Ratiob  
 
1.  ‐ 60 24 3:2.5 :1 
2.  ‐ 80c 24 0.3: 0:1 
3.  ‐ 80c 48 0.3:0:1 
4.  Silica RT 48 4.5:0:1 
5.  Silica 60 24 3:0:1 
6.  Silica 80c 24 0.5:0:1 
7.  Silica 80c 48 0.5:0:1 
8.  NaOH RT 24 Degraded  
9.  Neutral Alumina RT 24 Degraded 
10.  -  120d 8 0 : 0 : 1 
a Reaction conditions: 166a (21 mg, 0.01 mmol), additive (1 eq), EtOH (7 mL) 
b Determined by 1H NMR 
c Reaction carried out in a pressure tube.  
d Irradiated in a microwave at 120 °C. 
 




Figure 11: NOESY spectrum of cis-166a-I (400 MHz, 20 oC, CDCl3). 
 
With the optimised conditions for the isomerisation in hand (heated at 130°C in MW 
for 8 h, Table 12, entry 10) we moved onto the synthesis of cis-167a. Hydrogenation 
of the corresponding alkene was achieved by stirring cis-166a-I at RT in the presence 
of palladium under a hydrogen atmosphere for 24 h, yielding cis-167a in 88%. 
Crowley had previously reported that boiling 167 derivatives in xylene for 90 h, allows 
the cyclisation to perhydroquinolizinones 168.137 However, in our hands, no 
conversion of cis-167a to the desired 168a occurred under these conditions (Scheme 
46, route 1). Similar results occurred when heating cis-167a in toluene in the MW for 
8 h. Further optimisation for the synthesis of quinolizinones 168a will be required. In 
both cases 53% of the starting material cis-167a was recovered, indicating that some 
decomposition took place.  




Scheme 46: Synthetic route to quinolizinone 168a. 
 
Utilising the optimised conditions for the transamination of 162a [ATA 256, IPA (2 
eq.), DMSO (10% [v/v], 50 °C, Table 11, enty 5], the same reaction was performed for 
the transamination of 162b (Scheme 47). A mixture of cis/trans-166b and cis/trans-
166b-I was obtained in a 3.5:1 ratio, in 28% overall yield. The 
epimerisation/isomerisation of the 166b mixture was attempted under the same 
optimised conditions for 166a (heated in a microve at 120 °C for 8 h, Table 12, entry 
10), without any success. This was not surprising, as the epimerisation of 2,5-
disubstituted pyrrolidines is known to be problematic, since the cis-isomer is no 
longer thermodynamically more stable.132-134, 138 Next, we performed an olefin 
hydrogenation by stirring the mixture of isomers cis/trans-163b and cis/trans-163a-I 
at RT in the presence of palladium under a hydrogen atmosphere for 24 h, yielding 
cis/trans-167b in 77% yield. Cyclisation to the indolizidine 168b was also attempted 
by heating in toluene in a pressure tube at 160 °C, but unfortunately, cyclisation did 
not occur and further optimisation will be required.  





Scheme 47: Synthetic route to perhydroindolizinone 168b. 
  
3.3.3 Synthesis of keto-unsaturated substrates 170a-c and subsequent 
transamination.  
Although the transaminase triggered IVAMR of the ketodieno esters 162a-b was 
successful, the reaction proceeded in moderate yields. This could be due to the low 
reactivity of unsaturated esters as Michael acceptors. We envisioned that bis-
unsaturated systems bearing other electron withdrawing groups, such as thioesters, 
nitrile and nitro groups, could provide substrates that are more reactive for the 
IVAMR. The biocatalysed transaminase triggered IMAMR of keto-α,β-unsaturated -
thioesters, -nitriles and -nitro compounds, however, has never been reported, so we 
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decided to focus our initial investigations on these type of substrates before moving 
to the vinylogous counterparts.  
The synthesis of the keto-α,β-unsaturated nitrile substrate 170a was achieved 
through a method reported by Blechert et al,139 consisting on a cross metathesis 
reaction between commercially available 5-hexen-2-one (163) and acrylonitrile 
(169), employing Grubbs 2nd generation catalyst L35 (Scheme 48a). The reaction 
afforded the desired 170a in a moderate 46% yield. The keto-α,β-unsaturated 
thioester 170b was synthesised in 3 steps, following methods reported by Mabury 
(Scheme 48b).140 The first step was the preparation of ylide 174. Thioester 173 was 
produced in good yield (73%) from bromoacetic acid (171) and ethanethiol (172), in 
the presence of DMAP and DCC. Stirring the crude product in dichloromethane with 
triphenylphosphine, followed by treatment of Na2CO3 provided ylide 174 in a 
moderate yield of 60%. Subsequent Wittig reaction with 5-hexen-2-one (163) yielded 
the desired keto-α,β-unsaturated thioester 170b in 65% yield . 
The synthesis of 170c via a Henry reaction between aldehyde 152 and nitromethane 
(Scheme 48c) was also attempted. However, the reaction using potassium hydroxide 
as a base, did not provide the desired 175 or 170c products, and only starting material 
152 was observed by 1H NMR analysis,. Similar results were obtained when using a 
method reported by Peters and co-workers141 using NaOH as base. Further 
optimisation of this reaction will be required in future investigations. 




Scheme 48: Synthetic route to keto-α,β-unsaturated substrates 170a-b and 
attempted synthesis of 170c.  
 
Next, we investigated the biocatalysed IMAMR of keto- α,β--unsaturated substrates 
170a-b using the optimal conditions found for the ketodieno esters 162a-b (ATA-256, 
IPA (2 eq.), DMSO (10% [v/v], 50 °C, Table 11, entry 5). Unfortunately, the 
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transamination of both substrates 170a-b was unsuccessful and only starting 
material was observed in both cases (determined by GC-MS) (Table 13, entries 1 and 
3 and corresponding control reactions, entries 2 and 4). Further optimisation of the 
reaction will need to be performed. Other amine donors, solvents and enzymes could 
be screened in an attempt to optimise the reaction.  
 
Table 13: Attempted transamination of keto-α,β-unsaturated substrates 170a-b a 
 
Entry Substrate ATA (selectivity) Conv (%)
b 
 
















a Reaction conditions: ATA-256 (5 mg/ mL), 170a-b (50 mM), iPrNH2 (2 eq), 
HEPES buffer (100 mM, pH 7.5), PLP (20 mM), DMSO (10% [v/v]), 50 oC, 180 
rpm, 48 h 
b
Determined by GC-MS. 
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c Only starting material observed in the GC-MS. 
 
3 Conclusion and future work 
In conclusion, ketodienones 156a-b and ketodieno esters 162a-b were successfully 
synthesised utilising an ozonolysis reaction followed by subsequent Wittig or HWE 
reaction. Unfortunately, the attempted transamination reaction of ketodienones 
156a-b resulted in complete decomposition of the starting material. However, the 
biocatalysed transaminase triggered IVAMR of ketodieno esters 162a-b proved 
successful, yielding the desired piperidine and pyrrolidine products 162a-b in a 39 
and 28% yield, respectively. Both crude samples were obtained as a mixture of 
isomers: cis-166a, trans-166a and cis-166a-I in a ratio of 3:2.5:1 and cis/trans-166b 
and cis/trans-166b-I in a ratio 3.5:1.  
A tandem epimerisation-isomerisation of the 2,6-disubstituted piperidines 166a 
provided cis-166a-I as the only diastereomer in a 47% yield. Hydrogenation of the 
double bond in the lateral ester chain of cis-166a-I was performed, and cis-167a was 
obtained in good yield (88%). In the case of the 2,5-disubstituted pyrolidines 166b, 
the epimerisation-isomerisation proved unsuccessful. The hydrogenation of the 
double bonds in the lateral ester chains of the 166b isomers provided a mixture of 
cis/trans-167b in 77% yield. Cyclisation of 167a-b to the corresponding quinolizinone 
168a and indolizidine 168b was attempted, but further optimisation is required. 
Finally, the keto-α,β-unsaturated thioester 170a and the keto-α,β-unsaturated nitrile 
170b were synthesised, in order to explore new Michael acceptors in the 
biocatalysed transaminase triggered IMAMR. Our first attempts with these novel 
substrates, using our standard biotransamination conditions (ATA-256, IPA (2 eq.), 
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DMSO (10% [v/v], 50 °C), were, however, not successful. Optimisation of the TA 
reaction could be investigated using different enzymes, amine donors and solvents 
as well as expanding the scope towards the study of the corresponding vinylogous 
aza-Michael reaction if optimal conditions are found. 
 
3.5 Experimental 
General methods and considerations: 
For materials, glassware, TLC, flash chromatography, FT-IR, NMR, GC-MS, MW and 
optical rotations: see Section 2.5 
Ozone Generator: All ozonolysis reactions were carried out using a Triogen® model 
LAB 2B generating ozone at 10 g/h. 
Melting Points: Melting points were measured using a Stuart® SMP10 melting point 
apparatus and are not corrected.  
HPLC-DAD: Attempts to determine the enantioselectivity were carried out on an 
Agilent 1100 series HPLC equipped with a G1313B diode array detector and a G1311A 
Quat pump. Chiral columns tried for analysis were: Lux 5µ Cellulose-1, Lux 5µ 
Cellulose-3 Lux 5µ Cellulose-5 Lux 5µ Amylose-1, Lux 5µ Amylose-2 (Phenomenex®, 
250 mm x 4.6 mm). Racemic standards were prepared by reductive amination using 
sodium cyanoborohydride and ammonium acetate (see experimental procedure for 
further details).142 
General procedure for ozonolysis reaction: A stream of ozone was bubbled through 
a solution of the corresponding alkenes 1-methylcyclopentene (151, 9.50 mmol) and 
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5-hexen-2-one (163, 9.50 mmol) in CH2Cl2 (100 mL) at 78 C until the solution had 
turned into a pale blue colour that persisted. Triphenylphosphine (2.60 g, 9.94 mmol) 
was added slowly and warmed up to room temperature over a 10 h period. The 
solution was concentrated under reduced pressure and the resulting residue was 
purified by flash column chromatography. 
5-oxohexanal (152): Compound 152 was synthesised from 1-
methylcyclopentene (151, 743 mg, 9.1 mmol) using the general 
procedure for ozonolysis to give the named compound as a colourless oil. Yield: 806 
mg, 78%. RF: 0.40 (EtOAc / cyclohexane 7:3). FTIR (neat) Vmax: 2985, 2941, 2831, 
2729, 1710, 1411, 1369, 1162, 587, 519 cm-1. 1H NMR (400 MHz, CDCl3) δ: 9.74 (s, 
1H), 2.52 – 2.45 (m, 4H), 2.12 (s, 3H), 1.91 – 1.82 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ: 208.2, 202.1, 43.0, 42.4, 30.1, 16.1. HRMS (m/z): Calculated C6H11O2 [M+H]+: 
115.0759, found: 115.0756. Data in accordance with literature.143  
4-oxopentanal (164): Compound 164 was synthesised from 5-hex-
en-2-one (163, 1.06 g, 10.8 mmol) using the general procedure for 
ozonolysis to give the named compound as a yellow oil. Yield: 604 mg, 56%. RF: 0.45 
(EtOAc / cyclohexane 7:3). FTIR (neat) Vmax: 2910, 2834, 2731, 1709, 1367, 1169 cm-
1. 1H NMR (400 MHz, CDCl3) δ: δ 9.78 (s, 1H), 2.74 (s, 4H), 2.19 (s, 3H).13C NMR (101 
MHz, CDCl3) δ: 206.6, 200.6, 37.5, 35.6, 29.9. HRMS (m/z): Calculated C5H9O2 [M+H]+: 
101.0602, found: 101.0599. Data in accordance with literature.144  
(2E)-7-oxooct-2-enal (154): 
(Triphenylphosphoranylidene) acetaldehyde (153, 1.2 eq,  
2.37 g, 7.8 mmol) was added to 5-oxohexanal (152, 905 mg, 6.5 mmol) in dry CH2Cl2, 
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the reaction was irradiated in a microwave at 120 °C for 4 h to give the titled 
compound as a yellow oil. Yield: 545 mg, 49%. RF: 0.78 (EtOAc / cyclohexane 8:2) 
FTIR (neat) Vmax: 2941, 2819, 1712, 1684, 1637, 1128, 967, 917, 730 cm-1. 1H NMR 
(400 MHz, CDCl3) δ: 9.48 (d, J = 7.8 Hz, 1H), 6.80 (dt, J = 15.6, 6.7 Hz, 1H), 6.10 (ddd, 
J = 15.6, 7.9, 1.1 Hz, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.37 – 2.28 (m, 2H), 2.13 (s, 3H), 1.83 
– 1.73 (m, 2H).13C NMR (101 MHz, CDCl3) δ: 208.0, 194.0, 157.7, 133.4, 42.5, 32.0, 
30.1, 21.6. HRMS (m/z): Calculated C8H13O2 [M+H]+: 141.0915, found: 141.0908. Data 
in accordance with literature.145 
General Procedure for Wittig reaction for the synthesis of 156a-b:  
Ylide 155a or 155b (1.06 mmol, 2 eq.) was added to the corresponding aldehyde 
1156a-b (0.53 mmol) in dry CH2Cl2 and the reaction mixture was heated in a pressure 
tube at 40 °C for 48 h.  
(3E,5E)-deca-3,5-diene-2,9-dione (156a): Compound 
156a was synthesised from 154 (73 mg, 0.53 mmol) 
and 1-(triphenylphosphoranylidene)-2-propanone (155a, 337 mg, 1.06 mmol), using 
the general procedure for Wittig reaction for the synthesis of 156a-b to give the 
named compound as a yellow oil. Yield: 35 mg, 37%. RF: 0.42 (EtOAc / cyclohexane 
7:3) FTIR (neat) Vmax: 2939, 1710, 1675, 1359, 1254, 1164, 979, 535 cm-1. 1H NMR 
(400 MHz, CDCl3) δ: 7.07 (dd, J = 16.0, 10.0 Hz, 1H), 6.24 – 6.09 (m, 2H), 6.05 (d, J = 
15.7 Hz, 1H), 2.44 (t, J = 7.2 Hz, 2H), 2.25 (s, 3H), 2.18 (q, J = 7.2 Hz, 2H), 2.12 (s, 3H), 
1.76 – 1.67 (m, 2H). 13C NMR (101 MHz, CDCl3) δ: 208.3, 199.3, 157.7, 157.6, 137.5, 
136.3, 43.2, 38.2, 34.0, 30.5, 22.7. HRMS (m/z): Calculated C11H17O2 [M+H]+: 
181.1222, found: 181.1223. 




Compound 156b was synthesised from 154 (73 mg, 
0.53 mmol) and (benzoylmethylene)triphenylphosphorane (155b, 403 mg, 1.06 
mmol) using the general procedure for Wittig reaction for the synthesis of 156a-b to 
give the named compound as a brown oil. Yield: 149 mg, 40%. RF: 0.35 (EtOAc / 
cyclohexane 7:3). FTIR (neat) Vmax: 2934, 2934, 1707, 1658, 1597, 1584, 1574, 1007, 
694, 666 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.96 – 7.90 (m, 2H), 7.58 – 7.53 (m, 1H), 
7.48 (t, J = 8 Hz, 2H), 7.45 – 7.35 (m, 1H), 6.90 (d, J = 15.0 Hz, 1H), 6.39 – 6.16 (m, 2H), 
2.47 (t, J = 7.3 Hz, 2H), 2.23 (q, J = 7.2 Hz, 2H), 2.14 (s, 3H), 1.75 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ: 208.6, 191.0, 145.1, 138.3, 132.7, 130.0, 128.7, 128.5, 128.4, 
124.1, 42.8, 32.5, 30.2, 22.7. HRMS (m/z): Calculated C16H19O2 [M+H]+: 243.1385, 
found: 243.1382. 
Diethyl allylphosphonate (158): Triethylphosphite (2 mL, 11.7 
mmol) and allyl bromide (157, 1.1 mL, 12.7 mmol) were heated 
at 140 °C for 4 h. Some of the excess of allyl bromide was removed under reduced 
pressure and the crude product was purified by column chromatography to give the 
titled compound as a yellow oil. Yield: 1.27 g, 61%. RF: 0.37 (EtOAc / cyclohexane 
2:8). Mp = 190-194 °C. FTIR (neat) Vmax: 3474, 2983, 1640, 1250, 1020, 957, 825, 621, 
486 cm-1. 1H NMR (400 MHz, CDCl3) δ: 5.84 – 5.68 (m, 1H), 5.23 – 5.12 (m, 2H), 4.15 
– 3.99 (m, 4H), 2.58 (ddd, J = 9.7, 8.0, 1.2 Hz, 2H), 1.28 (t, J = 7.1 Hz, 6H). 31P NMR 
(162 MHz, CDCl3) δ: 27.7. 13C NMR (101 MHz, CDCl3) δ: 127.6 (d, J = 11.3 Hz), 120.0 
(d, J = 14.4 Hz), 62.0 (d, J = 6.6 Hz), 31.9 (d, J = 139.2 Hz), 16.5 (d, J = 6.2 Hz). HRMS 
(m/z): Calculated C7H16O3P [M+H]+: 179.0831, found: 179.0834. Data in accordance 
with literature.127  
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(4E)-6-(diethylphosphoryl)hex-4-en-2-one (160): To a 
solution of diethyl allylphosphonate (158, 500 mg, 2.80 
mmol) and methyl vinyl ketone (159, 0.24 mL, 2.79 mmol) in 
dry CH2Cl2 (500 mL), Grubbs 2nd generation catalyst (L35, 48 mg, 0.002 mmol) was 
added. The mixture was stirred under reflux for 1.5 h. The reaction was monitored 
by 31P NMR. If no gas evolution occurred, 1% mol of additional catalyst (L34) was 
added. Once the reaction had reached completion, solvent was removed under 
reduced pressure and the residue was purified by column chromatography, to give 
the titled compound as a dark brown oil. Yield: 432 mg, 66%. RF: 0.4 (MeOH / CH2Cl2 
1:9). FTIR (neat) Vmax: 3375, 2983, 2932, 1701, 1656, 1629, 1237, 1163, 1020, 969, 
792, 730, 542, 509 cm-1. 31P NMR (162 MHz, CDCl3) δ: 24.8. 1H NMR (400 MHz, CDCl3) 
δ: 6.72 – 6.59 (m, 1H), 6.17 – 6.08 (m, 1H), 4.12 – 3.98 (m, 4H), 2.70 (ddd, J = 23.0, 
7.8, 1.2 Hz, 2H), 2.20 (s, 3H), 1.26 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ: 
136.6 (d, J = 11.3 Hz), 135.1 (d, J = 13.3 Hz), 62.3 (d, J = 6.6 Hz), 30.9 (d, J = 138.3 Hz), 
16.4 (d, J = 6.0 Hz). HRMS (m/z): Calculated C9H18O4P [M+H]+: 221.0942, found: 
221.0935. Data in accordance with literature.146  
General Procedure for the Horner- Wadsworth -Emmons reaction for the synthesis 
of 162a-b:  
To a solution of the commercially available triethyl-4-phosphocrotonate (161, 0.8 mL, 
3.6 mmol) in THF (40 mL), LDA (1 M in THF, 1.84 mL, 1.84 mmol) was added at 40 
C and the solution was left to stir for 30 min at 40 C. The corresponding 
ketoaldehyde 152 or 164 was added (3.5 mmol) in THF (12 mL), the resulting mixture 
was stirred for 20 min at 40 C, then warmed up to room temperature and stirred 
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for an additional 10 min. The reaction was quenched with saturate aq. NH4Cl (10 mL) 
and the solution was extracted with EtOAc (3 × 30 mL). The combined organic layers 
were washed with brine, dried over NaSO4 and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography. 
Ethyl-(2E,4E)-9-oxodeca-2,4-dienoate (162a): Compound 
162a was synthesised from 152 (400 mg, 3.5 mmol) using 
the general procedure for Horner-Wadsworth-Emmons 
reaction to give the named compound as a yellow oil. Yield: 354 mg, 48%. RF: 0.37 
(EtOAc / cyclohexane 2:8). FTIR (neat) Vmax: 2940, 2889, 1712, 1662, 1623, 1427, 
1454, 1348, 1252, 1191, 1159, 966, 887 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.23 (dd, 
J = 16, 8 Hz, 1H), 6.21 – 6.01 (m, 2H), 5.78 (d, J = 15.3 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 
2.44 (dd, J = 9.3, 5.3 Hz, 2H), 2.17 (q, J = 7.2 Hz, 2H), 2.13 (s, 3H), 1.71 (dt, J = 13.6, 
6.8 Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H).13C NMR (101 MHz, CDCl3) δ: 208.6, 167.3, 144.8, 
143.2, 129.2, 119.9, 60.4, 42.8, 32.3, 30.2, 22.7, 14.4. HRMS (m/z): Calculated 
C12H19O3 [M+H]+: 211.1329, found: 211.1328. 
Ethyl-(2E,4E)-8-oxonona-2,4-dienoate (162b): Compound 
162b was synthesised from 164 (440 mg, 4.4 mmol) using the 
general procedure for Horner-Wadsworth-Emmons reaction 
to give the named compound as a yellow oil. Yield: 338 mg, 39%. RF: 0.54 (EtOAc / 
cyclohexane 1:1). FTIR (neat) Vmax: 3436, 2983, 2913, 1705, 1641, 1616, 1367, 1243, 
1196, 1156, 1133, 1031, 1002 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.22 (dd, J = 12, 8 
Hz, 1H), 6.24 – 6.00 (m, 2H), 5.79 (d, J = 15.5 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 2.61 – 
2.54 (m, 2H), 2.43 (q, J = 6.9 Hz, 2H), 2.15 (s, 3H), 1.28 (t, J = 7.0 Hz, 3H). 13C NMR 
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(101 MHz, CDCl3) δ: 207.5, 167.3, 144.6, 142.1, 129.3, 120.2, 60.4, 42.4, 30.2, 27.0, 
14.0. HRMS (m/z): Calculated C11H17O3 [M+H]+: 197.1172, found: 197.1172.  
General procedure D, for the transamination of ketodieno esters 162a-b: 
Commercially available (S)-selective ATA-256 (25 mg) or (R)-selective ATA-025 (25 
mg) was rehydrated in HEPES buffer (4.0 mL, 100 mM, pH 7.5) containing PLP (2.00 
mM) and isopropylamine (2 eq, 43 μL, 0.5 mmol). The pH of the mixture was adjusted 
to 7.5, using aq HCl solution (1 M) and the total volume of the reaction was adjusted 
to 4.5 mL by addition of HEPES buffer (100 mM, pH 7.5). The corresponding 
substrate162a-b was added (50 mM, 0.5 mL in DMSO) and the reaction mixture was 
incubated at 50 oC, 180 rpm for 48 h. The reaction was monitored by GC-MS. After 
completion, the reaction mixture was filtered through a 0.2 μL HPLC filter and the 
corresponding filtrate was passed through an Isolute® column SX-C2 using MeOH as 
eluent (75 mL). This first filtrate was discarded and the Isolute column was then 
flushed with methanolic ammonia solution (75 mL) to release the corresponding 
amines 166a-b. This second filtrate was concentrated under reduced pressure and 
the crude residue was purified by flash column chromatography to provide the 
corresponding amines 166a-b as an isomeric mixture. 
General procedure E, for the control experiments for the transamination of 162a-
b: The general procedure A above was followed, omitting the addition of the enzyme. 
General Procedure F, for enzyme immobilisation onto resin: 
Enzyme ATA-256 (31.2 mg) was dissolved in HEPES buffer (100 mM, 2 mL). The resin 
(ECR1030M, 516 mg) was washed with a small volume of HEPES buffer (0.1 M), 
filtered, and added to the enzyme-buffer solution. The mixture was incubated (25 °C, 
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80 rpm, 24 h) and then centrifuged (5000 rpm, 3 min). The enzyme carrier resin was 
filtrated and dried under vacuum. The enzyme absorption onto the resin was 
measured, from the solution, using a Nanodropä One spectrophotometer, to be 7.54 
mg/mL (250 mg resin). The resin beads were then filtered and stored below 5 °C. 
General procedure G, for the biotransformations of 162a using resin-supported 
transaminase (ECR1030M): 
HEPES buffer solution (100 mM, 1.5 mL, pH 7.5), IPA (17.2 mL) and PLP (2.00 mM, 0.2 
mL in HEPES) were added to an Eppendorf vial (10 mL), and the pH was adjusted to 
7.5 using HCl and NaOH solutions (2 M). The resin-supported ω-TA enzyme [(S)-
selective ATA-256 supported onto ECR1030M)] was then added (10 mg), followed by 
substrate 162a (21 mg) in DMSO (0.25 mL). The mixture was then incubated (50 oC, 
180 rpm) for 48 h, and the progress of the reaction was monitored by GC-MS. After 
48 h, the solution was centrifuged for 5 min (5000 rpm) and decanted. The solution 
was made basic using NaOH solution (2 M), extracted with ethyl acetate (4 x 10 mL), 
and further centrifuged. The combined organic layers were then passed through an 
Isolute SCX-2 column, using MeOH as eluent (75 mL). This first filtrate was discarded 
and the Isolute column was then flushed with methanolic ammonia solution (75 mL) 
in an attempt to release the corresponding amines. This second filtrate was 
concentrated under reduced pressure. No product 166a was observed. 
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General procedure H, for the epimerisation/isomerisation of 166a-b: The 
corresponding mixture of isomers (0.255 mmol) was dissolved in EtOH (7 mL) and 
irradiated in MW at 120 °C for 8 h. The solution was concentrated under reduced 
pressure and the resulting residue was purified by flash column chromatography to 
give cis-166a-I as a dark brown oil. 
General procedure I, for reductive amination of 162a-b for the synthesis of racemic 
166a-b:142 
Ammonium acetate (13 eq, 2.15 mg, 2.8 mmol) was added to the corresponding 
ketodieno esters 162a-b (1 eq, 0.22 mmol) in ethanol (3 mL) at RT and stirred for 25 
min. Sodium cyanoborohydride (0.7 equiv, 10 mg, 0.16 mmol) was added at RT and 
then the reaction mixture was stirred for 4-8 days at room temperature. The reaction 
was then quenched with HCl (6 M), washed with diethyl ether (2 x 10 mL) and the 
aqueous extract was basified to pH 8 with NaOH (2 M). The liberated amine was 
extracted with CH2CL2(3 x 15 mL). The combined organic extracts were dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified 
by flash column chromatography. 
Ethyl (2E)-4-[(2S,6S)-6-methylpiperidin-2-yl]but-2-
enoate [cis-()-166-I]: Compound cis-166a-I was 
synthesised from 162a (53 mg, 0.25 mmol) using general 
procedure D with ATA-256, followed by epimerisation/isomerisation (general 
procedure G) to give the named compound as a dark brown oil. Yield: 21 mg, 39%. 
RF: 0.28 (MeOH / DCM 5:95). [α]D26 = – 8.8 (c 0.9, EtOH). FTIR (neat) Vmax: 3315, 2928, 
2857, 1717, 1654, 1441, 1309, 1265, 1177, 1034, 982 cm-1. 1H NMR (400 MHz, CDCl3) 
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δ: 6.90 – 6.78 (m, 1H), 5.88 (d, J = 15.6 Hz, 1H), 4.16 (q, J = 7.3 Hz, 2H), 2.88 – 2.70 
(m, 2H), 2.69 – 2.49 (m, 1H), 2.48 – 2.36 (m, 1H), 1.85 – 1.76 (m, 1H), 1.75 – 1.59 (m, 
1H), 1.44 – 1.08 (m, with a t at 1.26, J = 8 Hz, and a d at 1.20, J = 4 Hz, 8H). 13C NMR 
(101 MHz, CDCl3) δ: 166.3, 144.5, 124.3, 60.5, 56.3, 53.3, 38.6, 32.7, 30.5, 24.0, 21.7, 
14.3. HRMS (m/z): Calculated C12H22NO2 [M+H]+: 212.1645, found: 212.1662. 
(E)-ethyl 4-((2R,6R)-6-methylpiperidin-2-yl)but-2-
enoate [cis-(+)-166a-I]: Compound cis-166a-I was 
synthesised from 162a (53 mg, 0.25 mmol) using 
general procedure D with ATA-025, followed by epimerisation/isomerisation 
(general procedure G) to give the named compound as a dark brown oil. Yield: 19 
mg, 37%. RF: 0.28 (MeOH / DCM 5:95). [α]D26 = + 5.7 (c 0.7, EtOH). HRMS (m/z): 




(166b): The mixture cis/trans-166b and cis/trans-166b-I 
were synthesised from 162a (49 mg, 0.25 mmol) 
following general procedure D with ATA-256, to give the 
named compound as a yellow oil as an isomeric mixture (cis/trans-166b and 
cis/trans-166b-I, 3.5:1). Yield: 14 mg, 28%. RF: 0.45 (MeOH / DCM 5:95). [α]D26 = – 
11.42 (c 0.7, CHCl3). FTIR (neat) Vmax: 2966, 2929, 1872, 1640, 1441, 1410, 1145, 976 
cm-1. 1H NMR (400 MHz, CDCl3) δ: 6.53 – 6.48 (m, 1H, 166b-I, diastereomer 1), 6.44 
– 6.39 (m, 1H, 166b-I, diastereomer 2), 5.94 – 5.71 (m, 6H, cis/trans-166b and 
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cis/trans-166b-I), 4.28 – 4.07 (m, 8H, cis/trans-166b and cis/trans-166b-I), 3.55 – 3.44 
(m, 2H, cis/trans-166b), 3.01 – 2.81 (m, 10H, cis/trans-166b and cis/trans-166b-I), 
2.22 – 2.02 (m, 4H, cis/trans-166b-I), 1.79 – 1.48 (m, 8H, cis/trans-166b and cis/trans-
166b-I), 1.47 – 1.37 (m, 8H, cis/trans-166b and cis/trans-166b-I), 1.33 – 1.15 (m, 24H, 
cis/trans-166b and cis/trans-166b-I). 13C NMR (101 MHz, CDCl3) δ: 167.9, 167.2, 
166.0, 164.0, 162.9, 140.1, 138.9, 137.2, 127.3, 126.7, 124.8, 124.9, 122.5, 63.9, 59.3, 
58.3, 58.1, 55.5, 52.9, 52.7, 52.3, 52.2, 51.6, 34.5, 33.2, 32.5, 32.2, 31.6, 31.5, 31.2, 
29.1, 21.1, 20.8, 20.0, 19.8, 18.4, 15.6. HRMS (m/z): Calculated C11H19NO2 [M+H]+: 




(166b): Compound cis/trans-166b-P and cis/trans-166b- 
were synthesised from 162b using general procedure A 
with ATA-025 to give the named compound as a yellow oil. Yield: 12 mg, 24%. RF: 
0.45 (MeOH / DCM 5:95). [α]D26 = –80 (c 0.6, CHCl3)
General procedure for the hydrogenation reaction for the synthesis of 167a-b: 
Compound cis-166a-I or the isomeric mixture cis/trans-166b and cis/trans-166b-I 
(0.128 mmol) was dissolved in ethanol (3 mL) in the presence of Pd/C (10% wt, 0.046 
mmol) and stirred at RT for 24 h. The crude mixture was filtered over Celite, 
concentrated under reduced pressure and purified by flash column chromatography. 




one (167a): Compound 167a was synthesised from cis-
166a-I (27 mg, 0.123 mmol) following the general 
procedure for the hydrogenation reaction to give the named compound as a yellow 
oil. Yield: 24 mg, 88%. RF: 0.32 (MeOH / DCM 5:95). [α]D26 = –27.7 (c 0.52, CHCl3) . 
FTIR (neat) Vmax: 2936, 2853, 2746, 1733, 1279, 1032, 1960 cm-1. 1H NMR (400 MHz, 
CDCl3) δ: 4.11 (q, J = 7.2 Hz, 2H), 3.12 – 3.00 (m, 1H), 2.98 – 2.86 (m, 1H), 2.40 – 2.19 
(m, 2H), 2.15 – 2.02 (m, 1H), 1.93 (m, 2H), 1.86 – 1.52 (m, 7H), 1.49 (d, J = 6.5 Hz, 3H), 
1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 173.3, 60.7, 58.1, 54.6, 33.8, 
32.9, 30.8, 27.9, 23.0, 20.9, 19.6, 14.4. HRMS (m/z): Calculated C12H23NO2 [M+H]+: 
214.1807, found: 214.1803.147  
Ethyl 4-[(2S,5S)-5-methylpyrrolidin-2-yl]butanoate and ethyl 
4-[(2R,5S)-5-methylpyrrolidin-2-yl]butanoate (167b): 
Compound cis/trans-167b was synthesised from the isomeric 
mixture cis/trans-166b and cis/trans-166b-I (18 mg, 0.091 mmol) following the 
general procedure for the hydrogenation reaction to give the named compound as a 
yellow oil. d.r. n.d. Yield: 14 mg, 77%. RF: 0.32 (MeOH / DCM 5:95) [α]D26 = – 5.71 (c 
0.7, CHCl3) . FTIR (neat) Vmax: 2920, 1700, 1656, 1550, 756 cm-1. 1H NMR (400 MHz, 
CDCl3) δ: 4.18 – 4.06 (m, 4H), 3.53 – 3.39 (m, 4H), 3.00 – 2.78 (m, 4H), 2.50 – 1.49 (m, 
18H), 1.43 – 1.13 (m, 12H).13C NMR (101 MHz, CDCl3) δ: 198.2, 63.9, 60.6, 58.5, 57.2, 
53.6, 53.0, 36.7, 33.2, 31.8, 31.3, 29.8, 29.4, 29.0, 21.07, 20.95, 20.06, 18.41, 1.16. 
HRMS (m/z): Calculated C11H21NO2 [M+H]+: 200.1650, found: 200.1645. 
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(2E)-6-oxohept-2-enenitrile (170a): To an equimolar solution 
of 5-hexen-2-one (163, 117 μL, 1.01 mmol) and acrylonitrile 
(67 μL, 1.02 mmol) in dry DCM (22 mL), copper chloride (10 mg, 0.074 mmol) was 
added. Grubbs 2nd Generation (L34, 21.5 mg, 0.025 mmol) was added and the 
reaction was stirred for 3 h at 40 °C. The solvent was removed under reduced 
pressure and the product was purified by flash silica gel chromatography to give the 
named compound as a colourless oil. Yield: 57 mg, 46%. RF: 0.55 (EtOAc / 
cyclohexane 3:2). FTIR (neat) Vmax: 2221, 1713, 1412, 1363, 1163, 971, 741 cm-1. 1H 
NMR (400 MHz, CDCl3) δ: 6.57 – 6.47 (m, 1H), 5.32 (d, J = 16 Hz, 1H), 2.60 (t, J = 8 Hz, 
2H), 2.51 – 2.43 (m, 2H), 2.16 (s, 3H).13C NMR (101 MHz) δ: 206.2, 154.1, 115.8, 100.9, 
53.6, 30.1, 27.1. HRMS (m/z): Calculated C7H10NO [M+H]+: 124.07623, found: 
124.0757.148  
Ethyl 2-(triphenylphosphoranylidene)ethanethioate (174): A 
solution of bromoacetic acid (173, 6.97 g, 50.16 mmol), 4-
(dimethylamino)pyridine (610 mg, 4.99 mmol) and ethanethiol 
(4.83 mL, 65.22 mmol) in dry DCM (225 mL) was cooled to 0 °C. 
Dicyclohexylcarbodiimide (10.86 g, 52.63 mmol) was added slowly and the solution 
was warmed to room temperature overnight. The solution was filtered over Celite 
and the Celite cake was washed multiple times with Et2O. The filtrate was washed 
with sat aq. NaHCO3, followed by water and then brine. The organic layer was dried 
over Na2SO4 and concentrated under vacuum to yield a yellow oil (6.64 g, 73%). 
Triphenyl phosphine (9.98 g, 8.64 mmol) was added to the crude product in toluene 
(57 mL) and the resulting mixture was stirred at room temperature for 3 days. The 
toluene was removed under vacuum to give a white solid which was then dissolved 
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in CH2Cl2 (75 mL) and vigorously stirred with 50 mL of 10% aq Na2CO3 solution for 30 
min. The layers were separated and the aqueous layer was extracted CH2Cl2 (2 x 30 
mL). The combined organic phases were partially concentrated in vacuo to give the 
named compound in salt like white crystals. Yield: 10.98 g, 60%. RF: 0.35 (EtOAc / 
cyclohexane 1:1). Mp = 186–191 °C. FTIR (neat) Vmax: 1579, 1337, 1085, 871, 692, 
512, 302 cm-1. 1H NMR (400 MHz) δ: 7.65 – 7.58 (m, 6H), 7.57 – 7.51 (m, 3H), 7.49 – 
7.41 (m, 6H), 3.65 (d, J = 21.8 Hz, 1H), 2.83 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ: 180.6, 180.5, 133.2, 133.1, 132.3, 132.3, 129.1, 128.9, 
127.3, 126.4, 47.6, 46.5, 23.2, 16.5. 31P NMR (162 MHz, CDCl3) δ: 14.2. HRMS (m/z): 
Calculated C22H21OPS [M+H]+: 365.1129, found: 365.1133. Data in accordance with 
literature.149  
 
(E)-S-ethyl 7-oxooct-2-enethioate (170b): A solution 
of 5-oxohexanal (152, 64 mg, 0.56 mmol) and ylide 174 
(277 mg, 0.73 mmol) in DCM (5 mL) was heated in a pressure vial at 40 °C overnight. 
The solution was concentrated under vacuum and purified by column 
chromatography to give the named compound as a dark brown oil. Yield: 68 mg, 65%. 
RF: 0.65 (EtOAc / cyclohexane 1:1), FTIR (neat) Vmax: 2931, 1713, 1664, 1630, 1450, 
1413, 1358, 1264, 1159, 1137, 1060, 973, 802, 732 cm-1. 1H NMR (400 MHz, CDCl3) δ: 
6.83 (dt, J = 12, 4 Hz, 1H), 6.10 (dt, J = 16, 4 Hz, 1H), 2.93 (q, J = 7.4 Hz, 2H), 2.45 (t, J 
= 7.3 Hz, 2H), 2.27 – 2.16 (m, 2H), 2.13 (s, 3H), 1.80 – 1.69 (m, 2H), 1.27 (t, J = 7.4 Hz, 
3H).13C NMR (101 MHz, CDCl3) δ: 208.2, 144.1, 129.4, 42.7, 31.4, 30.2, 23.2, 21.9, 
14.9. HRMS (m/z): Calculated C10H27O2S [M+H]+: 201.0949, found: 201.0944. 




General procedure for the attempted synthesis of 170c: 
To a solution of 152 (394 mg, 3.24 mmol) and nitromethane (178 μL, 3.29 mmol) in 
EtOH or MeOH (1 mL), NaOH or KOH (10 M, 0.32 mL) was added dropwise at 0 °C and 
left stir for 30 min and the reaction mixture went yellow. The reaction was acidified 
with acetic acid (185 μL, 3.18 mmol) and the aqueous phase was extracted with Et2O. 
The combined organic extracts were washed with water, dried over MgSO4 and 
concentrated under reduced pressure. No product 170c was observed. 
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4.1 Introduction  
 
Chiral molecules are ubiquitous throughout nature. They play a crucial role in many 
areas of academia and industry and the use of asymmetric catalysis for their 
construction has become an important area of research.150 The enantioselective 
hydrogenation of ketones and the enantioselective addition of organometallic 
reagents to prochiral carbonyl compounds are amongst the most popular methods 
to produce chiral alcohols, which are very relevant building blocks. In particular, this 
chapter will exclusively focus on the enantioselective addition of organometallic 
reagents to aldehydes.  
 
4.1.1 Enantioselective addition of organometallic reagents to aldehydes. 
Chiral alcohols are highly valuable building blocks and the use of organometallic 
reagents for their construction is one of the most efficient approaches.151-154 Catalytic 
enantioselective versions of this reaction have been broadly studied for species of 
low to medium reactivity, such as organozinc,155-163 organoaluminium164-167 and 
organotitanium reagents.168-171 In the last five years, a few examples with the more 
reactive organomagnesium and organolithium reagents have also been described.172-
178 
The first catalytic enantioselective addition of organozinc reagents to carbonyl 
compounds dates back to 1886 (Scheme 49). Noyori et al. reported the alkylation of 
aromatic aldehydes with diethylzinc in the presence of chiral ligand L36.172 Since 
then, a substantial amount of research has been achieved in this area with an 
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extensive library of chiral ligands which are able to perform this transformation.151, 
152, 154, 155, 179, 180  
 
Scheme 49: Catalytic enantioselective addition of diethylzinc to aldehydes 
 
Woodward and co-workers reported the addition of organoaluminium reagents to 
aliphatic and aromatic aldehydes using chiral phosphoramidite L37 and Ni(acac)2 as 
catalyst for the synthesis of secondary alcohols (Scheme 50, method 1).181 Milder 
reaction conditions are achieved when a DABCO-(R3Al)2 complex is used (Scheme 50, 
method 2). Unfortunately, yields and ee are lower for aliphatic aldehydes, compared 
to aromatic aldehydes, for both of the reaction conditions.  




Scheme 50: Synthesis of secondary alcohols from the addition of organoaluminium 
reagents to aldehydes reported by Woodward et al.  
 
The enantioselective addition to carbonyl compounds with the more readily available 
lower-cost organolithium and organomagnesium reagents (compared to organozinc 
and organoaluminium compounds) has been explored for several decades. However, 
the high reactivity profile of these reagents limits their use in catalytic 
enantioselective methodologies, and most of the few examples known involve the 
use of stoichiometric amounts of chiral ligands and low temperatures.175 The first 
successful catalytic enantioselective addition of Grignard reagents to aldehydes was 
described by Harada and co-workers for the alkylation reaction of aldehydes, using 
the chiral ligand L38 (Scheme 51) and titanium tetraisopropoxide (Ti(OiPr)4).176 Other 
examples on the catalytic enantioselective addition of Grignard reagents to 
aldehydes were reported later by Maciá,182 Harada,183, 184 Da185, 186 and 
Harutyunyan.187 





Scheme 51: Catalytic enantioselective Harada's addition of Grignard reagent to 
aldehydes. 
 
Harutyunyan et al. reported the catalytic enantioselective 1,2-addition of β-branched 
Grignard reagents to a variety of α,β-unsaturated ketones (Scheme 52a,188-191 b)192 
and heteroaryl ketones (Scheme 52c).193 The 1,2-addition reactions with Grignard 
reagents uses a copper- Josiphos-type (5 mol%) catalysts to enantioselective 
construct chiral tertiary alcohols with high yields and ee. They report that bulkier 
Grignard reagents are required to provide higher enantioselectivities and without the 
use of copper as part of the catalytic system no tertiary alcohols are observed.  




Scheme 52: Catalytic enantioselective 1,2-addition of Grignard reagents to α,β-
unsaturated ketones and heteroaryl ketones by Harutyunyan. 
 
4.1.2 Ar-BINMOLs in the enantioselective addition to carbonyl compounds.  
 
Enantiopure 1,1-binaphthalene-2-α-arylmethan-2-ols (Ar-BINMOL) were first 
synthesised by Kiyooka and co-workers in 1996 via a [1,2]-Wittig rearrangement 
(Scheme 53a) and later an improved synthesis was reported by Xu et al. (Scheme 
53b), consisting of the benzylation of enantiopure (S)-BINOL with an aryl bromide, 
followed by a lithium-assisted [1,2]-Wittig arrangement.  
 




Scheme 53: Synthesis of Ar-BINMOL ligands via Kyooka (A) and Xu (B) methods. 
 
Enantiopure Ar-BINMOL ligands have proven efficient in the addition of organozinc 
reagents to carbonyl compounds.185, 194 Xu et al. reported excellent yields and 
enantioselectivities for the addition of Et2Zn to aromatic aldehydes using Ar-BINMOL 
L41 in the presence of Ti(OiPr)4 (Scheme 54). 




Scheme 54: Enantioselective synthesis of secondary alcohols by asymmetric addition 
of Et2Zn to aromatic aldehydes reported by Xu and co-workers.  
 
Maciá et al. reported the addition of alkyl Grignard reagents (including the more 
challenging MeMgBr) to both aliphatic182 and aromatic aldehydes195 and aryl 
Grignard reagents196 to the more challenging ketone substrates,177 with the use of 
Ar-BINMOL derived ligands L42, L43 and L44 as well as super-stoichiometric amounts 
of titanium tetraisopropoxide (Ti(OiPr)4) (Scheme 55). 




Scheme 55: Catalytic enantioselective addition of Grignard reagents to aldehydes 
and ketones by Maciá et al. 
 
Maciá et al. have also reported the use of Ar-BINMOL chiral ligands with other readily 
accessible nucleophiles such as organolithium,197, 198 organoaluminum,199 and 
organotitanium200 for the catalytic enantioselective alkylation of aldehydes(Scheme 
56).  
 





Scheme 56: Use of Ar-BINMOL ligands for the catalytic enantioselective addition of 
nucleophiles to aldehydes. 
 
4.1.3 Hydrozirconation reaction for the use of alkenes as nucleophiles.  
The catalytic enantioselective 1,2-addition of organometallic reagents to carbonyl 
compounds has its limitations. The use of these very reactive (and sometimes 
pyrophoric) non-stabilised carbanions as nucleophiles is restricted in a variety of 
situations. In order to produce high levels of enantioselectivity, many organometallic 
reagents require the use of cryogenic temperatures, which is extremely expensive in 
large scale reactions.201 Furthermore, there are other complicating factors when 
using various organometallic reagents, such as difficulties in the use of functionalised 
reagents as well as safety implications which prevent their use in large scale reactions 
and thus in industrial processes.202 Taking in to consideration the importance of 
establishing sustainable enantioselective catalytic systems, it is of paramount 
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importance that methods are develop for the nucleophilic 1,2-addition to carbonyl 
compounds at room temperature. 
Organozirconium reagents are becoming increasingly popular and play an important 
role in organic synthesis.203 These reagents are less reactive compared to other 
organometallic reagents, do not have severe toxicity and zirconium is one of the 
cheapest transition metals. Zirconium has an abundance of 0.022% within the 
lithosphere,204 making it almost as abundant as C. Additionally, the hydrozirconation 
of alkenes is performed at room temperature, as well as being highly tolerant 
towards functional groups.205 
The widely used hydrozirconation reagent 208, was prepared from Cp2ZrCl with 
LiAlH4 by Walies et al.206 However, as a result of the pioneering work performed by 
Schwartz et al., the reagent is often referred to as ‘Schwartz reagent’(208, Scheme 
57).207, 208  
The hydrozirconation reaction of an alkene with the commercially available (or in-
situ prepared) Schwartz reagent (208) allows the preparation of alkylzirconium 
reagents.209, 210 The bulky zirconocene moiety leads to high regioselectivity during 
the hydrozirconation reaction on terminal alkenes, with the metal being attached at 
the less-hindered terminal position of the alkyl group. The hydrozirconation reaction 
of internal olefins is also possible, but the hydrozirconation products will rearrange 
via Zr–H elimination and re-addition, to lead to alkylzirconocenes with the metal at 
the less-hindered terminal position of the alkyl group (Scheme 57). The carbon-
zirconium bond resembles that of a Grignard reagent, however only small 
electrophiles are able to directly attack the complex due to steric crowding around 
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the zirconium atom; the bulky zirconocene moiety contributes to good functional 
group tolerance by sheltering the reactive point.210 Despite of this, organozirconium 
reagents are able to undergo C-C bond-formation. An essential example of 
applicability of these reagents are the nickel- or palladium catalysed cross coupling 
reactions of organozirconium derivatives.203  
 
Scheme 57:Hydrozirconation reaction of an alkene using Schwartz reagent.  
 
Organozirconocene chloride compounds are restricted synthetic reagents as they 
have naturally low reactivity towards electrophilic reagents. This is most likely a 
result of large steric hindrance or from specific interactions of C-C and C-H bonds of 
alkyl groups with low-lying empty d-orbitals. Organozirconium reagents are generally 
inert towards carbonyl compounds, but with the combination of an additive such as 
dialkylzinc reagents will result in a rapid 1,2-addition. The use of additives such as 
ZnBr2, Ag (I) or Me2Zn allows organozirconium reagents to be readily added to 
aldehydes.175, 211-213 Srebnik et al. described the use of ZnBr2 as effective catalysts for 
the additon of organozirconocene chloride compounds to aromatic and aliphatic 
aldehydes.213 In similar fashion, Wipf et al. reported the use of Me2Zn as additive for 
the addition of organozirconium compounds to aldehydes. However, none of these 
methodologies are enantioselective.  
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The use of organozirconium reagents in catalytic enantioselective additions is 
exceedingly beneficial as it enables the use of alkenes which are readily available, 
easy to handle and inexpensive. Furthermore, compared to other organometallic 
reagents, organozirconium reagents provide an increased scope of compatible 
functional groups.214  
In particular, Fletcher et al. have developed an enantioselective copper-catalysed 
1,4-addition of organozirconium reagents to enones215-219, acyclic enones220 
cyclopent-4-ene-1,3-dione monoacetals221 α,β-unsaturated ketones222 and lactones 
(Scheme 58).223 Enantioselective 1,6-additions or organozirconium reagents to 
produce functionalised steroid derivatives (200)224 and the breast cancer drug 
fulvestrant (Faslodex®, Scheme 58) have also been reported.225 In all cases, the 
organozirconium nucleophile was prepared via an in situ hydrozirconation reaction 
of the corresponding alkene.  




Scheme 58: Enantioselective copper-catalysed 1,4- and 1,6-additon of 
organozirconium reagents by Fletcher et al. 
 
Our group recently developed a methodology for the catalytic enantioselective 1,2-
addition of organozirconium reagents to aldehydes (Scheme 60).214 This 
methodology consists on the use of the Schwartz reagent to generate alkylzirconium 
nucleophiles via in situ hydrozirconation of alkenes, followed by the Ar-BINMOL 
catalysed enantioselective addition to aromatic aldehydes, which is facilitated by the 
use of ZnBr2 and Ti(OiPr)4 as additives. The reaction proceeds under mild conditions 
and provides good yield and enantioselectivity. However, the substrate scope did not 
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include aliphatic aldehydes, which are of particularly relevance as they give access to 
chiral alkyl alcohols, which play a crucial role in many biological systems and are 
ubiquitous throughout pharmaceuticals, food additives, agrochemicals and 
cosmetics.187 The synthesis of chiral secondary alkyl alcohols by nucleophilic addition 
to alkyl carbonyl compounds is hampered by the highly enolisable character of the 
alkyl aldehyde, together with its multiple conformations and the lack of π-stacking 
interactions with the catalyst. 
 
Scheme 60: Catalytic enantioselective addition of in situ generated organozirconium 
reagents to aromatic aldehydes. 
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4.2 Aims and Objectives 
 
Chiral aliphatic alcohols are ubiquitous throughout daily life. They are a fundamental 
figure throughout biological activity. Sexual, trail, alarm and aggregation 
pheromones, fragrance emitted by flowers, chemical communication and attraction 
or repulsion between living organisms are just some examples of how they are used 
within biological systems.226 Enantiopure alkyl alcohols are very valuable in a number 
of industries, such as cosmetic and fragrance, pharmaceutical and agriculture.226   
A variety of catalytic asymmetric methodologies227 have been developed for 
preparing these valuable chiral aliphatic secondary alcohols in high enantiomeric 
excess, including reduction or hydrogenation of prochiral aliphatic ketones228-230 and 
addition of organometallic reagents (alkylzinc,152, 155, 157, 231 alkyl aluminium165-167, 232 
and alkyltitanium169-171 to aliphatic aldehydes150, 233-235). The addition of 
organozirconium compounds to aliphatic aldehydes, however, has not been studied. 
Organozirconium reagents offer advantages such as being one of the cheapest 
transition metals, have low toxicity and are mild and versatile organometallic 
reagents.  
Under the current global climate, the growing need for ‘greener’ methodologies is 
ever more important. Therefore, we envisaged the use of the organozirconium 
reagents to create a more sustainable catalytic methodology for the 1,2-addition to 
aliphatic aldehydes.  
Based on preliminary results by Maciá et al.,214 and the recognising the potential of 
this methodology the aims of this chapter will be as follows: 
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(i) Optimisation of the catalytic enantioselective addition of 
organozirconium reagents to aliphatic aldehydes using Ar-BINMOLs as 
ligands. 
(ii) Expand the scope of the reaction to a range of aliphatic aldehydes and 
alkenes.  
 
4.3 Results and Discussion- Catalytic enantioselective 1,2-addition of 
organozirconium reagents to aliphatic aldehydes using Ar-BINMOL ligands.  
The catalytic enantioselective 1,2-addition of organozirconium reagents to aromatic 
aldehydes with Ar-BINMOLs and organozirconium reagents has been recently 
reported by our group.214 This is a significant achievement as it is the first of its kind 
to use readily available and easy-to-handle alkenes as nucleophiles. Herein, we aim 
to explore the catalytic enantioselective 1,2-addition of organozirconium reagents – 
prepared in situ from the corresponding alkenes – to more challenging, enolisable 
aliphatic aldehydes.  
The addition of 1-hexene (223a) to cyclohexanecarboxaldehyde (225a) using the very 
versatile (Ra,S)-Ph-BINMOL (L42)173, 174, 195, 236, 237 as the ligand for the reaction was 
chosen a model reaction for these studies. Our investigation commenced by testing 
the optimised conditions for the addition of organozirconium reagents to aromatic 
aldehydes.214 The first step of the reaction consisted of the treatment of 1-hexene 
(223a, 2.2 eq.) with Schwartz reagent (208, 2 eq.), resulting in a change from a white 
suspension to a clear yellow solution, which suggested that the corresponding 
organozirconium compound (224) had been successfully formed. The use of Schwartz 
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reagent allows the hydrozirconation of 1-hexene (223a), providing the corresponding 
organometallic reagent 224, which acts as the nucleophile for the addition to the 
carbonyl. Next, ZnBr2 (1 eq.) was added to the in situ prepared 224, followed by the 
addition of a solution of Ti(OiPr)4 (0.5 eq.) and (Ra,S)-Ph-BINMOL (L42, 20 mol%) in 
dichloromethane. Last, cyclohexanecarboxaldehyde (225a, 1.0 eq, 0.125 M) was 
added dropwise and the reaction was left stirring at 35 C overnight. To our delight, 
99% conversion to the desired 226a was obtained, in 86% ee and a moderate yield 
of 60% (Table 14, entry 1). In addition, only 1% of the reduced product 225a-R was 
observed. We believe this by-product is formed by reduction of aldehyde 225a, via 
β-hydride elimination in the organozirconium reagent, to provide a metal-bonded 
hydride (and the corresponding alkene), which adds to the carbonyl substrate, 
generating the corresponding alcohol.  
 
Scheme 59: Model reaction for the study of the catalytic enantioselective 1,2-
addition of organozirconium reagents to aliphatic aldehydes. 
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In order to improve both yield and ee, we began the optimisation with an extensive 
screening of the zinc and titanium additives loading, in order to find the best ratio 
between the two that provides desired alcohol 226a. Firstly, we focused on changing 
the loading of ZnBr2; both lowering the amount to 0.025 eq. and increasing it to 1 eq. 
resulted in no conversion to 226a, with >99% conversion to the reduced product 
226a-R (Table 14, entries 2 and 3). The use of 1.5 eq. of ZnBr2 provided 95% 
conversion to 226a (along with 1% of 225a-R) but a lower enantioselectivity of 18% 
(Table 14, entry 4). Keeping ZnBr2 at 0.5 eq., we adjusted the amount of titanium 
tetraisopropoxide that was present in the reaction. Increasing the Ti(OiPr)4 loading 
to 2 eq., resulted in a large decrease in conversion to the desired product 226a (24%) 
and 75% conversion to the reduced product 225a-R, as well as lower ee (Table 14, 
entry 5). Lowering the equivalents of Ti(OiPr)4 to 1 eq. resulted in >99% conversion 
to the reduced product 225a-R (Table 14, entry 6). Varying the ratios between 
Ti(OiPr)4 and ZnBr2 to 2:1 and 2:2 (Table 14, entries 7 and 8) showed no improvement 
in enantioselectivity or conversion when compared with the original ratio of 3:1 
(Table 14, entry 1). 
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1.  2.2 42 2 35 1.5 0.5 99 1 86 
2.  2.2 42 2 35 1.5 0.025 0 >99 - 
3.  2.2 42 2 35 1.5 1 0 >99 - 
4.  2.2 42 2 35 1.5 1.5 95 1 18 
5.  2.2 42 2 35 2 0.5 24 75 48 
6.  2.2 42 2 35 1 0.5 0 >99 - 
7.  2.2 42 2 35 2 1 97 1 58 
8.  2.2 42 2 35 2 2 94 2 52 
9.  3 42 2 35 1.5 0.5 96 3 44 
10.  2.2 42 1.5 35 1.5 0.5 98 1 72 
11. d 2.2 42 2 35 1.5 0.5 99 1 64 
12.  2.2 42 2 r.t 1.5 0.5 36 64 70 
13. d 2.2 42 2 r.t 1.5 0.5 85 15 40 
14.  2.2 43 2 35 1.5 0.5 32 62 8 
15.  2.2 42 2 35 1.5 0 0 >99 - 
16.  2.2 - 2 35 1.5 0.5 0 >99 - 
17.  2.2 42 2 35 - 0.5 0 11 - 
a Reaction conditions: 225a, (0.3 mmol), 223a (x eq.), L42 or L43 (20 mol%), Cp2ZrHCl (x 
eq), Ti(OiPr)4 (x eq), ZnBr2 (x eq), DCM (0.3 + 0.1 mL), T, 12 h 
b 
Determined by GC-MS 
c Determined by Chiral GC (see experimental for further details)  
d Reaction carried out with CuCl (1.5 eq) instead of ZnBr2 
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With the optimal ratio between the zinc additive and the titanium source, we 
increased the amount of 1-hexene used within the reaction to 3 eq., which 
unfortunately showed a decrease in both conversion to 226a (72%) and ee (44%) 
(Table 14, entry 9). Lowering the amount of Schwartz reagent to 1.5 eq., slightly 
decreased the ee to 72% (Table 14, entry 10). We then decided to try CuCl as an 
alternative additive instead of ZnBr2, which afforded 98% conversion and lower 
enantioselectivity (64% ee) (Table 14, entry 11). We decreased the temperature to 
room temperature, in the hope that the enantioselectivity would be higher (Table 
14, entries 12 and 13) and would make the reaction more sustainable. Unfortunately, 
the conversion to 225a-R substantially increased, especially when using the zinc 
based additive (Table 14, entry 12).  
It has been previously reported that 4-Py-BINMOL (L43) is the most effective ligand 
for the catalytic enantioselective 1,2-addition of Grignard reagents to aliphatic 
aldehydes .187 However, when L43 was employed as the ligand for the addition of 1-
hexene (223a) to cyclohexanecarboxaldehyde (225a), only 32% conversion was 
observed for the desired 226a with lower ee (8%), whilst the amount of reduced by-
product 225a-R detected substantially increased (Table 14, entry 14). 
Previous mechanistic studies on the Ar-BINMOL catalysed enantioselective 1,2-
additon of organolithium reagents to carbonyl compounds,238 indicate that the 
catalytic active species are monomeric and the autoinduction effect (the chiral 
product participating in the catalytic system) is neglectable in the presence of the 
ligand. Based on previous studies by Seebach and Walsh onthe Ti(OiPr)4 assisted 
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addition of organozinc reagents to aldehydes ,169, 170  we propose intermediates 227 
and 228 (Figure 12) as possible catalytic species in our system. 
 
 
Figure 12: Proposed Intermediates 227 and 228 from mechanistic studies reported 
by Fernández, Seebach and Walsh. 
 
There are multiple mechanistic pathways by these catalytic enantioselective 1,2-
addition reaction of organozirconium reagents could proceed. We believe the in situ 
generated organozirconium reagents undergo transmetallation with the zinc 
bromide, followed by a second transmetallation with the excess of titanium 
isopropoxide to provide catalytic intermediate/species 227 (Figure 12).209, 210, 239 A 
control reaction, performed in the absence of ZnBr2, showed no conversion to the 
desired 226a and only the reduced product 225a-R was obtained (Table 14, entry 15), 
which supports our hypothesis. It cannot be ignored, however, that the activation of 
aldehydes via a zinc-halide complexation is a well known effect.240 Additional control 
reactions, performed in the absence of Ti(OiPr)4 and (Ra,S)-Ph-BINMOL (L42), also 
resulted in no conversion to our desired product but 11% and >99% conversion to 
the reduced product 225a-R respectively, was observed (Table 14, entries 16 and 17).  
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With the now optimised conditions (L42, 20 mol%), 2.2 eq. of alkene, 2 eq. Cp2ZrCl, 
1.5 eq. Ti(OiPr)4, 0.5 eq. ZnBr2, 35 °C Table 14, entry 1), the scope of the reaction with 
different aliphatic aldehydes was investigated (Table 15). The addition of 1-hexene 
(223a) to isobutyraldehyde (225b) and 2-ethylbutanal (225c) afforded the 
corresponding products 226b and 226c with excellent conversions (>99%) and high 
enantioselectivities of 76 and 70%, respectively (Table 15, entries 1 and 2). The 
isolated yields (42% and 54%, respectively) were moderate, due to the high volatility 
of the products, but the reduced by-products 225b-R and 225c-R were not observed 
in any case. Similar results were obtained for the reaction with pivaldehyde (225d) 
and 1-hexene (223a) which afforded 226d with 93% conversion (7% reduced 
product), moderate yield (50%, due to volatility of the product) and high 
enantioselectivity of 84% (Table 15, entry 3). The use of octanal (225e) as the 
substrate resulted in excellent conversion to the desired product 226e (91%)  along 
with 4% conversion to the reduced product 225e-R  and moderate isolated yield of 
50%. The enantiomeric excess of 226e was determined by HPLC analysis on the 
corresponding acetal (see Exp section for further details, Table 15, entry 4). The 
addition of 1-hexene (223a) to both 3-phenylpropionaldehyde (225f) and 
cinnamaldehyde (225g) led to the desired products 226f and 226g with relatively low 
yields (39% and 25% respectively) and high ee of 74% and 78% (Table 15, entries 5 
and 6). The addition of 1-hexene (223a) to phenylpropargyl aldehyde (225h) 
proceeded with a moderate yield and high ee 56% (Table 15, entry 7). 
Next, we tested the use of a variety of alkenes as nucleophiles for the addition to 
aliphatic aldehydes. The reaction with cyclohexanecarboxaldehyde (225a) and 4-
phenyl-1-butene (223b) provided moderate yield (33%) but high enantioselectivity 
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(68%) (Table 15, entry 8). Entries 9-10 (Table 15) show that this methodology is also 
compatible with functionalised alkenes. The use of 4–[(tert-butyldimethylsilyl)oxy]-
1-butene (223c) as a nucleophile afforded 226j with a low yield of 27% and a 
moderate ee 58% (Table 15, entry 9). The reactions with 4-halo-1-butenes as 
nucleophiles provided the desired alcohols 226k and 226l in 51 and 36% yield, 
respectively, and high enantioselectivity (84 and 60% ee, respectively, determined 
on the corresponding acetates). It is worth noting that the majority of the yields are 








Table 15: Catalytic enantioselective addition of alkenes to aliphatic aldehydes.a 
 
Entry Product Conv. 
(%)b 





















91 4 48 74(R)f,g 
a Reaction conditions: 225a-g, (0.3 mmol), 223a-c (2.2 eq), L42 (20 mol%), Cp2ZrHCl (2 eq), Ti(OiPr)4 
(1.5 eq), ZnBr2 (0.5 eq), DCM (0.3 + 0.1 mL) 35 °C, 12 h. 
b 
Determined by GC-MS. 
c Isolated yield after flash chromatography 
d Configuration in brackets assigned by comparison of the optical rotation with the literature (see 
experimental for further details). 
e Determined by Chiral GC (see experimental for further details). 
f Determined by Chiral HPLC (see experimental for further details). 
g Determined on the corresponding acetate derivative (see experimental for further details).  
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Table 16 Continued: Catalytic enantioselective addition of alkenes to aliphatic 
aldehydes.a 































73 20 51 84(R)e,f 
11.  
 
66 34 36 60(R)e,f 
a Reaction conditions: 225a-g, (0.3 mmol), 223a-c (2.2 eq), L42 (20 mol%), Cp2ZrHCl (2 eq), 
Ti(OiPr)4 (1.5 eq), ZnBr2 (0.5 eq), DCM (0.3 + 0.1 mL) 35 °C, 12 h. 
b 
Determined by GC-MS. 
c Isolated yield after flash chromatography. 
d Configuration in brackets assigned by comparison of the optical rotation with the literature 
(see experimental for further details). 
e Determined by Chiral GC (see experimental for further details). 
f Determined by Chiral HPLC (see experimental for further details). 
g Determined on the corresponding acetate derivative (see experimental for further details). 
 




In conclusion, we have successfully developed and optimised an enantioselective 1,2-
addition of alkenes to aliphatic aldehydes using the very versatile (Ra,S)-Ph-BINMOL 
ligand L42. This is of significant value as, to the best of our knowledge, it is the first 
example of the addition of organozirconium reagents to aliphatic aldehydes. Addition 
to aliphatic substrates is more challenging as they are enolisable and have multiple 
conformations. However, this methodology overcomes these problems and the 
scope of the reaction includes not only a variety of aliphatic aldehydes but also allows 
for a range of functionalised nucleophiles. This is a substantial improvement as 
usually not many functionalised nucleophiles are suitable for addition to aliphatic 
aldehydes. The reaction proceeds with enantioselectivities, ranging from 56-86%, 
good to high conversions (53–99%) and moderate yields (27-60%), are obtained 
under the optimised conditions (L42 2.2 eq. of alkene, 2 eq. Cp2ZrCl, 1.5 eq. Ti(OiPr)4, 
0.5 eq. ZnBr2, 35 °C). The one-pot reaction is more sustainable as it is performed 
under mild conditions, making it an efficient procedure for the synthesis of valuable 
chiral aliphatic secondary alcohols.  
 
4.5 Experimental  
General Considerations.  
For Materials, Glassware, TLC, Flash Chromatography, FT-IR, NMR, GC-MS, MW and 
Optical rotations: see Section 2.5 
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The assignment of the configuration in products 226 was performed by comparison 
of the sign of the optical rotation with the literature for known samples. In the case 
of unknown samples, the same configuration was assigned by analogy. 
Enantioselectivity determination was carried out by gas chromatography or HPLC 
analysis: 
GC-FID: Gas chromatography analysis was performed on an Agilent 
Technologies® 7890A GC System and a Hewlett Packard® 5890 Series II GC System, 
with a CycloSil-β (Agilent Technologies, 30 m x 0.25 mm) and a CP-Chirasil-DEX CB 
(Varian, 25 m x 0.25 mm) column, respectively; injector and detector temperatures: 
250 °C.  
HPLC-DAD: HPLC analysis was carried out on an Agilent 1100 series HPLC 
equipped with a G1313B diode array detector and a G1311A Quat pump. Chiral 
columns used for analysis were Lux 5µ Cellulose-1. 
Melting Point: Melting point analysis were measured in a Stuart® SMP10 melting 
point apparatus. 
Ligands (Ra,S)-Ph-BINMOL (L42) and (Ra,S)-4-py-BINMOL (L43)- were prepared 
according to literature procedures.182 
Synthesis of (R)-2'-(benzyloxy)-[1,1'-binaphthalen]-2-
ol (197, R = Ph, precursor to L42): (R)‐BINOL (195, 2.0 g, 
7.0 mmol) was dissolved in acetone (50 mL), then K2CO3 
(1.5 eq, 1.5 g, 10.5 mmol) and benzyl bromide (1.0 eq, 
0.83 mL, 7.0 mmol) were added and the mixture was heated at 60 °C for 6 h. The 
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reaction crude was concentrated under reduced pressure and extracted with EtOAc 
(3 × 15 mL). The combined organic layers were then dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude material was then used in the next 
step without further purification.  
Synthesis of (R)-2'-(pyridin-4-ylmethoxy)-(1,1'-
binaphthalen)-2-ol (197, R = 4-Py, precursor of L43): 
(R)‐BINOL (195, 2.0 g, 7.0 mmol) was dissolved in 
acetone (40 mL) and a solution of K2CO3 (3.0 eq, 2.9 g, 
21.0 mmol) in 4 mL of water was added. Next, 4-(bromomethyl)pyridine (1.0 eq, 1.77 
g, 7.0 mmol) was added and the mixture was heated at 65 °C for 12 h. The reaction 
crude was filtered under vacuum over Celite®, washing the cake with EtOAc (3 × 50 
mL) and solvent was evaporated under vacuum. The crude material was purified by 
flash chromatography to give the named compound as a white powder. Yield: 66%. 
RF: 0.15 (EtOAc/ hexane 1:1) Mp = 182–184 °C. FTIR (neat): 3064, 1610, 1504, 1325, 
1264, 1044, 798 cm-1. 1H NMR (400 MHz, CDCl3) δ: 8.26 (d, J = 4.5 Hz, 2H), 7.97 (d, J 
= 9.0 Hz, 1H), 7.91 (d, J = 8.9 Hz, 1H), 7.87 (d, J = 7.8 Hz, 2H), 7.42–7.34 (m, 3H), 7.34–
7.26 (m, 3H), 7.21 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 
5.2 Hz, 2H), 5.08 (d, J = 13.9 Hz, 1H), 5.03 (d, J = 13.8 Hz, 1H), 3.18 (br s, 1H). 13C NMR 
(100.6 MHz, CDCl3) δ: 154.3, 151.6, 148.9, 146.9, 134.0, 133.8, 130.9, 129.9, 129.1, 
128.2, 127.5, 126.5, 125.2, 124.7, 123.3, 121.2, 117.7, 115.4, 114.8, 69.4. Data in 
accordance with literature.182 




octahydro-(1,1'-binaphthalen)-2-ol (L42):. n-BuLi (2.5 M in 
hexane, 2.5 eq.) was slowly added to a solution of the 
corresponding precursor 197-Ph (1.5 g, 4.0 mmol) in dry 
THF (30 mL) at –78 °C. The mixture was stirred for 2 h at –78 °C and then quenched 
with water at 0 °C. The resulting mixture was extracted with EtOAc (3 × 10 mL), 
filtered and the combined organic layers were washed with brine, dried over MgSO4 
and concentrated under vacuum. The crude material was purified by flash 
chromatography to give the desired product as a white powder. Yield: 85% RF: 0.21 
(EtOAc/ hexane 1:1). Mp = 72–75 °C. FTIR (neat) Vmax: 3297, 3337, 2927, 1591, 1448, 
1018, 808, 698 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.30 (d, J = 8.0 Hz, 1H), 7.24 – 7.17 
(m, 3H), 7.14 (d, J = 8.0 Hz, 1H), 7.11 – 7.06 (m, 2H), 7.01 (d, J = 8.3 Hz, 1H), 6.81 (d, J 
= 8.3 Hz, 1H), 5.43 (s, 1H), 4.96 (br s, 1H), 2.80 (t, J = 6.0 Hz, 3H), 2.69 (dd, J = 13.3, 
6.7 Hz, 2H), 2.19 (dd, J = 14.2, 6.1 Hz, 2H), 1.99 – 1.89 (m, 1H), 1.80 – 1.50 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ: 149.8, 142.7, 139.9, 137.8, 136.5, 136.1, 133.6, 129.8, 
129.7, 129.6, 128.1, 127.3, 126.8, 124.7, 124.3, 113.1, 73.5, 29.9, 29.2, 27.4, 27.2, 
23.2, 22.9, 22.8, 22.7. Data in accordance with literature.182 
(Ra)-2'-[(S)-Hydroxy(pyridin-4-yl)methyl]-(1,1'-
binaphthalen)-2-ol (L43): n-BuLi (5.0 eq, 2.5 M in hexane) 
was slowly added to a solution of 197-Py (1.51 g, 4.0 mmol) 
in dry THF (40 mL) at room temperature. The mixture was 
stirred for 12 h at 70 °C and then the reaction was quenched with water at 0 °C. The 
resulting mixture was extracted with EtOAc (3 × 15 mL), filtered and the combined 
organic layers were dried over MgSO4, filtered and concentrated under vacuum. The 
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crude product was purified by chromatography on flash silica gel to give the desired 
product as a white solid. Yield: 164 mg, 21%. RF: 0.17 (EtOAc /hexane 1:1). Mp: 100–
103 °C. FTIR (neat) Vmax: 3297, 3055, 1606, 1506, 1342, 813, 747 cm-1..1H NMR (300 
MHz, CDCl3) δ: 8.15 (d, J = 6.2 Hz, 2H), 7.95 – 7.73 (m, 4H), 7.42 (ddd, J = 8.1, 6.5, 1.6 
Hz, 1H), 7.36 – 7.26 (m, 3H), 7.25 – 7.13 (m, 3H), 6.97 (d, J = 5.8 Hz, 2H), 6.90 (d, J = 
8.3 Hz, 1H), 5.64 (s, 1H), 3.56 (br s, 2H). 13C NMR (75 MHz, CDCl3) δ: 152.8, 152.0, 
148.3, 139.8, 134.2, 133.4, 132.9, 131.8, 130.2, 129.4, 128.9, 128.2, 128.1, 126.8, 
126.8, 126.5, 125.0, 124.8, 123.6, 121.5, 118.3, 117.3, 72.1. Data in accordance with 
literature.182  
 
Synthesis of tert-butyl(diphenyl)silyl-3-butenyl ether (223b): 
was carried out according to literature procedure To a 
solution of 3-buten-1-ol (1 eq, 0.43 mL, 5 mmol) and imidazole 
(2 eq, 681 mg, 10 mmol) in DMF (10 mL) at 0 °C was added dropwise tert-
butyldiphenylsilyl chloride (1.2 eq, 1.29 mL, 6 mmol). The reaction mixture was 
warmed up to RT and then stirred for 3 h. The reaction was quenched with water (10 
mL) and the organic layer was separated. The aqueous phase was then extracted with 
Et2O (3  10 mL) and the combined organic extracted were washed with saturated 
aqueous NaHCO3 (10 mL) and brine (10 mL), dried over MgSO4, and concentrated 
under reduced pressure. The isolated product was purified by flash chromatography 
to afford the named compound as a colourless oil Yield: 1.14 g, 74% RF: 0.24 (Et2O 
/hexane 1:1). FTIR (neat) Vmax: 2958, 2858, 1473, 1428, 1195, 1088, 736, 699, 611, 
504, 489 cm-1. 1H NMR (400 MHz, CDCl3) δ: 8.20 – 7.96 (m, 4H), 7.68 (m, 6H), 6.17 
(tdd, J = 17.1, 8.9, 5.4 Hz, 1H), 5.46 – 5.23 (m, 2H), 4.07 (dq, J = 14.1, 7.0 Hz, 2H), 2.80 
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– 2.57 (m, 2H), 1.51 – 1.32 (s, 9H). 13C NMR (101 MHz, CDCl3) δ: 135.7, 135.4, 134.0, 
129.7, 127.8, 116.6, 63.6, 37.4, 27.0, 19.4. Data in accordance with literature.241  
 
General procedure for the catalytic enantioselective 1,2-addition of alkenes to 
aldehydes: To a stirred suspensions of Cp2ZrHCl (1 eq, 154 mg, 0.6 mmol) in dry 
CH2Cl2 (0.3 mL) under argon at RT, the corresponding alkene (2.2 eq, 0.66 mmol) was 
added dropwise and the solution was stirred for 30 min. The mixture turned to a clear 
yellow solution, which indicated the successful formation of the organozirconium 
reagent. Next, flame-dried ZnBr2 (0.5 eq, 34 mg, 0.15 mmol) was added to the 
solution at RT and stirred for 2 min. Next, a solution of Ti(OiPr)4 (1.5 eq, 134 L, 0.45 
mmol) and (Ra,S)-Ph-BINMOL (23 mg, 20 mol%) in dry CH2Cl2 (0.1 mL) was added and 
stirred for an additional 2 min at RT. Finally, the freshly distilled aldehyde (0.3 mmol) 
was added and the solution was stirred at 35 C overnight. The reaction was 
quenched with water (2 mL) and the layers were separated and the aqueous layer 
was extracted with Et2O (3  10 mL). The combined layers were dried with MgSO4, 
filtered and concentrated under reduced pressure. The product was purified by flash 
silica gel chromatography. 
General procedure for the preparation of racemic alcohols 226a-h: 
A solution of Grignard reagent (hexylmagnesium bromide), prepared from 1-
bromohexane (1.3 eq, 0.85 mL, 6.03 mmol) and magnesium turnings (1.2 eq, 133 mg, 
5.49 mmol) in diethyl ether (6 mL), was added dropwise to the corresponding 
aldehyde 225a-h (1 eq, 4.56 mmol) in diethyl ether (3 mL) . After the addition, the 
reaction mixture was stirred at RT for 2 h and then quenched with water (3 mL). The 
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aqueous mixture was extracted with Et2O (3 × 20 mL) and the combined organic 
layers were washed with aqueous HCl (1M, 10 mL). The organic layer was then 
washed with brine (2 × 10 mL), dried over MgSO4 and concentrated under reduced 
pressure. The crude material was purified by flash chromatography (Et2O/ 
cyclohexane, 3:7). 
General procedure for the preparation of racemic alcohols 226i-l: Racemic alcohols 
226i-l were prepared using the general procedure for the catalytic enantioselective 
1,2‐addition of alkenes above using rac-L42. 
(R)-1-Cyclohexylheptan-1-ol (226a): Compound 226a was 
synthesised using the general procedure for the catalytic 
enantioselective 1,2‐addition of alkenes to aldehydes, from 
cyclohexanecarboxaldehyde (225a, 36 μL, 0.3 mmol) and 1-hexene (223a, 82 μL, 0.66 
mmol) to give the named compound as a yellow oil. Yield: 36 mg, 60%. RF: 0.36 (Et2O 
/ hexane 3:7). ee: 86%. [α]D23 = +17.4 (c 1.5, CH2Cl2). {Lit [α]D25 = −10.5 (c 0.2, CHCl3) 
for 84% ee of S enantiomer}. FTIR (neat) Vmax: 3380, 2919, 2852, 1449, 1377, 1084, 
1064 cm-1. 1H NMR (400 MHz, CDCl3) δ: 3.39 – 3.29 (m, 1H), 1.81 – 1.70 (m, 3H), 1.70 
– 1.60 (m, 2H), 1.51 – 1.42 (m, 2H), 1.36 – 0.93 (m, 15H), 0.87 (t, J = 6.8 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ: 76.1, 43.8, 34.0, 33.3, 33.0, 29.4, 27.8, 26.6, 26.5, 26.3, 
24.8. m/z: 180 (M+-H2O, 11%), 115 (26), 114 (14), 113 (47), 97 (76), 96 (21), 95 (100), 
83 (10), 82 (14), 81 (10), 69 (14), 67 (16), 57 (12), 55 (59). HRMS (m/z): Calculated 
C13H25O [M-H]+: 197.1905, found: 197.1904. ee determination by chiral GC analysis, 
CP Chirasil-DEX CB column, T = 86°C retention times: tr = 42.1 min, tr = 42.8 min (major 
enantiomer). Data in accordance with literature.242  
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(R)-2-Methylnonan-3-ol (226b): Compound 226b was 
synthesised from isobutyraldehyde (225b, 27 μL, 0.3 
mmol) and 1-hexene (223a, 82 μL, 0.66 mmol) using the general procedure for the 
catalytic enantioselective 1,2‐addition of alkenes to aldehydes to give the named 
compound as a yellow oil. Yield: 20 mg, 42%. RF: 0.42 (Et2O / hexane 4:8) ee: 76%. 
[α]D23 = +13.3 (c 0.6, CH2Cl2). (c 0.6, CH2Cl2). {Lit [α]D25 = −14.1 (c 0.7, CHCl3) for 96% 
ee of S enantiomer}.  FTIR (neat) Vmax: 3352, 2950, 2923, 2872, 2854, 1446, 1378, 
1059 cm-1.  1H NMR (400 MHz, CDCl3) δ: 3.41 – 3.30 (m, 1H), 1.64 (m, 1H), 1.50 – 1.41 
(m, 2H), 1.41 – 1.22 (m, 9H), 0.93 – 0.82 (m, 9H). 13C NMR (101 MHz, CDCl3) δ: 76.9, 
34.3, 33.6, 32.0, 29.6, 26.2, 22.8, 19.0, 17.2, 14.3. m/z: 140 (M+-H2O, 11%), 115 (26), 
97 (82), 73 (47), 69 (20), 57 (14), 55 (100). HRMS (m/z): Calculated C10H21O [M-H]+: 
157.1592, found: 157.1587. ee determination by chiral GC analysis, CP Chirasil-DEX 
CB column, T = 89°C, retention times: tr = 43.3 min, tr = 42.5 min (major enantiomer). 
Data in accordance with literature.243  
(R)-3-Ethylnonan-4-ol (226c): Compound 226c was 
synthesised from 2-ethylbutyraldehyde (225c, 37 μL, 
0.3 mmol) and 1-hexene (223a, 82 μL, 0.66 mmol) using 
the general procedure for the catalytic enantioselective 1,2‐addition of alkenes to 
aldehydes to give the named compound as a yellow oil. Yield: 30 mg, 54%. RF: 0.33 
(Et2O / cyclohexane 2:8) ee: 70% [α]D23 = +6.7 (c 0.4, CH2Cl2). FTIR (neat) Vmax: 3373, 
2958, 2925, 2873, 2858, 1461, 1379, 1143 cm-1. 1H NMR (400 MHz, CDCl3) δ: 3.69 – 
3.52 (m, 1H), 1.45 – 1.16 (m, 16H), 1.06 – 0.81 (m, 9H). 13C NMR (101 MHz, CDCl3) δ: 
73.3, 46.9, 34.2, 32.0, 29.6, 26.4, 22.8, 22.2, 21.3, 14.3, 12.1, 12.0. m/z: 168 (M+-H2O, 
1%), 115 (28), 101 (23), 97 (98), 83 (15), 70 (15), 69 (21), 59 (24), 57 (19), 55 (100) 
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HRMS (m/z): Calculated C12H25O [M-H]+: 185.1905, found: 185.1909. ee 
determination by chiral GC analysis, CP Chirasil-DEX CB column, T = 102°C, retention 
times: tr = 75.1 min, tr = 75.2 min (major enantiomer). 
(R)-2,2-Dimethylnonan-3-ol (226d): Compound 226d was 
synthesised from trimethylacetaldehyde (225d, 33 μL, 0.3 
mmol) and 1-hexene (223a, 82 μL, 0.66 mmol) using the general procedure for the 
catalytic enantioselective 1,2‐addition of alkenes to aldehydes to give the named 
compound as a yellow oil. Yield: 26 mg, 50%. RF: 0.29 (Et2O / cyclohexane 3:7). ee: 
84%. [α]D23  = +8.9 (c 0.9, CH2Cl2). {Lit [α]D25 = +15.0 (c 5.1, benzene) for 84% ee}. FTIR 
(neat) Vmax: 3392, 2954, 2925, 2859, 1479, 1466, 1393, 1364, 1075, 1009, 957, 734, 
703, 566, 543 cm-1. 1H NMR (400 MHz, CDCl3) δ: 3.17 (d, J = 7.4 Hz, 1H), 1.64 – 1.40 
(m, 3H), 1.36 – 1.18 (m, 8H), 0.87 (br s, 12H). 13C NMR (101 MHz, CDCl3) δ: 80.1, 35.1, 
32.1, 31.6, 29.6, 27.2, 25.8, 22.8, 14.3. m/z: 154 (M+-H2O, 0.18%), 115 (31), 114 (13), 
97 (100), 87 (28), 69 (31), 57 (40), 56 (12), 55 (80). HRMS (m/z): Calculated C11H23O 
[M-H]+: 171.1749, found: 171.1743. ee determination by chiral GC analysis, CP 
Chirasil-DEX CB column, T = 102°C, retention times: tr = 38.6 min, tr = 40.2 min (major 
enantiomer). Data in accordance with literature.244  
(R)-Tetradecan-7-ol (226e): Compound 226e 
was synthesised from octanal (225e, 47 μL, 0.3 
mmol) and 1-hexene (223a, 82 μL, 0.66 mmol) 
using the general procedure for the catalytic enantioselective 1,2‐addition of alkenes 
to aldehydes to give the named compound as a white solid. Yield: 31 mg, 48% RF: 
0.37 (Et2O / cyclohexane 3:7). Mp = 36–39 °C. ee: 74% (determined on the 
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corresponding acetate). [α]D22 = +13.3 (c 0.7, CH2Cl2). FTIR (neat) Vmax: 3343, 2956, 
2929, 2872, 1470, 1381, 1045, 952, 817 cm-1. 1H NMR (400 MHz, CDCl3) δ: 3.55 (s, 
1H), 1.40 (br s, 7H), 1.26 (br s, 16H), 0.86 (t, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ: 72.2, 37.6, 32.0, 30.0, 30.0, 29.5, 27.0, 25.8, 25.8, 22.9, 22.8, 14.3. m/z: 196 (M+-
H2O, 8%), 129 (36), 115 (38), 111 (41), 97 (100), 83 (11), 69 (94), 57 (20), 55 (74). 
HRMS (m/z): Calculated C14H29O [M-H]+: 213.2219, found: 213.2213. 
(R)-1-Phenylnonan-3-ol (226f): Compound 226f 
was synthesised from 3-phenylpropionaldehyde 
(225f, 37 μL, 0.3 mmol) and 1-hexene (223a, 82 
μL, 0.66 mmol) using the general procedure for the catalytic enantioselective 1,2‐
addition of alkenes to aldehydes to give the named compound as a yellow oil. Yield: 
26mg, 40%. RF: 0.34 (Et2O / cyclohexane 3:7). ee: 74%. [α]D23 = +40 (c 0.3, CH2Cl2). 
{Lit [α]D21 = −8.2 (c 0.3, CHCl3) for 72% ee}. FTIR (neat) Vmax: 3372, 2951, 2857 cm-1.  
1H NMR (400 MHz, CDCl3) δ: 7.26 – 7.07 (m, 5H), 3.65 – 3.49 (m, 1H), 2.78 – 2.56 (m, 
2H), 1.78 – 1.61 (m, 2H), 1.51 (s, 1H), 1.45 – 1.12 (m, 10H), 0.81 (t, J = 6.8 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ: 142.4, 128.6, 128.5, 125.9, 71.6, 39.2, 37.7, 32.2, 32.0, 29.5, 
25.7, 22.8, 14.2. m/z: 202 (M+-H2O, 32%), 131 (50), 117 (47), 115 (18), 105 (22), 104 
(92), 92 (23), 91 (100), 69 (17), 55 (13). HRMS (m/z): Calculated C15H23O [M-H]+: 
219.1754, found: 219.1755. ee determination by chiral HPLC analysis, Phenomenex® 
LUX Cellulose-1, Hex/i-PrOH 98:2, flow = 1 mL/min, T = RT, retention times: tr = 16.1 
min (major enantiomer), tr = 27.6 min. Data in accordance with literature.245  
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(E,R)-1-Phenylnon-1-en-3-ol (226g): Compound 
226g was synthesised from trans-cinnamaldehyde 
(225g, 38 μL, 0.3 mmol) and 1-hexene (223a, 82 μL, 
0.66 mmol) using the general procedure for the catalytic enantioselective 1,2‐
addition of alkenes to aldehydes to give the named compound as a yellow oil. Yield: 
22 mg, 34%. RF: 0.18 (Et2O / cyclohexane 2:8). ee: 78%. [α]D26 = −66.7 (c 1.2, CH2Cl2). 
{Lit [α]D21 = −5.6 (c 1.07, CHCl3) for 91% ee}. FTIR (neat) Vmax: 3357, 2954, 2927, 2856, 
1600, 1465, 1450, 1204 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.40 – 7.36 (m, 2H), 7.33 
– 7.28 (m, 2H), 7.24 – 7.20 (m, 1H), 6.56 (d, J = 15.8 Hz, 1H), 6.21 (dd, J = 15.9, 6.8 Hz, 
1H), 4.35 – 4.18 (m, 1H), 1.76 – 1.51 (m, 3H), 1.42 – 1.17 (m, 7H), 0.87 (t, J = 6.8 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ: 136.9, 132.7, 130.4, 128.7, 127.8, 126.6, 73.3, 37.5, 
31.9, 29.4, 25.6, 22.8, 14.2. m/z: 218 (M+ 3%), 148 (14), 134 (11), 133 (100), 131 (17), 
130 (29), 129 (16), 128 (16), 115 (64), 113 (14), 105 (47), 104 (21), 103 (31), 91 (45) 
79 (17), 78 (18), 77 (46), 55 (55), 51 (14). HRMS (m/z): Calculated C15H23O [M+H]+: 
219.1749, found: 219.1749. ee determination by chiral HPLC analysis, Phenomenex® 
LUX Cellulose-1, Hex/i-PrOH 97:3, flow = 1 mL/min, T = RT, retention times: tr = 20.4 
min, (major enantiomer), tr = 37.8 min.246  
(R)-1-Phenylnon-1-yn-3-ol (226h): Compound 226h 
was synthesised from phenylpropargyl aldehyde 
225h (40 μL, 0.3 mmol) and 1-hexene 223a (82 μL, 
0.66 mmol) using the general procedure for the catalytic enantioselective 1,2‐
addition of alkenes to aldehydes to give the named compound as a yellow oil. Yield: 
26 mg, 40% RF: 0.24 (Et2O / cyclohexane 2:8) ee: 56% [α]D23 = −22.2 (c 3.6, CH2Cl2). {Lit 
[α]D23 = −1.5 (c 0.69, CHCl3) for 92% ee).  FTIR (neat) Vmax: 3338, 2927, 2857, 1667, 1598, 
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1489, 1443 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.46 – 7.40 (m, 2H), 7.35 – 7.28 (m, 
3H), 4.60 (t, J = 6.6 Hz, 1H), 2.18 (br s, 1H), 1.85 – 1.73 (m, 2H), 1.56 – 1.43 (m, 2H), 
1.40 – 1.25 (m, 6H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ: 131.8, 128.4, 
122.8, 90.4, 84.9, 63.1, 38.0, 31.9, 29.1, 25.3, 22.7, 14.2. m/z: 216 (M+ 4%), 198 (58), 
155 (40), 154 (14), 152 (10), 142 (15), 141 (67), 139 (12), 129 (69), 128 (100), 127 (11), 
115 (65), 105 (15), 103 (21), 102 (86), 91 (16), 77 (20), 76 (18), 75 (10), 74 (10), 70 
(14), 55 (12). HRMS (m/z): Calculated C15H19O [M-H]+: 215.1436, found: 215.1445. ee 
determination by chiral HPLC analysis, Phenomenex® LUX Cellulose-1, Hex/i-PrOH 
97:3 flow = 1 mL/min, retention times: tr = 15.0 min, (major enantiomer). tr = 44.5 
min. Data in accordance with literature.247  
(R)-1-Cyclohexyl-6-phenylhexan-1-ol (226i): 
Compound 226i was synthesised from aldehyde 
cyclohexcarboxaldehyde 225a (36 μL, 0.3 mmol) and 4-
phenyl-1-butene 223b (99 μL, 0.66 mmol) using the general procedure for the 
catalytic enantioselective 1,2‐addition of alkenes to aldehydes to give the named 
compound as a yellow oil. Yield: 24 mg, 33% RF: 0.19 (Et2O / cyclohexane 3:7) ee: 
68% [α]D23 = +40 (c 0.4, CH2Cl2). FTIR (neat) Vmax: 3368, 3026, 2922, 2852, 1603, 1496, 
1450, 1077, 977, 745, 697 cm-1 1H NMR (400 MHz, CDCl3) δ: 7.23 – 7.17 (m, 2H), 7.15 
– 7.08 (m, 3H), 3.36 – 3.19 (m, 1H), 2.61 – 2.49 (m, 2H), 1.77 – 1.63 (m, 3H), 1.64 – 
1.51 (m, 4H), 1.49 – 0.86 (m, 11H). 13C NMR (101 MHz, CDCl3) δ: 142.8, 128.5, 128.4, 
125.7, 76.2, 43.7, 36.1, 34.0, 31.7, 29.3, 27.8, 26.6, 26.4, 26.3, 25.8. m/z: 228 (M+ 
21%) 145 (27), 128 (16), 132 (23), 117 (29), 105 (16), 104 (100), 95 (29), 92 (19), 91 
(89) 83 (10), 81 (14), 67 (17), 55 (23). HRMS (m/z): sample could not be ionised. ee 
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determination by chiral HPLC analysis, Phenomenex® LUX Cellulose-1, Hex/i-PrOH 
97:3 flow = 1 mL/min, T= RT, tr = 9.67 min, tr = 10.12 min (major enantiomer). 
(R)-5-(tert-Butyl-dimethyl-silanyloxy)-1- 
cyclohexylheptan-1-ol (226j): Compound 226j was 
synthesised from cyclohexcarboxaldehyde (225a, 36 μL, 
0.3 mmol) and tert-butyl(diphenyl)silyl-3-butenyl ether 
(223b, 205 mg, 0.66 mmol) using the general procedure for the catalytic 
enantioselective 1,2‐addition of alkenes to aldehydes to give the named compound 
as a brown oil. Yield: 34 mg, 27%. RF: 0.25 (Et2O / hexane 3:7). ee: 58%. [α]D23 = 
+10.81 (c 3.7, CH2Cl2). FTIR (neat) Vmax: 3369, 2927, 2854, 1428, 1106, 823, 699, 613, 
503, 187 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.67 (dd, J = 4.2, 3.4 Hz, 4H), 7.44 – 7.34 
(m, 6H), 3.67 (t, J = 6.1 Hz, 2H), 3.36 – 3.29 (m, 1H), 1.83 – 1.70 (m, 3H), 1.70 – 0.88 
(m with s at 1.05 25H). 13C NMR (101 MHz, CDCl3) δ: 135.5, 134.0, 129.5, 127.6, 76.0, 
63.8, 43.5, 33.7, 32.5, 29.2, 27.6, 26.8, 26.5, 26.3, 26.2, 22.1, 19.2. HRMS (m/z): 
Calculated C27H41O2Si [M+H]+: 425.2876, found: 425.2867. ee determination by chiral 
HPLC analysis, Phenomenex® LUX Cellulose-1, Hex/i-PrOH 97:3, flow = 1 mL/min, T= 
RT retention times: tr = 5.92 min (major enantiomer), tr = 7.41 min. 
(R)-5-Bromo-1-cyclohexylpentan-1-ol (226k): 
Compound 226k was synthesised from 
cyclohexcarboxaldehyde (225a, 36 μL, 0.3 mmol) and 4-
bromo-1-butene (223c, 67 μL, 0.66 mmol) using the general procedure for the 
catalytic enantioselective 1,2‐addition of alkenes to aldehydes to give the named 
compound as a yellow oil. Yield: 38mg, 51%. RF: 0.60 (Et2O / cyclohexane 1:1). ee: 
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84% (determined on the corresponding acetate). [α]D25 = +12 (c 1, CH2Cl2). FTIR (neat) 
Vmax: 3368, 2928, 2851, 1450, 1237, 1087, 1064, 1047, 975, 893, 562 cm-1. 1H NMR 
(400 MHz, CDCl3) δ: 3.41 (t, J = 6.9 Hz, 2H), 3.37 – 3.32 (m, 1H), 1.94 – 1.83 (m, 2H), 
1.83 – 1.69 (m, 4H), 1.69 – 1.57 (m, 4H), 1.57 – 0.89 (m, 8H). 13C NMR (101 MHz, 
CDCl3) δ: 76.1, 43.8, 34.0, 33.3, 33.0, 29.4, 27.8, 26.6, 26.5, 26.3, 24.8. m/z: 230 (M+ 
-H2O 1%) 167 (41), 165 (40), 113 (62), 96 (12), 95 (100), 85 (85), 84 (20), 83 (19), 82 
(13), 68 (10), 67 (48), 57 (25), 55 (51). HRMS (m/z): Calculated C11H21OBr [M+Na]+: 
271.0673, found: 271.0668. 
 
(R)-5-Chloro-1-cyclohexylpentan-1-ol (226l): Compound 
226l was synthesised from cyclohexcarboxaldehyde 
(225a, 36 μL, 0.3 mmol) and 4-chloro-1-butene (223c, 65 
μL, 0.66 mmol) using the general procedure for the catalytic enantioselective 1,2‐
addition of alkenes to aldehydes to give the named compound as a yellow oil. Yield: 
22 mg, 36%. RF: 0.58 (Et2O / cyclohexane 1:1). ee: 60% (determined on the 
corresponding acetate). [α]D25 = +20 (c 0.8, CH2Cl2). FTIR (neat) Vmax: 3369, 2923, 
2851, 1449, 1309, 1088, 1065, 977, 892, 734, 651 cm-1. 1H NMR (400 MHz, CDCl3) 
δ:3.57 – 3.48 (m, 2H), 3.39 – 3.27 (m, 1H), 1.84 – 1.70 (m, 5H), 1.70 – 1.55 (m, 4H), 
1.53 – 0.90 (m, 9H). 13C NMR (101 MHz, CDCl3) δ: 76.0, 45.1, 43.7, 33.3, 32.7, 29.3, 
27.7, 26.6, 26.4, 26.2, 23.4. m/z: 186 (M+-H2O 2%), 123 (21), 121 (62), 120 (13), 113 
(44), 101 (13), 96 (13), 95 (100), 85 (62), 84 (17), 82 (14), 81 (15), 67 (47), 57 (22), 55 
(49). HRMS (m/z): Calculated C11H2OCl [M-H]+: 203.1197, found: 203.1206. 
General procedure for the synthesis benzoate derivatives (226e’, 226k’ and 
226l’):214 The corresponding chiral aliphatic alcohol (0.10 mmol) was dissolved in 
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anhydrous DCM (1 mL, 0.1 M). Sequentially, at 0 °C, Et3N (28 μL, 0.2 mmol, 2.0 eq), 
DMAP (1.3 mg, 0.20 mmol, 2.0 eq) and benzyl chloride (12 μL, 0.1 mmol, 1.0 eq.) 
were added. The reaction mixture was stirred overnight at RT. The reaction was 
quenched with water (1 mL), extracted with Et2O (3 × 5 mL). The combined organic 
layers were dried over MgSO4 and concentrated under vacuum. The crude material 
was purified by flash silica gel chromatography. 
(R)-Tetradecan-7-yl benzoate (226e’): The 
corresponding compound was synthesised from (R)-
226e (10 mg, 0.047 mmol) using the general 
procedure for the synthesis of benzoate derivatives 
to give the named compound as a white solid. Yield: 7 mg, 55%. RF: 0.73 (Et2O/ 
hexane 2:8) Mp = 42–45 °C. ee: 74% [α]D23 = +20 (c 1.2, CH2Cl2). FTIR (neat) Vmax: 
3349, 2926, 2855, 190, 1723, 1211, 1936, 1014, 703 cm-1. 1H NMR (400 MHz, CDCl3) 
δ: 8.17 (d, J = 8.1 Hz, 2H), 7.76 – 7.57 (m, 1H), 7.53 (t, J = 7.7 Hz, 2H), 3.63 – 3.53 (m, 
1H), 1.50 – 1.36 (m, 6H), 1.28 (br s, 16H), 0.88 (t, J = 6.3 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ: 162.5, 134.7, 130.7, 129.0, 72.2, 37.6, 32.0, 29.8, 29.5, 29.5, 25.8, 25.8, 22.8, 
22.8, 14.3. m/z: 281 (14), 208 (15), 207 (100), 105 (68), 77 (11). HRMS (m/z): 
Calculated C21H35O2 [M+H]+: 319.2637, found: 319.2630. ee determination by chiral 
HPLC analysis, Phenomenex® LUX Cellulose-1, Hexane 100, flow = 1 mL/min, T = RT. 
retention times: tr = 9.97 min, tr = 10.27 min (major enantiomer). 
(R)-5-Bromo-1-cyclohexylpentyl benzoate (226k’): The corresponding compound 
was synthesised from (R)- 226k (40 mg, 0.16 mmol) using the general procedure for 
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the synthesis of benzoate derivatives to give the named 
compound as a brown oil. Yield: 11 mg, 19%. RF: 0.79 
(Et2O/ cyclohexane 3:7) ee: 84%. FTIR (neat) Vmax: 2927, 
2854, 1716, 1450, 1273, 1113, 712 cm-1. [α]D23 = +24 (c 0.5, CH2Cl2). 1H NMR (400 
MHz, CDCl3) δ: 8.09 – 8.01 (m, 2H), 7.58 – 7.53 (m, 1H), 7.45 (t, J = 7.6 Hz, 2H), 5.08 
– 4.97 (m, 1H), 3.38 (t, J = 6.8 Hz, 1H), 1.95 – 1.00 (m, 5H). 13C NMR (101 MHz, CDCl3) 
δ: 166.5, 132.9, 130.6, 129.7, 128.5, 78.3, 41.5, 33.7, 32.7, 30.6, 29.9, 29.3, 28.2, 26.5, 
26.2, 24.2. m/z: 313 ( 1), 232 (12), 230 (13), 122 (17), 109 (18), 105 (100), 96 (19), 95 
(24), 82 (11), 81 (29), 79 (13), 77 (37) 67 (26), 55 (14). HRMS (m/z): Calculated 
C18H25O2Br [M+Na]+: 375.0936, found: 375.0952. ee determination by chiral HPLC 
analysis, Phenomenex® LUX Cellulose-1, Hex/i-PrOH 99:1, flow = 1 mL/min, T = RT, 
retention times: tr = 16.34 min, tr = 17.40 min (major enantiomer). 
(R)-5-Chloro-1-cyclohexylpentyl benzoate (226l’): The 
corresponding compound was synthesised from (R)-
226l (15 mg, 0.073 mmol) using the general procedure 
for the synthesis of benzoate derivatives to give the 
named compound as a brown oil. Yield: 6mg, 27%. RF: 0.82 (Et2O / cyclohexane 3:7) 
ee: 60% [α]D23 = +10 (c 0.4, CH2Cl2). FTIR (neat) Vmax: 3369, 2927, 1423, 1106, 823, 
700, 613, 503, 487 cm-1. 1H NMR (400 MHz, CDCl3) δ: 8.09 – 8.00 (m, 2H), 7.59 – 7.52 
(m, 1H), 7.47 – 7.41 (m, 2H), 5.07 – 4.93 (m, 1H), 3.50 (t, J = 6.7 Hz, 2H), 1.88 – 1.57 
(m, 10H), 1.54 – 1.42 (m, 2H), 1.36 – 0.98 (m, 5H). 13C NMR (101 MHz, CDCl3) δ: 166.5, 
133.0, 130.8, 129.7, 128.5, 78.3, 45.0, 41.5, 32.6, 30.7, 29.9, 29.3, 28.2, 26.5, 26.3, 
23.0. m/z: 281 (M0.4%), 186 (17), 109 (10), 105 (100), 96 (16), 81 (15), 77 (24) 67 
(15), 55 (10). HRMS (m/z): Calculated C18H25O2Cl [M+Na]+: 331.1441, found: 
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331.1425. ee determination by chiral HPLC analysis, Phenomenex® LUX Cellulose-1, 
Hex/i-PrOH 97:3, flow = 1 mL/min, T = °C, retention times: tr = 15.64 min, tr = 16.12 
min (major enantiomer). 
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